



US009238801B2

(12) **United States Patent**  
**Li et al.**

(10) **Patent No.:** US 9,238,801 B2  
(45) **Date of Patent:** \*Jan. 19, 2016

- (54) **KETOL-ACID REDUCTOISOMERASE USING NADH**
- (71) Applicant: **BUTAMAX(TM) ADVANCED BIOFUELS LLC**, Wilmington, DE (US)
- (72) Inventors: **Yougen Li**, Lawrenceville, NJ (US); **Der-Ing Liao**, Wilmington, DE (US); **Mark J. Nelson**, Newark, DE (US); **Daniel P. Okeefe**, Ridley Park, PA (US)
- (73) Assignee: **Butamax Advanced Biofuels LLC**, Wilmington, DE (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **13/838,869**
- (22) Filed: **Mar. 15, 2013**
- (65) **Prior Publication Data**  
US 2014/0057329 A1 Feb. 27, 2014
- (63) Continuation of application No. 12/637,905, filed on Dec. 15, 2009, now Pat. No. 8,945,899, which is a continuation-in-part of application No. 12/337,736, filed on Dec. 18, 2008, now Pat. No. 8,129,162.
- (60) Provisional application No. 61/109,297, filed on Oct. 29, 2008, provisional application No. 61/015,346, filed on Dec. 20, 2007.
- (51) **Int. Cl.**
- |                   |           |
|-------------------|-----------|
| <b>C12N 9/02</b>  | (2006.01) |
| <b>C12N 15/00</b> | (2006.01) |
| <b>C12P 21/06</b> | (2006.01) |
| <b>C12P 21/04</b> | (2006.01) |
| <b>C07H 21/04</b> | (2006.01) |
| <b>C12N 9/04</b>  | (2006.01) |
| <b>C12N 15/70</b> | (2006.01) |
| <b>C12N 15/10</b> | (2006.01) |
| <b>C12Q 1/26</b>  | (2006.01) |
| <b>C12P 7/16</b>  | (2006.01) |
| <b>C12N 15/81</b> | (2006.01) |
| <b>C12P 7/42</b>  | (2006.01) |
- (52) **U.S. Cl.**
- |           |  |
|-----------|--|
| CPC ..... | <b>C12N 9/0006</b> (2013.01); <b>C12N 15/102</b> (2013.01); <b>C12N 15/1058</b> (2013.01); <b>C12N 15/70</b> (2013.01); <b>C12N 15/81</b> (2013.01); <b>C12P 7/16</b> (2013.01); <b>C12P 7/42</b> (2013.01); <b>C12Q 1/26</b> (2013.01); <b>C12Y 101/01086</b> (2013.01); <b>C12N 2320/13</b> (2013.01); <b>Y02E 50/10</b> (2013.01) |
|-----------|--|
- (58) **Field of Classification Search**  
CPC ..... C12N 9/0006  
See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

- 4,683,202 A 7/1987 Mullis et al.  
4,865,973 A 9/1989 Kollerup et al.

5,643,779 A	7/1997	Erlich et al.
6,586,229 B1	7/2003	Ben-Bassat et al.
7,541,173 B2	6/2009	Bramucci et al.
7,659,104 B2	2/2010	Bramucci et al.
7,851,188 B2	12/2010	Donaldson et al.
7,910,342 B2	3/2011	Liao et al.
7,993,889 B1	8/2011	Donaldson et al.
8,017,364 B2	9/2011	Bramucci et al.
8,071,358 B1	12/2011	Dundon et al.
8,129,162 B2 *	3/2012	Li et al. .... 435/189
8,178,328 B2	5/2012	Donaldson et al.
8,188,250 B2	5/2012	Bramucci et al.
8,206,970 B2	6/2012	Eliot et al.
8,222,017 B2 *	7/2012	Li et al. .... 435/189
8,241,878 B2	8/2012	Anthony et al.
8,273,558 B2	9/2012	Donaldson et al.
8,283,144 B2	10/2012	Donaldson et al.
8,372,612 B2	2/2013	Larossa et al.
8,389,252 B2	3/2013	Larossa
8,455,224 B2	6/2013	Paul
8,455,225 B2	6/2013	Bramucci et al.
8,465,964 B2	6/2013	Anthony et al.
8,518,678 B2	8/2013	Flint et al.
8,557,562 B2	10/2013	Bramucci et al.
8,614,085 B2	12/2013	Van Dyk et al.
8,637,281 B2	1/2014	Paul et al.
8,637,289 B2	1/2014	Anthony et al.
8,652,823 B2	2/2014	Flint et al.
8,669,094 B2	3/2014	Anthony et al.
8,691,540 B2	4/2014	Bramucci et al.
8,735,114 B2	5/2014	Donaldson et al.

(Continued)

## FOREIGN PATENT DOCUMENTS

WO	WO9408020	4/1994
WO	WO0112833	2/2001

(Continued)

## OTHER PUBLICATIONS

Sambrook et al. Molecular Cloning, 1989, Cold Spring Harbor Laboratory Press, pp. 8.46-8.52 and pp. 11.2-11.19.\*  
Paulsen et al. NC\_004129.6. ilvC ketol-acid reductoisomerase AAY94467.1. 2005.\*

Abbad-Andaloussi et al., Carbon and Electron Flow in Clostridium butyricum grown in Chemostat Culture on Glycerol and on Glucose, Microbiology 142:1149-1158, 1996.

Arthur et al. Contribution of VanY D,D-Carboxypeptidase to Glycopeptide Resistance in Enterococcus faecalis by Hydrolysis of Peptidoglycan Precursors, Antimicrob. Agents Chemother. 38:1899-1903, 1994.

Aulabaugh, et al., Oxaryl Hydroxamates as Reaction-Intermediate Analogues for Ketol-Acid Reductoisomerase, Biochemistry 29:2824-2830 1990.

Biou, et al. The crystal structure of plant acetohydroxy acid isomeroreductase complexed with NADPH, two magnesium ions and a herbicidal transition state analog determined at 1.65 Å resolution, EMBO Journal 16:3405-3415, 1997.

(Continued)

Primary Examiner — Yong Pak

(57) **ABSTRACT**

Methods for the evolution of NADPH specific ketol-acid reductoisomerase enzymes to acquire NADH specificity are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from *Pseudomonas* that have undergone co-factor switching to utilize NADH are described.

(56)	References Cited				
U.S. PATENT DOCUMENTS					
8,765,433 B2	7/2014	Gude et al.	2014/0377824 A1	12/2014	Satagopan et al.
8,785,166 B2	7/2014	Anthony et al.	2015/0037855 A1	2/2015	Bhadra et al.
8,795,992 B2	8/2014	Bramucci et al.	2015/0111269 A1	4/2015	Li et al.
8,828,694 B2	9/2014	Anthony et al.			
8,828,704 B2	9/2014	Donaldson et al.			
8,871,488 B2	10/2014	Dauner et al.			
8,889,385 B2	11/2014	Donaldson et al.			
8,895,307 B2	11/2014	Li et al.			
8,906,666 B2	12/2014	Alsaker et al.			
8,911,981 B2	12/2014	Li et al.			
8,940,511 B2	1/2015	Larossa			
8,945,859 B2	2/2015	Donaldson et al.			
8,945,899 B2	2/2015	Li et al.			
8,951,774 B2	2/2015	Donaldson et al.			
8,951,937 B2	2/2015	Flint et al.			
8,956,850 B2	2/2015	Anthony et al.			
8,962,298 B2	2/2015	Donaldson et al.			
8,969,065 B2	3/2015	Anthony et al.			
8,980,612 B2	3/2015	Donaldson et al.			
2002/0061569 A1	5/2002	Haselbeck et al.			
2004/0234649 A1	11/2004	Lewis et al.			
2004/0248250 A1	12/2004	Nakai et al.			
2005/0112739 A1	5/2005	Golubkov et al.			
2007/0031918 A1	2/2007	Dunson et al.			
2007/0092957 A1	4/2007	Donaldson et al.			
2008/0182308 A1	7/2008	Donaldson et al.			
2009/0081746 A1	3/2009	Liao et al.			
2009/0163376 A1	6/2009	Li et al.			
2010/0081154 A1	4/2010	Flint et al.			
2010/0081179 A1	4/2010	Anthony et al.			
2010/0081182 A1	4/2010	Paul et al.			
2010/0093020 A1	4/2010	Bramucci et al.			
2010/0120105 A1	5/2010	Anthony et al.			
2010/0143997 A1	6/2010	Buelter et al.			
2010/0197519 A1	8/2010	Li et al.			
2011/0076733 A1	3/2011	Urano et al.			
2011/0124060 A1	5/2011	Anthony et al.			
2011/0136192 A1	6/2011	Paul et al.			
2011/0195505 A1	8/2011	Euler et al.			
2011/0244536 A1	10/2011	Nagarajan et al.			
2011/0250610 A1	10/2011	Bramucci et al.			
2011/0275129 A1	11/2011	Buelter et al.			
2012/0058541 A1	3/2012	Alsaker et al.			
2012/0064561 A1	3/2012	Flint et al.			
2012/0149080 A1	6/2012	Bramucci et al.			
2012/0196341 A1	8/2012	Donaldson et al.			
2012/0237988 A1	9/2012	Anthony et al.			
2012/0258873 A1	10/2012	Gibson et al.			
2013/0035515 A1	2/2013	Dobson et al.			
2013/0071898 A1	3/2013	Anthony et al.			
2013/0171706 A1	7/2013	Donaldson et al.			
2013/0203138 A1	8/2013	McElvain et al.			
2013/0252296 A1	9/2013	Maggio-Hall et al.			
2013/0316414 A1	11/2013	Paul et al.			
2013/0344551 A1	12/2013	Li et al.			
2014/0004526 A1	1/2014	Dauner et al.			
2014/0030782 A1	1/2014	Anthony et al.			
2014/0030783 A1	1/2014	Anthony et al.			
2014/0038263 A1	2/2014	Flint et al.			
2014/0038268 A1	2/2014	Flint et al.			
2014/0051133 A1	2/2014	Govindarajan et al.			
2014/0051137 A1	2/2014	Flint et al.			
2014/0057329 A1	2/2014	Li et al.			
2014/0093930 A1	4/2014	Li et al.			
2014/0096439 A1	4/2014	Bramucci et al.			
2014/0141479 A1	5/2014	Anthony et al.			
2014/0170732 A1	6/2014	Bramucci et al.			
2014/0186910 A1	7/2014	Rothman et al.			
2014/0186911 A1	7/2014	Anthony et al.			
2014/0273116 A1	9/2014	Kelly et al.			
2014/0273129 A1	9/2014	Bhalla et al.			
2014/0308735 A1	10/2014	Anthony et al.			
2014/0335582 A1	11/2014	Donaldson et al.			
2014/0349349 A1	11/2014	Dauner et al.			

## FOREIGN PATENT DOCUMENTS

WO	2005040392	5/2005
WO	WO2008098227	8/2008
WO	WO2008130995	10/2008
WO	WO2009056984	5/2009
WO	WO2009059253	5/2009
WO	WO2009078108	6/2009
WO	WO2009086423	7/2009
WO	WO2010051527	5/2010
WO	WO2010062597	6/2010
WO	WO2011019894	2/2011

## OTHER PUBLICATIONS

- van der Geize, et al., Targeted Disruption of the *kstD* Gene Encoding a 3-Ketosteroid delta-1-Dehydrogenase Isoenzyme of *Rhodococcus erythropolis* Strain SQ1, *Appl. Environ. Microbiol.* 66:2029-2039, 2000.
- Chunduru, et al., Mechanism of Ketol Acid Reductoisomerase—Steady State Analysis and Metal Ion Requirement, *Biochemistry* 28:486-493 1989.
- de Cavalho, et al., *Mycobacterium* sp., *Rhodococcus erythropolis*, and *Pseudomonas putida* Behavior in the Presence of Organic Solvents, *Microsc. Res. Tech.* 64:215-22, 2004.
- de la Plaza, et al., Biochemical and molecular characterization of alpha-ketoisovalerate decarboxylase, an enzyme involved in the formation of aldehydes from amino acids by *Lactococcus lactis*, *FEMS Microbiol. Lett.* 238:367-374, 2004.
- Deshpande, Ethanol Production from Cellulose by Coupled Saccharification/Fermentation using *Saccharomyces cerevisiae* and Cellulase Complex from *Sclerotium rolfsii* UV-8 Mutant, *Appl. Biochem. Biotechnol.* 36:227, 1992.
- Dürre, et al., Solventogenic Enzymes of *Clostridium acetobutylicum*: Catalytic Properties, Genetic Organization, and Transcriptional Regulation, *FEMS Microbiol. Rev.* 17:251-262, 1995.
- Dürre New insights and novel developments in clostridial acetone/butanol/isopropanol fermentation *Appl. Microbiol. Biotechnol.* 49:639-648, 1998.
- Eichenbaum, et al., Use of the Lactococcal *nisA* Promoter To Regulate Gene Expression in Gram-Positive Bacteria: Comparison of Induction Level and Promoter Strength, *Appl. Environ. Microbiol.* 64:2763-2769, 1998.
- Fleming, et al., Extracellular Enzyme Synthesis in a Sporulation-Deficient Strain of *Bacillus licheniformis*, *Appl. Environ. Microbiol.* 61:3775-3780, 1995.
- Flint, et al., The Role and Properties of the Iron-Sulfur Cluster in *Escherichia coli* Dihydroxy-acid Dehydratase, *J. Biol. Chem.* 268:14732-14742, 1993.
- Ford, et al., Characterization of Ypr1p from *Saccharomyces cerevisiae* as a 2-methylbutyraldehyde reductase, *Yeast* 19:1087-1096, 2002.
- Fujimoto, et al., pAM401-Based Shuttle Vectors That Enable Overexpression of Promoterless Genes and One-Step Purification of Tag Fusion Proteins Directly from *Enterococcus faecalis*, *Appl. Environ. Microbiol.* 67:1262-1267, 2001.
- Gollop, et al., Physiological Implications of the Substrate Specificities of Acetohydroxy Acid Synthases from Varied Organisms, *J. Bacteriol.* 172:3444-3449, 1990.
- Groot, et al., Technologies for Butanol Recovery Integrated with Fermentations, *Process. Biochem.* 27:61-75, 1992.
- Guex, et al., Swiss-Model and the Swiss-PdbViewer: An Environment for Comparative Protein Modeling, *Electrophoresis* 18:2714-2723, 1997.
- Hermann, et al., Isolation and Characterization of Butanol-Resistant Mutants of *Clostridium acetobutylicum*, *Appl. Environ. Microbiol.* 50:1238-1243, 1985.
- Holtzclaw, et al., Degradative Acetylactate Synthase of *Bacillus subtilis*:Purification and Properties, *J. Bacteriol.* 121:917-922, 1975.

(56)

**References Cited****OTHER PUBLICATIONS**

- Jones, et al., Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in these Models, *Acta Crystallogr. A* 47:110-119, 1991.
- Kabeliz, et al., Effect of aliphatic alcohols on growth and degree of saturation of membrane lipids in *Acinetobacter calcoaceticus*, *FEMS Microbiol. Lett.* 220: 223-227, 2003.
- Datsenko, et al., One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products, *Proc. Natl. Acad. Sci. USA* 97:6640-6645, 2000.
- Kleerebezem, et al., Controlled Gene Expression Systems for Lactic Acid Bacteria: Transferable Nisin-Inducible Expression Cassettes for *Lactococcus*, *Leuconostoc*, and *Lactobacillus* spp., *Appl. Environ. Microbiol.* 63:4581-4584, 1997.
- Kostichka, et al., A small cryptic plasmid from *Rhodococcus erythropolis*: characterization and utility for gene expression, *Appl. Microbiol. Biotechnol.* 62:61-68, 2003.
- Krogh, et al., Hidden Markov Models in Computational Biology, *J. Mol. Biol.* 235:1501-1531, 1994.
- Larroy, et al., Characterization of the *Saccharomyces cerevisiae* YMR318C (ADH6) gene product as a broad specificity NADPH-dependent alcohol dehydrogenase: relevance in aldehyde reduction, *Biochem. J.* 361:163-172, 2002.
- Maguin, et al., New Termosensitive Plasmid for Gram-Positive Bacteria, *J. Bacteriol.* 174:5633-5638, 1992.
- Marinus, et al., Regulation of Isoleucine-Valine Biosynthesis in *Pseudomonas aeruginosa*, *Genetics* 63:547-56, 1969.
- Nagarajan, et al., Modular Expression and Secretion Vectors for *Bacillus subtilis*, *Gene* 114:121-126, 1992.
- Nakashima, et al., Isolation and Characterization of a Rolling-Circle-Type Plasmid from *Rhodococcus erythropolis* and Application of the Plasmid to Multiple-Recombinant-Protein Expression, *Appl. Environ. Microbiol.* 70:5557-5568, 2004.
- Nallaapareddy, et al., Construction of Improved Temperature-Sensitive and Mobilizable Vectors and Their Use for Constructing Mutations in the Adhesin-Encoding acm Gene of Poorly Transformable Clinical *Enterococcus faecium* Strains, *Appl. Environ. Microbiol.* 72:334-345, 2006.
- O'Sullivan, et al., High- and low-copy-number *Lactococcus* shuttle cloning vectors with features for clone screening, *Gene* 137:227-231, 1993.
- Payne, et al., Use of Alkaline Phosphatase Fusions to Study Protein Secretion in *Bacillus subtilis*, *J. Bacteriol.* 173:2278-2282, 1991.
- Renault, et al., Plasmid Vectors for Gram-positive Bacteria Switching from High to Low Copy Number, *Gene* 183:175-182, 1996.
- Scott, et al., Sequences of versatile broad-host-range vectors of the RK2 family, *Plasmid* 50:74-79, 2003.
- Smit, et al., Identification, Cloning, and Characterization of a *Lactococcus lactis* Branched-Chain alpha-Keto Acid Decarboxylase Involved in Flavor Formation, *Appl. Environ. Microbiol.* 71:303-311, 2005.
- Sulter, et al., Proliferation and metabolic significance of peroxisomes in *Candida boidinii* during growth on D-alanine or oleic acid as the sole carbon source, *Arch. Microbiol.* 153:485-489, 1990.
- Sulzenbacher, et al., Crystal Structure of *E. coli* Alcohol Dehydrogenase YqhD: Evidence of a Covalently Modified NADP Coenzyme, *J. Mol. Biol.* 342:489-502, 2004.
- Tabor, et al., A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes, *Proc. Acad. Sci. USA* 82:1074, 1985.
- Taghavi, et al., Electroporation of *Alcaligenes eutrophus* with(Mega)Plasmids and Genomic DNA Fragments, *Appl. Environ. Microbiol.* 60:3585-3691, 1994.
- Tanimoto, et al., Analysis of the Conjugal Transfer System of the Pheromone-Independent Highly Transferable *Enterococcus* Plasmid pMG1: Identification of a tra Gene (traA) Up-Regulated during Conjugation, *J. Bacteriol.* 184:5800-5804, 2002.
- Tao, et al., Construction of highly efficient *E. coli* expression systems containing low oxygen induced promoter and partition region, *Appl. Microbiol. Biotechnol.* 68:346-354, 2005.
- Thompson, et al., Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, *Nuc. Acid Res.* 22:4673-4680, 1994.
- Tomas, et al., Transcriptional Analysis of Butanol Stress and Tolerance in *Clostridium acetobutylicum*, *J. Bacteriol.* 186:2006-2018, 2004.
- Tyagi, et al., The crystal structure of a bacterial Class II ketol-acid reductoisomerase: Domain conservation and evolution, *Protein Sci.* 14:3089-3100, 2005.
- van Kranenburg, et al., Functional Analysis of Three Plasmids from *Lactobacillus plantarum*, *Appl. Environ. Microbiol.* 71:1223-1230, 2005.
- Walker, et al., Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system, *Proc. Natl. Acad. Sci. U.S.A.* 89:392-396, 1992.
- Wyckoff, et al., Characterization and Sequence Analysis of a Stable Cryptic Plasmid from *Enterococcus faecium* 226 and Development of a Stable Cloning Vector, *Appl. Environ. Microbiol.* 62:1481-1486, 1996.
- Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, published by Greene Publishing Assoc. and Wiley Interscience, 1987.
- Thomas D. Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA.
- Enzyme Structure and Mechanism, 2nd ed. Ferst; W.H. Freeman Press, NY, 1985; pp. 98-120.
- Guide to Yeast Genetics and Molecular and Cell Biology, Part A, 2004 Christine Guthrie and Gerald R. Fink, eds., Elsevier Academic Press, San Diego, CA.
- Manual of Methods for General Bacteriology, Phillip Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds., American Society for Microbiology, Washington, DC., 1994.
- Sambrook, Fritsch and Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- Silhavy et al. Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY, 1984.
- Branden, et al., Introduction to Protein Structure, Garland Publishing Inc., New York, p. 247, 1991.
- Kaneko, et al., Complete Genome Sequence of the Filamentous Nitrogen-fixing *Cyanobacterium Anabaena* sp. strain PCC 7120, *DNA Res.* 8:205-213, 227-253, 2001.
- Oaxaca, et al., Formation of Ethanol and Higher Alcohols by Immobilized *Zymomonas mobilis* in Continuous Culture, *ACTA Biotechnol.* 11:523-532, 1991.
- Eppink, et al., Switch of Coenzyme Specificity of p-Hydroxybenzoate Hydroxylase, *J. Mol. Biol.* 292:87-96, 1999.
- Nakanishi, et al., Switch of Coenzyme Specificity of Mouse Lung Carbonyl Reductase by Substitution of Threonine 38 with Aspartic Acid, *J. Biol. Chem.* 272:2218-2222, 1997.
- Kamerbeek, et al., Identifying Determinants of NADPH Specificity in Baeyer-Villiger Monooxygenases, *Eur. J. Biochem.* 271:2107-2116, 2004.
- Nishiyama, et al., Alteration of Coenzyme Specificity of Malate Dehydrogenase from *Thermus flavus* by Site-directed Mutagenesis, *J. Biol. Chem.* 268:4656-4660, 1993.
- Martinez-Julvez, et al., Towards a New Interaction Enzyme: Coenzyme, *Biophys. Chem.* 115:219-224, 2005.
- Rane, et al., Reversal of the Nucleotide Specificity of Ketol Acid Reductoisomerase by Site-Directed Mutagenesis Identifies the NADPH Binding Site, *Archiv. Biochem. Biophys.* 338:83-89, 1997.
- Ahn, et al., Crystal Structure of Class I Acetohydroxy Acid Isomeroreductase from *Pseudomonas aeruginosa*, *J. Mol. Biol.* 328:505-515, 2003.
- Paulsen, et al., Complete genome sequence of the plant commensal *Pseudomonas fluorescens* Pf-5, *Nature Biotechnol.* 23:8730878, 2005.
- Carugo, et al., NADP-Dependent Enzymes I: Conserved Stereochemistry of Cofactor Binding, Proteins: Structure, Function, and genetics 28:10-28, 1997.

(56)

**References Cited****OTHER PUBLICATIONS**

- Dumas, et al., Enzymology, Structure, and Dynamics of Acetohydroxy Acid Isomerase, *Acc. Chem. Res.* 34:399-408, 2001.
- Elmore, et al., Modification of the Nucleotide Cofactor-binding Site of Cytochrome P-450 Reductase to Enhance Turnover with NADH in vivo, *J. Biol. Chem.* 277:48960-48964, 2002.
- Fisher, et al., The X-ray Structure of Brassica napus beta-keto acyl carrier protein reductase and its implication for substrate binding and catalysis, *Structure* 8:339-347, 2000.
- Khoury, et al., Computational design of *Candida boidinii* xylose reductase for altered cofactor specificity, *Protein Sci.* 18:2125-2136, 2009.
- Kuzuyama, et al., Characterization of 1-deoxy-D-xylulose 5-Phosphate Reductoisomerase, an Enzyme Involved in Isopentenyl Diphosphate Biosynthesis, and Identification of Its Catalytic Amino Acid Residues, *J. Biol. Chem.* 275:19928-19932, 2000.
- Medina, et al., Probing the Determinants of Coenzyme Specificity in Ferredoxin-NADP+ Reductase by Site-directed Mutagenesis, *J. Biol. Chem.* 276:11902-11912, 2001.
- Wierenga, et al., Prediction of the Occurrence of the SDP-binding Beta-alpha-beta Fold in Proteins, Using an Amino Acid Sequence Fingerprint, *J. Mol. Biol.* 187:101-107, 1986.
- Brinkmann-Chen, et al., General approach to reversing ketol-acid reductoisomerase cofactor dependence from NADPH to NADH, *Proc. Natl. Acad. Sci.* 110:10946-10951, 2013.
- Rossmann, et al., Chemical and biological evolution of nucleotide-binding protein, *Nature* 250:194-199, 1974.
- Curien, et al., Nucleotide sequence and characterization of a cDNA encoding the acetohydroxy acid isomerase from *Arabidopsis thaliana*, *Plant Molecular Biology* 21:717-722, 1993.
- Dumas, et al., Purification and characterization of acetohydroxyacid reductoisomerase from spinach chloroplasts, *Biochem. J.* 262:971-976, 1989.
- Durner, et al., Ketol-Acid Reductoisomerase from Barley (*Hordeum vulgare*): Purification, Properties, and Specific Inhibition, *Plant Physiol.* 103:903-910, 1993.
- Feehey, et al., A single amino acid substitution in lactate dehydrogenase improves the catalytic efficiency with an alternative coenzyme, *Biochem. Biophys. Res. Commun.* 166:667-672, 1990.
- Inui, et al., Identification and sequence determination of the acetohydroxy acid isomerase gene from *Brevibacterium flavum* MJ233, *DNA Seq.* 4:95-103, 1993.
- Lauvergeat, et al., Site-directed mutagenesis of a serine residue in cinnamyl alcohol dehydrogenase, a plant NADPH-dependent dehydrogenase, affects the specificity for the coenzyme, *Biochemistry* 34:12426-12434, 1995.
- Levskaya, et al., Synthetic biology: engineering *Escherichia coli* to see light, *Nature* 438:441-442, 2005.
- Shiraishi, et al., Engineering of pyridine nucleotide specificity of nitrate reductase: mutagenesis of recombinant cytochrome b reductase fragment of *Neurospora crassa* NADPH:Nitrate reductase, *Archives of Biochemistry and Biophysics* 358:104-115, 1998.
- Tyagi, et al., Probing the mechanism of the bifunctional enzyme ketol-acid reductoisomerase by site-directed mutagenesis of the active site, *FEBS Journal* 272:593-602, 2005.
- Zhang, et al., Change of nucleotide specificity and enhancement of catalytic efficiency in single point mutants of *Vibrio harveyi* aldehyde dehydrogenase, *Biochemistry* 38:11440-11447, 1999.
- International Search Report dated Jul. 6, 2009 for International Application No. PCT/US2008/087429.
- U.S. Appl. No. 12/966,333, filed Dec. 13, 2010.
- EBI Accession No. UniProt: Q8ZAC2, Entry Date Jun. 6, 2003.
- EBI Accession No. UniProt: Q0AV19, Entry Date Jan. 15, 2008.
- EBI Accession No. UniProt: Q02138, Entry Date Jul. 1, 1993.
- EBI Accession No. UniProt: Q01292, Entry Date Apr. 1, 1993.
- EBI Accession No. UniProt: P06168, Entry Date Jan. 1, 1988.
- EBI Accession No. UniProt: P05793, Entry Date Nov. 1, 1988.
- EBI Accession No. UniProt: B1ZV88, Entry Date Jun. 6, 2003.
- She, et al., Q97YJ9—UNIPROTKB/Swiss-Prot Database, Oct. 31, 2006.
- Suerbaum, et al., UniProtKB Database, Accession Q7VGW6, 2003.
- Kaneko, et al., Q8YUM—UniProt Database, Mar. 23, 2010.
- GenBank No. NC\_009135.1, Copeland, et al., Apr. 30, 2009; pp. 1-3.
- GenBank No. NC\_005791.1, Hendrickson, et al., Apr. 25, 2009, pp. 1-3.
- GenBank No. NZ\_AAWX01000002.1, Copeland, et al., Feb. 7, 2007; pp. 1-3.
- GenBank No. NC\_001144.4, Johnston, et al., Jun. 16, 2008; pp. 1-3.
- GenBank No. NC\_002754.1, She, et al., Apr. 26, 2009; pp. 1-3.
- GenBank No. NC\_003364.1, Fitz-Gibbon, et al., Apr. 24, 2009; pp. 1-3.
- GenBank No. AAA25079, Peng, et al., Aug. 5, 1994; pp. 1-2.
- GenBank No. AAA25161, Marugg, et al., Apr. 21, 1994; pp. 1-5.
- GenBank No. AAA65614, Sokatch, Feb. 27, 2002; pp. 1-2.
- GenBank No. AAA65615, Sokatch, Feb. 27, 2002; pp. 1-2.
- GenBank No. AAA65617, Sokatch, Feb. 27, 2002; pp. 1-3.
- GenBank No. AAA65618, Sokatch, Feb. 27, 2002; pp. 1-3.
- GenBank No. AAS49166, Smit, et al., Dec. 27, 2004; pp. 1-5.
- GenBank No. AJ746364, de la Plaza, et al., Apr. 15, 2005; pp. 1-4.
- GenBank No. AY548760, Smit, et al., Dec. 27, 2004; pp. 1-2.
- GenBank No. BX957219 obsolete and replaced by BX950229, Hendrickson, et al., May 8, 2008; pp. 1-369.
- GenBank No. CAB14105, Kunst, et al., Oct. 1, 2009; pp. 1-10.
- GenBank No. CAB14334, Kunst, et al., Oct. 1, 2009; pp. 1-4.
- GenBank No. CAB14335, Kunst, et al., Oct. 1, 2009; pp. 1-4.
- GenBank No. CAB14336, Kunst, et al., Oct. 1, 2009; pp. 1-4.
- GenBank No. CAB14337, Kunst, et al., Oct. 1, 2009; pp. 1-4.
- GenBank No. CAB15618, Kunst, et al., Oct. 1, 2009; pp. 1-9.
- GenBank No. CAF29874, Hendrickson, et al., May 8, 2008; pp. 1-7.
- GenBank No. CAG34226, de la Plaza, et al., Apr. 15, 2005; pp. 1-3.
- GenBank No. L16975, Marugg, et al., Apr. 21, 1994; pp. 1-3.
- GenBank No. M57613, Madhusudhan, et al., Feb. 27, 2002; pp. 1-7.
- GenBank No. M73842, Peng, et al., Aug. 5, 1994; pp. 1-2.
- GenBank No. NC\_001142, Command, et al., Jun. 9, 2009; pp. 1-2.
- GenBank No. NC\_003030, Nolling, et al., Oct. 22, 2009; pp. 1-653.
- GenBank No. NC\_001136, Jacq, et al., Dec. 9, 2009; pp. 1-216.
- GenBank No. NC\_001145, Bowman, et al., Dec. 9, 2009; pp. 1-351.
- GenBank No. NC\_001988, Nollings, et al., Apr. 26, 2009; pp. 1-147.
- GenBank No. NC\_003197, McClelland, et al., Mar. 30, 2010; pp. 1-186.
- GenBank No. NP\_012550, Goffeau, et al., Nov. 5, 2009, pp. 1-10.
- GenBank No. NP\_010656, Jacq, et al., downloaded Apr. 15, 2010, pp. 1-3.
- GenBank No. NP\_014051, Bowman, et al., Dec. 9, 2009, pp. 1-3.
- GenBank No. NP\_149189, Nolling, et al., Apr. 26, 2009; pp. 1-7.
- GenBank No. NP\_349892, Nolling, et al., Apr. 14, 2010; pp. 1-3.
- GenBank No. NP\_417484, Riley, et al., Apr. 9, 2010; pp. 1-5.
- GenBank No. NP\_461346, McClelland, et al., Apr. 30, 2009; pp. 1-8.
- GenBank No. YP\_026248, Riley, et al., Jul. 30, 2009; pp. 1-4.
- GenBank No. Z99115 obsolete and replaced by AL009126, Kunst, et al., Nov. 15, 2007; pp. 1-114.
- GenBank No. Z99116 obsolete and replaced by AL009126, Kunst, et al., Oct. 1, 2009; pp. 1-382.
- GenBank No. Z99122 obsolete and replaced by AL009126, Kunst, et al., Apr. 18, 2005; pp. 1-112.
- GenBank No. ZP\_01224863.1, Mar. 24, 2006; pp. 1-2.
- GenBank No. NC\_003295.1, Salanoubat, et al., May 1, 2009; pp. 1-3.
- GenBank No. NC\_002516, Winsor, et al., Jun. 24, 2009; pp. 1-3.
- GenBank No. NC\_004129, Winsor, et al., Jun. 24, 2009; pp. 1-3.
- GenBank No. O82043, Gu, et al., Jun. 16, 2009; pp. 1-3.
- GenBank No. NP\_977840.1, Rasko, et al., May 1, 2009; pp. 1-3.
- GenBank No. NP\_978252.1, Rasko, et al., May 1, 2009; pp. 1-3.
- GenBank No. P05793, Daniels, et al., Jun. 16, 2009; pp. 1-9.
- GenBank No. ZP\_01313517.1, Copeland, et al., May 15, 2006; pp. 1-3.
- Entrez GenBank Accession No. UNIPROT: Q4K608, Paulsen, et al., Apr. 2006.
- Entrez GenBank Accession No. UNIPROT: Q6F821, Barbe, et al., Oct. 2004; pp. 1-2.

(56)

**References Cited**

## OTHER PUBLICATIONS

- Dumas, et al., Purification and characterization of a fusion protein of plant acetohydroxy acid synthase and acetohydroxy acid isomeroreductase, FEBS Lett. 408:156-160, 1997.
- Bellion et al., Microb. Growth C1 Compd., [Int. Symp.], 7th (1993), 415-32. (eds): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK.
- Dumas, et al., Isolation and kinetic properties of acetohydroxy acid isomeroreductase from spinach (*Spinacia oleracea*) chloroplasts overexpressed in *Escherichia coli*, Biochem. J. 288:865-874, 1992.
- Epelbaum, et al. Branched-chain amino acid biosynthesis in *Salmonella typhimurium*: a quantitative analysis, J. Bacteriol. 180:4056-4067, 1998.
- Kuzuyama, Mevalonate and nonmevalonate pathways for the biosyntheses of isoprene units, Biosci. Biotechnol. Biochem. 66:1619-1627, 2002.
- Garcia, et al. Fusel alcohols production in beer fermentation processes, Proc. Biochem. 29:303-309, 1994.
- Carlini, et al., Guerbet condensation of methanol with n-propanol to isobutyl alcohol over heterogeneous copper chromite/Mg-Al mixed oxides, J. Mol. Catalysis A 220:215-220, 2004.
- Rothstein, Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast, Meth. Enzymol. 194:281-301, 1991.
- Horton, et al., Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension, Gene 77:61-68, 1989.
- Dickinson, et al., An Investigation of the Metabolism to Isobutyl Alcohol in *Saccharomyces cerevisiae*, J. Biol. Chem. 273:25752-25756, 1998.
- Kumanovics, et al. Identification of FRA 1 and FRA2 as genes involved in regulating the yeast iron regulon in response to decreased mitochondrial iron-sulfur cluster synthesis. J. Biol. Chem. 283:10276-10286, 2008.
- Davison, et al. Continuous Direct Solvent Extraction of Butanol in a Fermenting Fluidized-Bed Bioreactor with Immobilized Clostridium acetobutylicum. Appl. Biochem. Biotech. 39/40:415-426, 1993.
- Altschul, et al., Basic Local Alignment Search Tool, J. Mol. Biol. 215:403-410, 1990.
- Spano, et al., Environmental stress response in wine lactic acid bacteria: beyond *Bacillus subtilis*, Crit. Rev. Microbiol. 32:77-86, 2006.
- Chang, et al., Construction and Characterization of Amplifiable Multicopy DNA Cloning Vehicles Derived from the P15A Cryptic Miniplasmid, J. Bacteriol. 134:1141-1156, 1978.
- Ferain, et al., Lactobacillus plantarum IdhL gene: overexpression and deletion, J. Bacteriol. 176:596-601, 1994.
- Godon, et al., Branched-chain amino acid biosynthesis genes in *Lactococcus lactic* subsp. *lactic*, J. Bacteriol. 174:6580-6589, 1992.
- Horinouchi, et al., Nucleotide sequence and functional map of pE194, a plasmid that specifies inducible resistance to macrolide, lincosamide, and streptogramin type B antibiotics, J. Bacteriol. 150:804-814, 1982.
- Higgins, et al., Clustal V: improved software for multiple sequence alignment, CABIOS 8:189-191, 1992.
- Higgins et al., Fast and sensitive multiple sequence alignments on a microcomputer, CABIOS Communications 5:151-153, 1989.
- Johnson, et al., DNA sequences at the ends of transposon Tn5 required for transposition, Nature 304:280-282, 1983.
- Rud, et al., A synthetic promoter library for constitutive gene expression in lactobacillus plantarum, Microbiol. 152:1011-1019, 2006.
- Yansura, et al., Use of the *Escherichia coli* lac repressor and operator to control gene expression in *Bacillus subtilis*, Proc. Natl. Acad. Sci. USA, vol. 81:439-443, 1984.
- Yuan, et al., Regulation of groE Expression in *Bacillus subtilis*: the Involvement of the cr-Like Promoter and the Roles of the Inverted Repeat Sequence (CIRCE), J. Bacteriol. 177:5427-5433, 1995.
- Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Plenum: New York, NY.
- Vasantha, et al., Genes for Alkaline Protease and Neutral Protease from *Bacillus amyloliquefaciens* Contain a Large Open Reading Frame Between the Regions Coding for Signal Sequence and Mature Protein, J. Bacteriol., 159:811-819, 1984.
- Methods in Yeast Genetics, 2005, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 201-202.
- Butanols, Ullman's Encyclopedia of Industrial Chemistry, 6th Edition, 5:716-719, 2003.
- GenBank EDR97797.1 Feb. 12, 2008. 1 page.
- GenBank Accession No. NC\_002505, *Vibrio cholerae* O1 biovar eltor str. N16961, Jul. 21, 2008.
- GenBank Accession No. AAU36450, *Psuedomonas aeruginosa* cellular proliferation protein, Feb. 14, 2002, viewed Nov. 14, 2008.
- GenBank Accession No. A3EGY6, ketol-acid reductoisomerase, *Vibrio chlorea*, Mar. 20, 2007, viewed Nov. 14, 2008.
- GenBank Accession No. NC\_000913, *Escherichia coli* str. K-12 substr. MG1655, May 17, 2008.
- GenBank Accession No. B9CVH4, viewed Feb. 8, 2011.
- GenBank Accession No. YP\_162876, ketol-acid reductoisomerase [*Zymomonas mobilis* subsp. *mobilis* ZM4 = ATCC 31821], Jun. 10, 2013.
- GenBank Accession No. ZP\_07930881, ketol-acid reductoisomerase [*Anaerostipes* sp. 3\_2\_56FAA], Nov. 27, 2012.
- U.S. Appl. No. 14/571,817, filed Dec. 16, 2014 (Butamax).
- U.S. Appl. No. 14/585,261, filed Dec. 30, 2014 (Butamax).

\* cited by examiner




FIG. 1A




FIG. 1B

## Sequence ID

17	(44)	VGLRKGSATVAKA
16	(44)	VGLRSGSATVAKA
18	(162)	IGLRKGSNTFAEA

FIG. 2A

## Sequence ID

9	(44)	VGLRKNGASWENAK
10	(44)	VGLRKNGASWNNAK
11	(44)	VGLRKNGASWENAK
17	(44)	VGLRKGSATVAKAE
15	(44)	VGLRKNGASWNKAV
12	(44)	IGVRKDGASWKAII
13	(44)	VGLEREGKSWEELAK
14	(44)	IGLRRGGKSWELAT
Consensus		VGLRKNGASWE AK

FIG. 2B




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7

Sequence 10

	81		100
47	(18) ~~~~KXVALIGXPSQGHAKWNLKD~~~~~NGFDTWVYGLRNG~KSWDKA		
48	(17) ~~~~RTVAVIGXPSQGHAKWNLKD~~~~~SGVEVWVGVPRG~KSFTEVA		
18	(51) FYGIRQISVGIVGWSQAPAQCNLKGCLTEAKSDVYVKHGLRKGSNSFAKA		
16	(17) ~~~~KXVALIGXPSQGHAKWNLKD~~~~~SGVDTWVGLRPGSATVAKA		
17	(17) ~~~~KXVALIGXPSQGRAQCNLKD~~~~~SGVDTWVGLRPGSATVAKA		
	101		100
47	(57) KXPK[RE]VYVTAACAA[RE]ADYVMTI[RE]PDELQPEVYEAETIAAPRLOAS[RE]		
48	(56) KXPK[RE]VYVTAACAA[RE]ADYVMTI[RE]PDELQPEVYEAETIAAPRLOAS[RE]		
18	(301) KXPK[RE]SSENGTLCDDMHE[RE]PDELQPEVYEAETIAAPRLOAS[RE]		
16	(37) KXPK[RE]VYVTAACAA[RE]ADYVMTI[RE]PDELQPEVYEAETIAAPRLOAS[RE]		
17	(57) KXPK[RE]VYVTAACAA[RE]ADYVMTI[RE]PDELQPEVYEAETIAAPRLOAS[RE]		
	151		200
47	(102) SLYFANGFIVVRFDQVK~~~[RE]PNTVOVPLVAKSKGPCHLVARTF3EQ~~~		
48	(101) MILFNGKGNRIPGQIN~~~[RE]PNTVOVAMVAPKSPCHLVKRYFQEQ~~~		
18	(180) ILCLERHGFLIGHLQSLQGQEPKHSISVIAVCPKGMSPSVRLYVQSKKEVNG		
16	(102) TLAFTARGPSIHYNQPV~~~[RE]KQDQVIMIAFVKAPQHTVRSZEFVKC~~~		
17	(102) TLAFTARGPSIHYNQPV~~~[RE]KQDQVIMIAFVKAPQHTVRSZEFVKC~~~		
	201		250
47	(144) GAVPALKFAYVQD[RE]TGTAVATEKALSYAAG[RE]GATRAGVLETFKQETETDOLFG		
48	(143) NGVPAFKVHQD[RE]TGTALKVALAYAK[RE]GCTRAGVLETFKQETETDOLFG		
18	(200) AGINNSFVAKHQD[RE]GCTRAGVLETFKQETETDOLFG		
16	(144) SGIPDLIRIYQD[RE]SGNAKHNVALSYAAG[RE]GCGRTGIIETTYKQETETDOLFG		
17	(144) SGIPDLIRIYQD[RE]SGNAKHNVALSYAAG[RE]GCGRTGIIETTYKQETETDOLFG		

FIG. 8

Sequence ID

	10	20	30	40	50	60
17	...	...	...	...	...	...
43	...	...	...	...	...	...
44	...	...	...	...	...	...
45	...	...	...	...	...	...
46	...	...	...	...	...	...
47	...	...	...	...	...	...
48	...	...	...	...	...	...
49	...	...	...	...	...	...
50	...	...	...	...	...	...
51	...	...	...	...	...	...
52	...	...	...	...	...	...
53	...	...	...	...	...	...
54	...	...	...	...	...	...
55	...	...	...	...	...	...
56	...	...	...	...	...	...
57	...	...	...	...	...	...
58	...	...	...	...	...	...
59	...	...	...	...	...	...
60	...	...	...	...	...	...
61	...	...	...	...	...	...
62	...	...	...	...	...	...
63	...	...	...	...	...	...
64	...	...	...	...	...	...
65	...	...	...	...	...	...
66	...	...	...	...	...	...
67	...	...	...	...	...	...
68	...	...	...	...	...	...
69	...	...	...	...	...	...
70	...	...	...	...	...	...
71	...	...	...	...	...	...
72	...	...	...	...	...	...
73	...	...	...	...	...	...
74	...	...	...	...	...	...
75	...	...	...	...	...	...
76	...	...	...	...	...	...
77	...	...	...	...	...	...
78	...	...	...	...	...	...
79	...	...	...	...	...	...
80	...	...	...	...	...	...
81	...	...	...	...	...	...
82	...	...	...	...	...	...
83	...	...	...	...	...	...
84	...	...	...	...	...	...
85	...	...	...	...	...	...
86	...	...	...	...	...	...
87	...	...	...	...	...	...
88	...	...	...	...	...	...
89	...	...	...	...	...	...
90	...	...	...	...	...	...
91	...	...	...	...	...	...
92	...	...	...	...	...	...
93	...	...	...	...	...	...
94	...	...	...	...	...	...
95	...	...	...	...	...	...
96	...	...	...	...	...	...
97	...	...	...	...	...	...
98	...	...	...	...	...	...
99	...	...	...	...	...	...
100	...	...	...	...	...	...
101	...	...	...	...	...	...
102	...	...	...	...	...	...
103	...	...	...	...	...	...
104	...	...	...	...	...	...
105	...	...	...	...	...	...
106	...	...	...	...	...	...
107	...	...	...	...	...	...
108	...	...	...	...	...	...
109	...	...	...	...	...	...
110	...	...	...	...	...	...
111	...	...	...	...	...	...
112	...	...	...	...	...	...
113	...	...	...	...	...	...
114	...	...	...	...	...	...
115	...	...	...	...	...	...
116	...	...	...	...	...	...
117	...	...	...	...	...	...
118	...	...	...	...	...	...
119	...	...	...	...	...	...
120	...	...	...	...	...	...
121	...	...	...	...	...	...
122	...	...	...	...	...	...
123	...	...	...	...	...	...
124	...	...	...	...	...	...
125	...	...	...	...	...	...
126	...	...	...	...	...	...
127	...	...	...	...	...	...
128	...	...	...	...	...	...
129	...	...	...	...	...	...
130	...	...	...	...	...	...
131	...	...	...	...	...	...
132	...	...	...	...	...	...
133	...	...	...	...	...	...
134	...	...	...	...	...	...
135	...	...	...	...	...	...
136	...	...	...	...	...	...
137	...	...	...	...	...	...
138	...	...	...	...	...	...
139	...	...	...	...	...	...
140	...	...	...	...	...	...
141	...	...	...	...	...	...
142	...	...	...	...	...	...
143	...	...	...	...	...	...
144	...	...	...	...	...	...
145	...	...	...	...	...	...
146	...	...	...	...	...	...
147	...	...	...	...	...	...
148	...	...	...	...	...	...
149	...	...	...	...	...	...
150	...	...	...	...	...	...
151	...	...	...	...	...	...
152	...	...	...	...	...	...
153	...	...	...	...	...	...
154	...	...	...	...	...	...
155	...	...	...	...	...	...
156	...	...	...	...	...	...
157	...	...	...	...	...	...
158	...	...	...	...	...	...
159	...	...	...	...	...	...
160	...	...	...	...	...	...
161	...	...	...	...	...	...
162	...	...	...	...	...	...
163	...	...	...	...	...	...
164	...	...	...	...	...	...
165	...	...	...	...	...	...
166	...	...	...	...	...	...
167	...	...	...	...	...	...
168	...	...	...	...	...	...
169	...	...	...	...	...	...
170	...	...	...	...	...	...
171	...	...	...	...	...	...
172	...	...	...	...	...	...
173	...	...	...	...	...	...
174	...	...	...	...	...	...
175	...	...	...	...	...	...
176	...	...	...	...	...	...
177	...	...	...	...	...	...
178	...	...	...	...	...	...
179	...	...	...	...	...	...
180	...	...	...	...	...	...
181	...	...	...	...	...	...
182	...	...	...	...	...	...
183	...	...	...	...	...	...
184	...	...	...	...	...	...
185	...	...	...	...	...	...
186	...	...	...	...	...	...
187	...	...	...	...	...	...
188	...	...	...	...	...	...
189	...	...	...	...	...	...
190	...	...	...	...	...	...
191	...	...	...	...	...	...
192	...	...	...	...	...	...
193	...	...	...	...	...	...
194	...	...	...	...	...	...
195	...	...	...	...	...	...
196	...	...	...	...	...	...
197	...	...	...	...	...	...
198	...	...	...	...	...	...
199	...	...	...	...	...	...
200	...	...	...	...	...	...
201	...	...	...	...	...	...
202	...	...	...	...	...	...
203	...	...	...	...	...	...
204	...	...	...	...	...	...
205	...	...	...	...	...	...
206	...	...	...	...	...	...
207	...	...	...	...	...	...
208	...	...	...	...	...	...
209	...	...	...	...	...	...
210	...	...	...	...	...	...
211	...	...	...	...	...	...
212	...	...	...	...	...	...
213	...	...	...	...	...	...
214	...	...	...	...	...	...
215	...	...	...	...	...	...
216	...	...	...	...	...	...
217	...	...	...	...	...	...
218	...	...	...	...	...	...
219	...	...	...	...	...	...
220	...	...	...	...	...	...
221	...	...	...	...	...	...
222	...	...	...	...	...	...
223	...	...	...	...	...	...
224	...	...	...	...	...	...
225	...	...	...	...	...	...
226	...	...	...	...	...	...
227	...	...	...	...	...	...
228	...	...	...	...	...	...
229	...	...	...	...	...	...
230	...	...	...	...	...	...
231	...	...	...	...	...	...
232	...	...	...	...	...	...
233	...	...	...	...	...	...
234	...	...	...	...	...	...
235	...	...	...	...	...	...
236	...	...	...	...	...	...
237	...	...	...	...	...	...
238	...	...	...	...	...	...
239	...	...	...	...	...	...
240	...	...	...	...	...	...
241	...	...	...	...	...	...
242	...	...	...	...	...	...
243	...	...	...	...	...	...
244	...	...	...	...	...	...
245	...	...	...	...	...	...
246	...	...	...	...	...	...
247	...	...	...	...	...	...
248	...	...	...	...	...	...
249	...	...	...	...	...	...
250	...	...	...	...	...	...
251	...	...	...	...	...	...
252	...	...	...	...	...	...
253	...	...	...	...	...	...
254	...	...	...	...	...	...
255	...	...	...	...	...	...
256	...	...	...	...	...	...
257	...	...	...	...	...	...
258	...	...	...	...	...	...
259	...	...	...	...	...	...
260	...	...	...	...	...	...
261	...	...	...	...	...	...
262	...	...	...	...	...	...
263	...	...	...	...	...	...
264	...	...	...	...	...	...
265	...	...	...	...	...	...
266	...	...	...	...	...	...
267	...	...	...	...	...	...
268	...	...	...	...	...	...
269	...	...	...	...	...	...
270	...	...	...	...	...	...
271	...	...	...	...	...	...
272	...	...	...	...	...	...
273	...	...	...	...	...	...
274	...	...	...	...	...	...
275	...	...	...	...	...	...
276	...	...	...	...	...	...
277	...	...	...	...	...	...
278	...	...	...	...	...	...
279	...	...	...	...	...	...
280	...	...	...	...	...	...
281	...	...	...	...	...	...
282	...	...	...	...	...	...
283	...	...	...	...	...	...
284	...	...	...	...	...	...
285	...	...	...	...	...	...
286	...	...	...	...	...	...
287	...	...	...	...	...	...
288	...	...	...	...	...	...
289	...	...	...	...	...	...
290	...	...	...	...	...	...
291	...	...	...	...	...	...
292	...	...	...	...	...	...
293	...	...	...	...	...	...
294	...	...	...	...	...	...
295	...	...	...	...	...	...
296	...	...	...	...	...	...
297	...	...	...	...	...	...
298	...	...	...	...	...	...
299	...	...	...	...	...	...
300	...	...	...	...	...	...
301	...	...	...	...	...	...
302	...	...	...	...	...	...
303	...	...	...	...	...	...
304	...	...	...	...	...	...
305	...	...	...	...	...	...
306	...	...	...	...	...	...
307	...	...	...	...	...	...
308	...	...	...	...		

## Sequence ID

	70	80	90	100	110	120
17				KVTFYDKDCCLS	LIKQ	
43				KVTFYDKDCCLS	LIKQ	
44				KVTFYDKDCCLS	LIKQ	
45				KVTFYDKDCCLS	LIKQ	
36				KVTFYDKDCCLS	LIKQ	
39				KVTFYDKDCCLS	LIKQ	
41				KVTFYDKDCCLS	LIKQ	
38				KVYYDKDCCLS	LVQG	
19				KVTFYDKDCCLS	LIXG	
40				KVYYDKDCCLS	LIXG	
42				KVTFYDKDCCLS	LVQG	
37				KVYYDKDCCLS	LVQG	
46				KVTFYDKDCCLS	LVQG	
34				KVTFYDKDCCLS	LVQG	
36			A	KVYYDKDCCLS	LVQG	
33				KVYYDKDCCLS	LVQG	
13				KCTSKIYTNDKMLD	LIXG	
30				TD-AIIVYDKDCCLS	VLDG	
14				A	KVYYDKDCCLS	LVQG
32				A	KVYYDKDCCLS	LVQG
31				V	KVYYDKDCCLS	VLDG
47				A	KVYYDKDCCLS	VLDG
48					KVYYDKDCCLS	LIXG
16						AMGCGSKLGAQWVKAQPSIYHATTYDFDQSYFPEKEMVTSKQHGYIVRQGQMLPFLPKPD

FIG. 9B

### Sequence ID

FIG. 9C

Sequence ID	100	200	300	400	500	600
17	.......	.......	.......	.......	.......	.......
43	~~~VTDVRAAVVKGADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
44	~~~VTUVASAVVAAADLVMI	~~~~PQSGLYKNEVEPDLKGATLAFS	~~~~SIRHYNOVVPK			
45	~~~VADVATAVVAAADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
46	~~~VROUVTRAVVAAADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
35	~~~VAVSIEDAAAGAIVVVM	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
39	~~~VMEVACAVVKGADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
41	~~~VKSUVKRAVVAADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
38	~~~VAVVEEAVVKAADI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
15	~~~VMEVACAVVKGADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
40	~~~VKSUVPEAVVKGADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
42	~~~VTDVSAAVVAAADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
37	~~~TSGVVASAVVAAADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
46	~~~VTDVTRAVVAAADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
34	~~~VLTAAZAAAKKASTLNL	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
36	~~~VRSVKEATKREADYTMIL	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
33	~~~VLTFAEAAAKWADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
13	~~~PLNTKDAVKDAGITI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
30	~~~VATFPGAAACQADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
14	~~~VYEIGEAVVKGADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
32	~~~VTTAAZAAKADVYIMR	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
31	~~~VPSVKEAAKQASTIMM	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
47	~~~VTVVARAAKQADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
48	~~~VRSVKEAVVKGADLVMI	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			
18	~~~VTLGKMRRTIGSCLVILL	~~~~PQSGLYKNSIEPNIKGATLAFS	~~~~SIRHYNOVVPK			

FIG. 9D

## Sequence ID

	250	260	270	280	290	300
17	...	...	...	...	...	...
43	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
44	X----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
36	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
38	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
39	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
41	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
38	S----DLOVEMVKAQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
35	A----DLOVEMVKAQEVKTYFVKG-----CGVPHLKVWVYKSCSABGIRSYATAN					
49	A----DLOVEMIAKQEVKTYFVKG-----CGIPOLENEKODAHEHAKETALSYATAV					
42	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
37	X----DLOVEMVKAQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
46	A----DLOVEMINAPKQEVKTYFVKG-----CGIPOLENEKODAHEHANVVALSYASGV					
34	X----DLOVEMINAPKQEVKTYFVKG-----CGVPHLKVWVYKSCSABGIRSYATAGI					
36	X----GLENENIAEVKTYFVKG-----CGTPCLSKVQDCEKHNKELSYATAV					
33	S----GLENENIAEVKTYFVKG-----CGVPHLKVWVYKSCSABGIRSYATAV					
13	K----DGLVEMINAPKQEVKTYFVKG-----CGVPALVWVYKSCSABGIRSYATAGI					
30	S----DGLVEMVKAQEVKTYFVKG-----CGTPCLSKVQDCEKHNKELSYAKAI					
34	K----DGLVEMVKAQEVKTYFVKG-----CGVPALVWVYKSCSABGIRSYAKAI					
32	S----DGLVEMVKAQEVKTYFVKG-----CGVPHLKVWVYKSCSABGIRSYAKAI					
31	S----DGLVEMVKAQEVKTYFVKG-----CGVPALVWVYKSCSABGIRSYAKGI					
43	A----NVLVEMVKAQEVKTYFVKG-----CGVPALVWVYKSCSABGIRSYAKGI					
48	S----EVNLVEMVKAQEVKTYFVKG-----CGVPALVWVYKSCSABGIRSYAKIV					
18	DPKNEISVIAVCPKCKGSPVRLVYQQKHEVNGACTNSCFXVQDVGKATVQLNSIAL	*	*	*	*	*

FIG. 9E

Sequence ID	310	320	330	340	350	360
11	G	G	G	G	G	G
12	C	C	C	C	C	C
13	G	G	G	G	G	G
14	T	T	T	T	T	T
15	A	A	A	A	A	A
16	G	G	G	G	G	G
17	T	T	T	T	T	T
18	A	A	A	A	A	A
19	C	C	C	C	C	C
20	G	G	G	G	G	G
21	T	T	T	T	T	T
22	A	A	A	A	A	A
23	C	C	C	C	C	C
24	G	G	G	G	G	G
25	T	T	T	T	T	T
26	A	A	A	A	A	A
27	C	C	C	C	C	C
28	G	G	G	G	G	G
29	T	T	T	T	T	T
30	A	A	A	A	A	A
31	C	C	C	C	C	C
32	G	G	G	G	G	G
33	T	T	T	T	T	T
34	A	A	A	A	A	A
35	C	C	C	C	C	C
36	G	G	G	G	G	G
37	T	T	T	T	T	T
38	A	A	A	A	A	A
39	C	C	C	C	C	C
40	G	G	G	G	G	G
41	T	T	T	T	T	T
42	A	A	A	A	A	A
43	C	C	C	C	C	C
44	G	G	G	G	G	G
45	T	T	T	T	T	T
46	A	A	A	A	A	A
47	C	C	C	C	C	C
48	G	G	G	G	G	G
49	T	T	T	T	T	T
50	A	A	A	A	A	A
51	C	C	C	C	C	C
52	G	G	G	G	G	G
53	T	T	T	T	T	T
54	A	A	A	A	A	A
55	C	C	C	C	C	C
56	G	G	G	G	G	G
57	T	T	T	T	T	T
58	A	A	A	A	A	A
59	C	C	C	C	C	C
60	G	G	G	G	G	G
61	T	T	T	T	T	T
62	A	A	A	A	A	A
63	C	C	C	C	C	C
64	G	G	G	G	G	G
65	T	T	T	T	T	T
66	A	A	A	A	A	A
67	C	C	C	C	C	C
68	G	G	G	G	G	G
69	T	T	T	T	T	T
70	A	A	A	A	A	A
71	C	C	C	C	C	C
72	G	G	G	G	G	G
73	T	T	T	T	T	T
74	A	A	A	A	A	A
75	C	C	C	C	C	C
76	G	G	G	G	G	G
77	T	T	T	T	T	T
78	A	A	A	A	A	A
79	C	C	C	C	C	C
80	G	G	G	G	G	G
81	T	T	T	T	T	T
82	A	A	A	A	A	A
83	C	C	C	C	C	C
84	G	G	G	G	G	G
85	T	T	T	T	T	T
86	A	A	A	A	A	A
87	C	C	C	C	C	C
88	G	G	G	G	G	G
89	T	T	T	T	T	T
90	A	A	A	A	A	A
91	C	C	C	C	C	C
92	G	G	G	G	G	G
93	T	T	T	T	T	T
94	A	A	A	A	A	A
95	C	C	C	C	C	C
96	G	G	G	G	G	G
97	T	T	T	T	T	T
98	A	A	A	A	A	A
99	C	C	C	C	C	C
100	G	G	G	G	G	G
101	T	T	T	T	T	T
102	A	A	A	A	A	A
103	C	C	C	C	C	C
104	G	G	G	G	G	G
105	T	T	T	T	T	T
106	A	A	A	A	A	A
107	C	C	C	C	C	C
108	G	G	G	G	G	G
109	T	T	T	T	T	T
110	A	A	A	A	A	A
111	C	C	C	C	C	C
112	G	G	G	G	G	G
113	T	T	T	T	T	T
114	A	A	A	A	A	A
115	C	C	C	C	C	C
116	G	G	G	G	G	G
117	T	T	T	T	T	T
118	A	A	A	A	A	A
119	C	C	C	C	C	C
120	G	G	G	G	G	G
121	T	T	T	T	T	T
122	A	A	A	A	A	A
123	C	C	C	C	C	C
124	G	G	G	G	G	G
125	T	T	T	T	T	T
126	A	A	A	A	A	A
127	C	C	C	C	C	C
128	G	G	G	G	G	G
129	T	T	T	T	T	T
130	A	A	A	A	A	A
131	C	C	C	C	C	C
132	G	G	G	G	G	G
133	T	T	T	T	T	T
134	A	A	A	A	A	A
135	C	C	C	C	C	C
136	G	G	G	G	G	G
137	T	T	T	T	T	T
138	A	A	A	A	A	A
139	C	C	C	C	C	C
140	G	G	G	G	G	G
141	T	T	T	T	T	T
142	A	A	A	A	A	A
143	C	C	C	C	C	C
144	G	G	G	G	G	G
145	T	T	T	T	T	T
146	A	A	A	A	A	A
147	C	C	C	C	C	C
148	G	G	G	G	G	G
149	T	T	T	T	T	T
150	A	A	A	A	A	A
151	C	C	C	C	C	C
152	G	G	G	G	G	G
153	T	T	T	T	T	T
154	A	A	A	A	A	A
155	C	C	C	C	C	C
156	G	G	G	G	G	G
157	T	T	T	T	T	T
158	A	A	A	A	A	A
159	C	C	C	C	C	C
160	G	G	G	G	G	G
161	T	T	T	T	T	T
162	A	A	A	A	A	A
163	C	C	C	C	C	C
164	G	G	G	G	G	G
165	T	T	T	T	T	T
166	A	A	A	A	A	A
167	C	C	C	C	C	C
168	G	G	G	G	G	G
169	T	T	T	T	T	T
170	A	A	A	A	A	A
171	C	C	C	C	C	C
172	G	G	G	G	G	G
173	T	T	T	T	T	T
174	A	A	A	A	A	A
175	C	C	C	C	C	C
176	G	G	G	G	G	G
177	T	T	T	T	T	T
178	A	A	A	A	A	A
179	C	C	C	C	C	C
180	G	G	G	G	G	G
181	T	T	T	T	T	T
182	A	A	A	A	A	A
183	C	C	C	C	C	C
184	G	G	G	G	G	G
185	T	T	T	T	T	T
186	A	A	A	A	A	A
187	C	C	C	C	C	C
188	G	G	G	G	G	G
189	T	T	T	T	T	T
190	A	A	A	A	A	A
191	C	C	C	C	C	C
192	G	G	G	G	G	G
193	T	T	T	T	T	T
194	A	A	A	A	A	A
195	C	C	C	C	C	C
196	G	G	G	G	G	G
197	T	T	T	T	T	T
198	A	A	A	A	A	A
199	C	C	C	C	C	C
200	G	G	G	G	G	G
201	T	T	T	T	T	T
202	A	A	A	A	A	A
203	C	C	C	C	C	C
204	G	G	G	G	G	G
205	T	T	T	T	T	T
206	A	A	A	A	A	A
207	C	C	C	C	C	C
208	G	G	G	G	G	G
209	T	T	T	T	T	T
210	A	A	A	A	A	A
211	C	C	C	C	C	C
212	G	G	G	G	G	G
213	T	T	T	T	T	T
214	A	A	A	A	A	A
215	C	C	C	C	C	C
216	G	G	G	G	G	G
217	T	T	T	T	T	T
218	A	A	A	A	A	A
219	C	C	C	C	C	C
220	G	G	G	G	G	G
221	T	T	T	T	T	T
222	A	A	A	A	A	A
223	C	C	C	C	C	C
224	G	G	G	G	G	G
225	T	T	T	T	T	T
226	A	A	A	A	A	A
227	C	C	C	C	C	C
228	G	G	G	G	G	G
229	T	T	T	T	T	T
230	A	A	A	A	A	A
231	C	C	C	C	C	C
232	G	G	G	G	G	G
233	T	T	T	T	T	T
234	A	A	A	A	A	A
235	C	C	C	C	C	C
236	G	G	G	G	G	G
237	T	T	T	T	T	T
238	A	A	A	A	A	A
239	C	C	C	C	C	C
240	G	G	G	G	G	G
241	T	T	T	T	T	T
242	A	A	A	A	A	A
243	C	C	C	C	C	C
244	G	G	G	G	G	G
245	T	T	T	T	T	T
246	A	A	A	A	A	A
247	C	C	C	C	C	C
248	G	G	G	G	G	G
249	T	T	T	T	T	T
250	A	A	A	A	A	A
251	C	C	C	C	C	C
252	G	G	G	G	G	G
253	T	T	T	T	T	T
254	A	A	A	A	A	A
255	C	C	C	C	C	C
256	G	G	G	G	G	G
257	T	T	T	T	T	T
258	A	A	A	A	A	A
259	C	C	C	C	C	C
260	G	G	G	G	G	G
261	T	T	T	T	T	T
262	A	A	A	A	A	A
263	C	C	C	C	C	C
264	G	G	G	G	G	G
265	T	T	T	T	T	T
266	A	A	A	A	A	A
267	C	C	C	C	C	C
268	G	G	G	G	G	G
269	T	T	T	T	T	T
270	A	A	A	A	A	A
271	C	C	C	C	C	C
272	G	G	G	G	G	

### Sequence ID

FIG. 9G

### Sequence ID

FIG. 9H

Sequence ID	490	500	510	520	530	540
1.7						
4.3						
4.4						
4.6						
4.7						
4.8						
4.9						
4.10						
4.11						
4.12						
4.13						
4.14						
4.15						
4.16						
4.17						
4.18						
4.19						
4.20						
4.21						
4.22						
4.23						
4.24						
4.25						
4.26						
4.27						
4.28						
4.29						
4.30						
4.31						
4.32						
4.33						
4.34						
4.35						
4.36						
4.37						
4.38						
4.39						
4.40						
4.41						
4.42						
4.43						
4.44						
4.45						
4.46						
4.47						
4.48						
4.49						
4.50						
4.51						
4.52						
4.53						
4.54						
4.55						
4.56						
4.57						
4.58						
4.59						
4.60						
4.61						
4.62						
4.63						
4.64						
4.65						
4.66						
4.67						
4.68						
4.69						
4.70						
4.71						
4.72						
4.73						
4.74						
4.75						
4.76						
4.77						
4.78						
4.79						
4.80						
4.81						
4.82						
4.83						
4.84						
4.85						
4.86						
4.87						
4.88						
4.89						
4.90						
4.91						
4.92						
4.93						
4.94						
4.95						
4.96						
4.97						
4.98						
4.99						
4.100						
4.101						
4.102						
4.103						
4.104						
4.105						
4.106						
4.107						
4.108						
4.109						
4.110						
4.111						
4.112						
4.113						
4.114						
4.115						
4.116						
4.117						
4.118						
4.119						
4.120						
4.121						
4.122						
4.123						
4.124						
4.125						
4.126						
4.127						
4.128						
4.129						
4.130						
4.131						
4.132						
4.133						
4.134						
4.135						
4.136						
4.137						
4.138						
4.139						
4.140						
4.141						
4.142						
4.143						
4.144						
4.145						
4.146						
4.147						
4.148						
4.149						
4.150						
4.151						
4.152						
4.153						
4.154						
4.155						
4.156						
4.157						
4.158						
4.159						
4.160						
4.161						
4.162						
4.163						
4.164						
4.165						
4.166						
4.167						
4.168						
4.169						
4.170						
4.171						
4.172						
4.173						
4.174						
4.175						
4.176						
4.177						
4.178						
4.179						
4.180						
4.181						
4.182						
4.183						
4.184						
4.185						
4.186						
4.187						
4.188						
4.189						
4.190						
4.191						
4.192						
4.193						
4.194						
4.195						
4.196						
4.197						
4.198						
4.199						
4.200						
4.201						
4.202						
4.203						
4.204						
4.205						
4.206						
4.207						
4.208						
4.209						
4.210						
4.211						
4.212						
4.213						
4.214						
4.215						
4.216						
4.217						
4.218						
4.219						
4.220						
4.221						
4.222						
4.223						
4.224						
4.225						
4.226						
4.227						
4.228						
4.229						
4.230						
4.231						
4.232						
4.233						
4.234						
4.235						
4.236						
4.237						
4.238						
4.239						
4.240						
4.241						
4.242						
4.243						
4.244						
4.245						
4.246						
4.247						
4.248						
4.249						
4.250						
4.251						
4.252						
4.253						
4.254						
4.255						
4.256						
4.257						
4.258						
4.259						
4.260						
4.261						
4.262						
4.263						
4.264						
4.265						
4.266						
4.267						
4.268						
4.269						
4.270						
4.271						
4.272						
4.273						
4.274						
4.275						
4.276						
4.277						
4.278						
4.279						
4.280						
4.281						
4.282						
4.283						
4.284						
4.285						
4.286						
4.287						
4.288						
4.289						
4.290						
4.291						
4.292						
4.293						
4.294						
4.295						
4.296						
4.297						
4.298						
4.299						
4.300						
4.301						
4.302						
4.303						
4.304						
4.305						
4.306						
4.307						
4.308						
4.309						
4.310						
4.311						
4.312						
4.313						
4.314						
4.315						
4.316						
4.317						
4.318						
4.319						
4.320						
4.321						
4.322						



६७

17  
18 3  
19 4  
20 5  
21 6  
22 7  
23 8  
24 9  
25 10  
26 11  
27 12  
28 13  
29 14  
30 15  
31 16  
32 17  
33 18  
34 19  
35 20  
36 21  
37 22  
38 23  
39 24  
40 25  
41 26  
42 27  
43 28  
44 29  
45 30  
46 31  
47 32  
48 33  
49 34  
50 35  
51 36  
52 37  
53 38  
54 39  
55 40  
56 41  
57 42  
58 43  
59 44  
60 45  
61 46  
62 47  
63 48  
64 49  
65 50  
66 51  
67 52  
68 53  
69 54  
70 55  
71 56  
72 57  
73 58  
74 59  
75 60  
76 61  
77 62  
78 63  
79 64  
80 65

**WORKS**

EIC: 9X

\*->qMfafafkVTVYDKDadlsGhdeylikGKleVA+Ic+GS+GKAKN+GILrD  
M KV+YI+D+dls +i+GKkVA+IKQGSQ3HAA+N+NL+D  
Sequence 10 17 1 -M----KVTVYDKDadls-----IKQGSQ3HAA+N+NL+D 37

SCVdVvVGD~~W~~dk~~W~~dkAea~~G~~kVktv~~a~~AVa+qADvV*m*ilPDefQae  
SCVdVv+VQ~~U~~dk~~W~~dkAea+G+kV +va A*v*a+AD+V*m*il+PDefQ++  
Sequence 10 17 38 SCVdVTV*m*ilPDefQae~~W~~dk~~W~~dkAea~~G~~kVtDVA+AVAGADLVMIITPDRFQSQ 87

vfeeeelepsLkypGatLaFAHGPNINHf~~W~~dvPrafPKDIDVINVAPKgPGH  
+Y++eIegn+k+NatLaP+KGY+IH+e+e+vPra D+DVIM+APK+PGH  
Sequence 10 17 69 LYKNEZIEPNIKNEGATIAFSGHGPAINHYC~~W~~VFR~~A~~--DLDVINTIAFRAAPGK 134

tVRR+eYvkGgGV~~P~~+LiAVyQ~~Q~~asGnAk+dIALsYA~~Q~~gGggRAG+IETTFK  
tVRR+e+vkGgG+P+LiA+yQ~~Q~~asGnAk++ALsYA+g+GggR+G+IETTFK  
Sequence 10 17 135 tVRRGFVYKGGGIFDILIAIYQ~~Q~~NSCNAXKVALSYA~~Q~~NGGSGTGIETTFK 184

eETETDLYGEGQaVLCCG~~G~~yteLVkaGFTETLV~~B~~aGY+P~~E~~mA~~Y~~F~~E~~CLHELKL  
+ETETDLYGEGQaVLCCG~~G~~yteLVkaGFTETLV~~B~~aGY+P~~E~~mA~~Y~~F~~E~~CLHELKL  
Sequence 10 17 185 DETETDLYGEGQaVLCCG~~G~~yteLVkaGFTETLV~~B~~aGY+P~~E~~mA~~Y~~F~~E~~CLHELKL 234

FIG. 10A

VDLayTEgGlanMrySISdTAsYQdyvtGprVIdseskeaNkevlkdlIQsG  
VDLayTEgGlanM+ySIS++AeTG+yvtGp+VI+++es++eM+++lk+IQ+G

Sequence 10 17 235 VDLayTEgGlanM+ySIS++AeTG+yvtGp+VI+++es++eM+++lk+IQ+G 284

eFAkewilEagaGyPketltalrrnsaeRqIXWkVGeklRsmmpWiaanK  
e+Ak++i+E++GyP ++ta xxn+s+R IE +Ge+LksmmpWI anK

Sequence 10 17 285 EYAKMPFSEGATGYP--SMTAXRRNNAANGIE-IIGSQLASMMFWIGANK 331

lvdkkdkncc-\*  
\*vdkkkn

Sequence 10 17 331 IVOKAKN 338

FIG. 108

Fig. 11A




Fig. 11B

Mutant	24	33	47	50	52	53	61	80	156
16445E4		L	P	V	D	G	F	I	V
16468D7	F	L	T	I	D	R	F	I	V
16469F3		L	E	A	D	A	F	I	
JB1C6	F	L	H	D	Y	Y	F	I	V

█ the cofactor specificity domain


∅ the cofactor binding affinity domain

Fig. 12B



the cofactor binding affinity domain

Fig. 12A



the cofactor specificity domain

Fig. 12C

Combining mutations in the cofactor binding affinity domain with mutations in the cofactor specificity determining domain

Fig. 12D

Mutant	24	33	47	50	52	53	61	80	156 (NADH)
JEA7	F	L	P	N	D	A	F	I	V
JED1	L	N	N	N	D	A	F	I	V
JEA1	F	L	P	F	D		F	I	V
JEG2	F	L	F	A	D	A	F	I	V
JEG4	F	L	N	N	D	A	F	I	V

Mutants with highly improved Km

## 1

**KETOL-ACID REDUCTOISOMERASE USING  
NADH**

This application is a continuation of U.S. Ser. No. 12/637, 905, filed Dec. 15, 2009, which is a continuation-in-part of U.S. Ser. No. 12/337,736, filed Dec. 18, 2008, now U.S. Pat. No. 8,129,162, and claims the benefit of the U.S. Provisional Applications 61/015,346, filed Dec. 20, 2007, and 61/109, 297, filed Oct. 29, 2008.

**FIELD OF THE INVENTION**

The invention relates to protein evolution. Specifically, ketol-acid reductoisomerase enzymes have been evolved to use the cofactor NADH instead of NADPH.

**BACKGROUND OF THE INVENTION**

Ketol-acid reductoisomerase enzymes are ubiquitous in nature and are involved in the production of valine and isoleucine, pathways that may affect the biological synthesis of isobutanol. Isobutanol is specifically produced from catabolism of L-valine as a by-product of yeast fermentation. It is a component of "fusel oil" that forms as a result of incomplete metabolism of amino acids by yeasts. After the amine group of L-valine is harvested as a nitrogen source, the resulting  $\alpha$ -keto acid is decarboxylated and reduced to isobutanol by enzymes of the Ehrlich pathway (Dickinson, et al., *J. Biol. Chem.*, 273: 25752-25756, 1998).

Addition of exogenous L-valine to the fermentation increases the yield of isobutanol, as described by Dickinson et al., *supra*, wherein it is reported that a yield of isobutanol of 3 g/L is obtained by providing L-valine at a concentration of 20 g/L in the fermentation. In addition, production of n-propanol, isobutanol and isoamylalcohol has been shown by calcium alginate immobilized cells of *Zymomonas mobilis* (Oaxaca, et al., *Acta Biotechnol.*, 11: 523-532, 1991).

An increase in the yield of C3-C5 alcohols from carbohydrates was shown when amino acids leucine, isoleucine, and/or valine were added to the growth medium as the nitrogen source (WO 2005040392).

While methods described above indicate the potential of isobutanol production via biological means these methods are cost prohibitive for industrial scale isobutanol production. The biosynthesis of isobutanol directly from sugars would be economically viable and would represent an advance in the art. However, to date the only ketol-acid reductoisomerase (KARI) enzymes known are those that bind NADPH in its native form, reducing the energy efficiency of the pathway. A KARI that would bind NADH would be beneficial and enhance the productivity of the isobutanol biosynthetic pathway by capitalizing on the NADH produced by the existing glycolytic and other metabolic pathways in most commonly used microbial cells. The discovery of a KARI enzyme that can use NADH as a cofactor as opposed to NADPH would be an advance in the art.

The evolution of enzymes having specificity for the NADH cofactor as opposed to NADPH is known for some enzymes and is commonly referred to as "cofactor switching". See for example Eppink, et al. (*J. Mol. Biol.*, 292: 87-96, 1999), describing the switching of the cofactor specificity of strictly NADPH-dependent p-Hydroxybenzoate hydroxylase (PHBH) from *Pseudomonas fluorescens* by site-directed mutagenesis; and Nakanishi, et al., (*J. Biol. Chem.*, 272: 2218-2222, 1997), describing the use of site-directed mutagenesis on a mouse lung carbonyl reductase in which Thr-38 was replaced by Asp (T38D) resulting in an enzyme

## 2

having a 200-fold increase in the  $K_M$  values for NADP(H) and a corresponding decrease of more than 7-fold in those for NAD(H). Co-factor switching has been applied to a variety of enzymes including monooxygenases, (Kamerbeek, et al., *Eur. J. Biochem.*, 271: 2107-2116, 2004); dehydrogenases; Nishiyama, et al., *J. Biol. Chem.*, 268: 4656-4660, 1993; Ferredoxin-NADP reductase, Martinez-Julyez, et al., *Bioophys. Chem.*, 115: 219-224, 2005); and oxidoreductases (US2004/0248250).

Rane et al., (*Arch. Biochem. Biophys.*, 338: 83-89, 1997) discuss cofactor switching of a ketol acid reductoisomerase isolated from *E. coli* by targeting four residues in the enzyme for mutagenesis, (R68, K69, K75, and R76); however the effectiveness of this method is in doubt.

Although the above cited methods suggest that it is generally possible to switch the cofactor specificity between NADH and NADPH, the methods are enzyme specific and the outcomes unpredictable. The development of a ketol-acid reductoisomerase having a high specificity for NADH with decreased specificity for NADPH would greatly enhance this enzyme's effectiveness in the isobutanol biosynthetic pathway and hence increase isobutanol production. However, no such KARI enzyme has been reported.

**SUMMARY OF THE INVENTION**

Applicants have solved the stated problem by identifying a number of mutant ketol-acid reductoisomerase enzymes that either have a preference for specificity for NADH as opposed to NADPH or use NADH exclusively in their reaction. The method involves mutagenesis of certain specific residues in the KARI enzyme to produce the co-factor switching.

Accordingly the invention provides A mutant ketol-acid reductoisomerase enzyme comprising the amino acid sequence as set forth in SEQ ID NO: 29; a nucleic acid molecule encoding a mutant ketol-acid reductoisomerase enzyme having the amino acid sequence as set forth in SEQ ID NO:19; a mutant ketol-acid reductoisomerase enzyme as set for in SEQ ID NO:19; a mutant ketol-acid reductoisomerase enzyme having the amino acid sequence selected from the group consisting of SEQ ID NO: 24, 25, 26, 27, 28, 67, 68, 70, 75, 79, 80, 81 and 82; and a mutant ketol-acid reductoisomerase enzyme as set forth in SEQ ID NO:17 comprising at least one mutation at a residue selected from the group consisting of 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, 165, and 170.

In another embodiment the invention provides a method for the evolution of an NADPH binding ketol-acid reductoisomerase enzyme to an NADH using form comprising:

- providing a ketol-acid reductoisomerase enzyme which uses NADPH having a specific native amino acid sequence;
- identifying the cofactor switching residues in the enzyme of (a) based on the amino acid sequence of the *Pseudomonas fluorescens* ketol-acid reductoisomerase enzyme as set for the in SEQ ID NO:17 wherein the cofactor switching residues are at positions selected from the group consisting of: 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, 165, and 170; and
- creating mutations in at least one of the cofactor switching residues of (b) to create a mutant enzyme wherein said mutant enzyme binds NADH.

In another embodiment the invention provides a method for the production of isobutanol comprising:

- providing a recombinant microbial host cell comprising the following genetic constructs:

- i) at least one genetic construct encoding an acetolactate synthase enzyme for the conversion of pyruvate to acetolactate;
- ii) at least one genetic construct encoding a ketol-acid reductoisomerase enzyme of either of claims 1 or 6;
- iii) at least one genetic construct encoding an acetylhydroxy acid dehydratase for the conversion of 2,3-dihydroxyisovalerate to  $\alpha$ -ketoisovalerate, (pathway step c);
- iv) at least one genetic construct encoding a branched-chain keto acid decarboxylase, of the conversion of  $\alpha$ -ketoisovalerate to isobutyraldehyde, (pathway step d);
- v) at least one genetic construct encoding a branched-chain alcohol dehydrogenase for the conversion of isobutyraldehyde to isobutanol (pathway step e); and
- b) growing the host cell of (a) under conditions where iso-butanol is produced.

In another embodiment the invention provides a method for the evolution and identification of an NADPH binding ketol-acid reductoisomerase enzyme to an NADH using form comprising:

- a) providing a ketol-acid reductoisomerase enzyme which uses NADPH having a specific native amino acid sequence;
- b) identifying the amino acid residues in the native amino acid sequence whose side chains are in close proximity to the adenosyl 2'-phosphate of NADPH as mutagenesis targets;
- c) creating a library of mutant ketol-acid reductoisomerase enzymes from the class I ketol-acid reductoisomerase enzyme of step (a), having at least one mutation in at least one of the mutagenesis target sites of step (b); and
- d) screening the library of mutant ketol-acid reductoisomerase enzymes of step (c) to identify NADH binding mutant of ketol-acid reductoisomerase enzyme.

Alternatively the invention provides a method for evolution of an NADPH specific ketol-acid reductoisomerase enzyme to an NADH using form comprising:

- a) providing a mutant enzyme having an amino acid sequence selected from the group consisting of SEQ ID NOs: 28, 67, 68, 69, 70, and 84;
- b) constructing a site-saturation library targeting amino acid positions 47, 50, 52 and 53 of the mutant enzyme of (a); and
- c) screening the site-saturation library of (b) to identify mutants which accept NADH instead of NADPH as cofactor.

Similarly the invention provides a method for evolution of an NADPH specific ketol-acid reductoisomerase enzyme to an NADH using form comprising:

- a) providing a DNA fragment encoding a mutant enzyme having an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, and 98 containing mutations in cofactor specificity domain;
- b) producing a DNA fragment cofactor specificity domain of (a);
- c) providing a DNA fragment encoding a mutant enzyme having mutations in cofactor binding affinity domain selected from the group consisting of SEQ ID NOs: 28, 67, 68, 69, 70, 84 and 86;
- d) incorporating mutations of step (b) into mutants of step (c); and
- e) screening mutants of step (d) for mutant enzymes having a ratio of NADH/NADPH utilization is greater than one.

#### BRIEF DESCRIPTION OF THE FIGURES AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description, the Figures, and the accompanying sequence descriptions, which form part of this application.

FIGS. 1A and 1B—Show four different isobutanol biosynthetic pathways. The steps labeled “a”, “b”, “c”, “d”, “e”, “f”, “g”, “h”, “i”, “j” and “k” represent the substrate to product conversions described below.

FIGS. 2A and 2B—Multiple sequence alignment (MSA) of KARI enzymes from different resources; FIG. 2A—MSA among three NADPH-requiring KARI enzymes; FIG. 2B—MSA among PF5-KARI and other KARI enzymes, with promiscuous nucleotide specificity, where, MMC5—is from *Methanococcus maripaludis* C5; MMS2—is from *Methanococcus maripaludis* S2; MNSB—is from *Methanococcus vanniellii* SB; ilv5—is from *Saccharomyces cerevisiae* ilv5; KARI-D1—is from *Sulfolobus solfataricus* P2 ilvC; KARI-D2—is from *Pyrobaculum aerophilum* P2ilvC; and KARI S1—is from *Ralstonia solanacearum* GMI1000 ilvC.

FIG. 3—Interaction of phosphate binding loop with NADPH based on homology modeling.

FIG. 4—KARI activities of top performers from library C using cofactor NADH versus NADPH. Activity and standard deviation were derived from triple experiments. The mutation information is as follows: C3A7=R47Y/S50A/T52D/V53W; C3A10=R47Y/S50A/T52G/V53W; C3B11=R47F/S50A/T52D/V53W; C3C8=R47G/S50M/T52D/V53W; and C4D12=R47c/S50MT52D/V53W

FIGS. 5A and 5B—FIG. 5A—Comparison of KARI activities of top performers from libraries E, F and G using cofactors NADH and NADPH. FIG. 5B—KARI activities of positive control versus wild type Pf5-ilvC using cofactors NADH. Activity and standard deviation were derived from at least three parallel experiments. “Wt” represents the wild type of Pf5-ilvC and “Neg” means negative control. Experiments for NADH and NADPH reactions in FIG. 5A were 30 min; in FIG. 5B were 10 min.

FIG. 6—Activities of top performers from library H using cofactors NADH versus NADPH. Activity and standard deviation were derived from triple experiments. Mutation information is as follows: 24F9=R47P/S50G/T52D; 68F10=R47P/T52S; 83G10=R47P/S50D/T52S; 39G4=R47P/S50C/T52D; 91A9=R47P/S50CT52D; and C3B11=R47F/S50A/T52D/V53W and Wt is wild type.

FIG. 7—Thermostability of wild type PF5-ilvC. The remaining activity of the enzyme after heating at certain temperatures for 10 min was the average number of triple experiments and normalized to the activity measured at room temperature.

FIG. 8—Multiple DNA sequence alignment among 5 naturally existing KARI molecules. The positions both bolded and boxed were identified by error prone PCR and the positions only boxed were targeted for mutagenesis.

FIGS. 9A through 9k—Alignment of the twenty-four functionally verified KARI sequences. The GxGXX(G/A) motif involved in the binding of NAD(P)H is indicated below the alignment.

FIGS. 10A and 10B—An example of the alignment of *Pseudomonas fluorescens* Pf-5 KARI to the profile HMM of KARI. The eleven positions that are responsible for co-factor switching are boxed.

FIG. 11A is a linear depiction of the KARI amino acid sequence with specific amino acids numbered. The cofactor specificity domain residues are shown in shaded rectangles.

The cofactor binding domain is shown in dotted ovals. FIG. 11B is a table that shows changed amino acids, using single letter code, at numbered positions in four KARI mutants.

FIG. 12A is a linear depiction of the KARI amino acid sequence. The cofactor specificity domain residues are shown in shaded rectangles. FIG. 12B is a linear depiction of the KARI amino acid sequence with specific amino acids of the cofactor binding domain shown in dotted ovals. FIG. 12C depicts incorporation of the domain swapping library into the mutants containing  $K_M$  improving mutations. FIG. 12D is a table summarizing the  $K_M$  values for NADH for mutations resulting from combining mutations in the cofactor binding affinity domain with mutations in the cofactor specificity determining domain.

Table 9—is a table of the Profile HMM of the KARI enzymes described in Example 3. The eleven positions in the

profile HMM representing the columns in the alignment which correspond to the eleven cofactor switching positions in *Pseudomonas fluorescens* Pf-5 KARI are identified as positions 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, and 170. The lines corresponding to these positions in the model file are highlighted in yellow. Table 9 is submitted herewith electronically and is incorporated herein by reference.

The following sequences conform with 37 C.F.R. 1.821-1.825 (“Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures—the Sequence Rules”) and are consistent with the World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37C.F.R. §1.822.

TABLE 1

Oligonucleotide Primers Used In This Invention		
SEQUENCE ID No.	SEQUENCE	Description
1	TGATGAACATCTCGCGTATTGCCGTCT	Reverse Primer for pBAD vector
2	GCGTAGACGTGACTGTTGGCTGNNTAAAGGCNN GGCTNNCTGGGCCAAGGCT GAAGCCCACGGCTTG	Forward primer library C
3	GCGTAGACGTGACTGTTGGCTGNNTAAAGGCTCG GCTACCGTTGCCAAGGCTGAAGCCCACGGCTTG	Forward primer for library E
4	GCGTAGACGTGACTGTTGGCTCGCTAAAGGCNN GCTACCGTTGCCAAGGCTGAAGCCCACGGCTTG	Forward primer for library F
5	GCGTAGACGTGACTGTTGGCTCGTAAAGGCTCG GCTNNNTGGCAAGGCTGAAGCCCACGGCTTG	Forward primer for library G
6	GCGTAGACGTGACTGTTGGCTGNNTAAAGGCNN GCTNNNTGGCAAGGCTGAAGCCCACGGCTTG	Forward primer for library H
7	AAGATTAGCGGATCCTACCT	Sequencing primer (forward)
8	AACAGCCAAGCTTTAGTTC	Sequencing primer (reverse)
20	CTCTCTACTGTTCTCCATACCG	pBAD_266-021308f
21	CAAGCCGTGGGCTTCAGCCTTGGCKNN	PF5_53Mt022908r
22	CGGTTTCAGTCAGTCGCTTGAAG	pBAD_866-021308
49	GCTCAAGCANNKAACCTGAAGG	pBAD-405-C33_090808f
50	CCTTCAGGTTKNNTGCTTGAGC	pBAD-427-C33_090808r
51	GTAGACGTGNNKGTTGGCTG	pBAD-435-T43_090808f
52	CAGGCCAACNNCACGTCTAC	pBAD-456-T43_090808r
53	CTGAAGCCNNKGGCNNKAAAGTGAC	pBAD-484-H59L61_090808f
54	GTCACTTKNNNCCKNNGGCTTCAG	pBAD-509-H59L61_090808r
55	GCAGCCGTTNNKGTCGCCACT	pBAD-519-A71_090808f
56	AGTCGGCACCKNNAACGGCTGC	pBAD-541-A71_090808r

TABLE 1-continued

Oligonucleotide Primers Used In This Invention		
SEQUENCE ID No.	SEQUENCE	Description
57	CATGATCCTGNNKCCGGACGAG	pBAD-545-T80_090808f
58	CTCGTCCGGKNNCAGGATCATG	pBAD-567-T80_090808r
59	CAAGAAGGGCNNKACTCTGGCCT	pBAD-608-A101_090808f
60	AGGCCAGAGTKNNNGCCCTCTTG	pBAD-631-A101_090808r
61	GTTGTGCCTNNKGCCGACCTCG	pBAD-663-R119_090808f
62	CGAGGTCGGCKNNAGGCACAAC	pBAD-685-R119_090808r
71	GTAGACGTGACTGTTGGCTGNNKAAAGGCNNKGC TNNKNNKGCCAAGGCTGAAGCCCACGG	PF5_4Mt111008.f
72	CCGTGGGCTTCAGCCTTGGCKNNKNNAGCKNNGC CTTTKNNCAGGCCAACAGTCACGTCTAC	PF5_4Mt111008.r
73	AAGATTAGCGGATCCTACCT	pBAD_230.f
74	GAGTGGCGCCCTTCTGATGTTCG	pBAD_601_021308r

Additional sequences used in the application are listed below. The abbreviated gene names in bracket are used in this disclosure.

SEQ ID NO: 9—*Methanococcus maripaludis* C5-ilvC (MMC5)—GenBank Accession Number NC\_009135.1 Region: 901034.902026

SEQ ID NO: 10 is the *Methanococcus maripaludis* S2-ilvC (MMS2)—GenBank Accession Number NC\_005791.1 Region: 645729.646721

SEQ ID NO: 11 is the *Methanococcus vannielii* SB-ilv5 (MVSB)—GenBank Accession Number NZ\_AAWX01000002.1 Region: 302214.303206

SEQ ID NO: 12 is the *Saccharomyces cerevisiae* ilv5 (ilv5)—GenBank Accession Number NC\_001144.4 Region: 838065.839252

SEQ ID NO: 13 is the *Sulfolobus solfataricus* P2 ilvC (KARI-D1)—GenBank Accession Number NC\_002754.1 Region: 506253.507260

SEQ ID NO: 14 is the *Pyrobaculum aerophilum* str. IM2 ilvC (KARI-D2)—GenBank Accession Number NC\_003364.1 Region: 1976281.1977267

SEQ ID NO: 15 is the *Ralstonia solanacearum* GMI1000 ilvC (KARI-S1)—GenBank Accession Number NC\_003295.1 Region: 2248264.2249280

SEQ ID NO: 16 is the *Pseudomonas aeruginosa* PAO1 ilvC—GenBank Accession Number NC\_002516 Region: 5272455.5273471

SEQ ID NO: 17 is the *Pseudomonas fluorescens* PF5 ilvC—GenBank Accession Number NC\_004129 Region: 6017379.6018395

SEQ ID NO: 18 is the *Spinacia oleracea* ilvC (Spinach-KARI)—GenBank Accession Number NC\_002516 Region: 1.2050.

SEQ ID NO: 19 is the amino acid sequence of the mutant (Y24F/R47Y/S50A/T52D/V53A/L61F/G170A) of the ilvC native protein of *Pseudomonas fluorescens*.

SEQ ID NO: 23 is the DNA SEQ of the mutant (Y24F/R47Y/S50A/T52D/V53A/L61F/G170A) of the ilvC native protein of *Pseudomonas fluorescens*.

SEQ ID NO: 24 is the amino acid SEQ of the mutant ZB1 (Y24F/R47Y/S50A/T52D/V53A/L61F/A156V)

SEQ ID NO: 25 is the amino acid SEQ of the mutant ZF3 (Y24F/C33L/R47Y/S50A/T52D/V53A/L61F)

SEQ ID NO: 26 is the amino acid SEQ of the mutant ZF2 (Y24F/C33L/R47Y/S50A/T52D/V53A/L61F/A156V)

SEQ ID NO: 27 is the amino acid SEQ of the mutant ZB3 (Y24F/C33L/R47Y/S50A/T52D/V53A/L61F/G170A)

SEQ ID NO: 28 is the amino acid SEQ of the mutant Z4B8 (C33L/R47Y/S50A/T52D/V53A/L61F/T80I/A156V/G170A)

SEQ ID NO: 29 is a consensus amino acid sequence comprising all experimentally verified KARI point mutations as based on SEQ ID NO:17.

SEQ ID NO: 30 is the amino acid sequence for KARI from *Natronomonas pharaonis* DSM 2160

SEQ ID NO: 31 is the amino acid sequence for KARI from *Bacillus subtilis* subsp. *subtilis* str. 168

SEQ ID NO: 32 is the amino acid sequence for KARI from *Corynebacterium glutamicum* ATCC13032

SEQ ID NO: 33 is the amino acid sequence for KARI from *Phaeospirillum molischianum*

SEQ ID NO: 34 is the amino acid sequence for KARI from *Zymomonas mobilis* subsp. *mobilis* ZM4

SEQ ID NO: 35 is the amino acid sequence for KARI *Alkalilimnicola ehrlichei* MLHE-1

SEQ ID NO: 36 is the amino acid sequence for KARI from *Campylobacter lari* RM2100

SEQ ID NO: 37 is the amino acid sequence for KARI from *Marinobacter aquaeolei* VT8

SEQ ID NO: 38 is the amino acid sequence for KARI *Psychrobacter arcticus* 273-4

SEQ ID NO: 39 is the amino acid sequence for KARI from *Hahella chejuensis* KCTC2396  
 SEQ ID NO: 40 is the amino acid sequence for KARI from *Thiobacillus denitrificans* ATCC25259  
 SEQ ID NO: 41 is the amino acid sequence for KARI from *Azotobacter vinelandii* AvOP  
 SEQ ID NO: 42 is the amino acid sequence for KARI from *Pseudomonas syringae* pv. *syringae* B728a  
 SEQ ID NO: 43 is the amino acid sequence for KARI from *Pseudomonas syringae* pv. tomato str. DC3000  
 SEQ ID NO: 44 is the amino acid sequence for KARI from *Pseudomonas putida* KT2440  
 SEQ ID NO: 45 is the amino acid sequence for KARI from *Pseudomonas entomophila* L48  
 SEQ ID NO: 46 is the amino acid sequence for KARI from *Pseudomonas mendocina* ymp  
 SEQ ID NO: 47 is the amino acid sequence for KARI from *Bacillus cereus* ATCC10987 NP\_977840.1  
 SEQ ID NO: 48 is the amino acid sequence for KARI from *Bacillus cereus* ATCC10987 NP\_978252.1  
 SEQ ID NO: 63 is the amino acid sequence for KARI from *Escherichia coli*—GenBank Accession Number P05793  
 SEQ ID NO: 64 is the amino acid sequence for KARI from Marine Gamma *Proteobacterium* HTCC2207—GenBank Accession Number ZP\_01224863.1  
 SEQ ID NO: 65 is the amino acid sequence for KARI from *Desulfuromonas acetoxidans*—GenBank Accession Number ZP\_01313517.1  
 SEQ ID NO: 66 is the amino acid sequence for KARI from *Pisum sativum* (Pea)—GenBank Accession Number O82043  
 SEQ ID NO: 67 is the amino acid sequence for mutant 3361G8 (C33L/R47Y/S50A/T52D/V53A/L61F/T80I)  
 SEQ ID NO: 68 is the amino acid sequence for mutant 2H10 (Y24F/C33L/R47Y/S50A/T52D/V53I/L61F/T80I/A156V)  
 SEQ ID NO: 69 is the amino acid sequence for mutant 1D2 (Y24F/R47Y/S50A/T52D/V53A/L61F/T80I/A156V).  
 SEQ ID NO: 70 is the amino acid sequence for mutant 3F12 (Y24F/C33L/R47Y/S50A/T52D/V53A/L61F/T80I/A156V).  
 SEQ ID NO: 75 is the amino acid sequence for mutant JB1C6 (Y24F/C33L/R47H/S50D/T52Y/V53Y/L61F/T80I/A156V)  
 SEQ ID NO: 76 is the amino acid sequence for mutant 16445E4 (C33L/R47P/S50V/T52D/V53G/L61F/T80I/A156V)  
 SEQ ID NO: 77 is the amino acid sequence for mutant 16468D7 (Y24F/C33L/R47T/S50I/T52D/V53R/L61F/T80I/A156V)  
 SEQ ID NO: 78 is the amino acid sequence for mutant 16469F3 (C33L/R47E/S50A/T52D/V53A/L61F/T80I)  
 SEQ ID NO: 79 is the amino acid sequence for mutant JEA1 (Y24F/C33L/R47P/S50F/T52D/L61F/T80I/A156V)  
 SEQ ID NO: 80 is the amino acid sequence for mutant JEG2 (Y24F/C33L/R47F/S50A/T52D/V53A/L61F/T80I/A156V)  
 SEQ ID NO: 81 is the amino acid sequence for mutant JEG4 (Y24F/C33L/R47N/S50N/T52D/V53A/L61F/T80I/A156V)  
 SEQ ID NO: 82 is the amino acid sequence for mutant JEA7 (Y24F/C33L/R47P/S50N/T52D/V53A/L61F/T80I/A156V)  
 SEQ ID NO: 83 is the amino acid sequence for mutant JED1 (C33L/R47N/S50N/T52D/V53A/L61F/T80I/A156V)  
 SEQ ID NO: 84 is the amino acid sequence for mutant 3361E1

SEQ ID NO: 85 is the amino acid sequence for mutant C2F6  
 SEQ ID NO: 86 is the amino acid sequence for mutant C3B11  
 SEQ ID NO: 87 is the amino acid sequence for mutant C4D12  
 SEQ ID NO: 88 is the amino acid sequence for mutant SE1  
 SEQ ID NO: 89 is the amino acid sequence for mutant SE2  
 SEQ ID NO: 90 is the amino acid sequence for mutant SB3  
 SEQ ID NO: 91 is the amino acid sequence for mutant SD3  
 SEQ ID NO: 92 is the amino acid sequence for mutant 9650E5  
 SEQ ID NO: 93 is the amino acid sequence for mutant 9667A11  
 SEQ ID NO: 94 is the amino acid sequence for mutant 9862B9  
 SEQ ID NO: 95 is the amino acid sequence for mutant 9875B9  
 SEQ ID NO: 96 is the amino acid sequence for mutant 11461D8  
 SEQ ID NO: 97 is the amino acid sequence for mutant 11463  
 SEQ ID NO: 98 is the amino acid sequence for mutant 11518B4

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the generation of mutated KARI enzymes to use NADH as opposed to NADPH. Such co-factor switched enzymes function more effectively in microbial systems designed to produce isobutanol. Isobutanol is an important industrial commodity chemical with a variety of applications, where its potential as a fuel or fuel additive is particularly significant. Although only a four-carbon alcohol, butanol has the energy content similar to that of gasoline and can be blended with any fossil fuel. Isobutanol is favored as a fuel or fuel additive as it yields only CO<sub>2</sub> and little or no SO<sub>x</sub> or NO<sub>x</sub> when burned in the standard internal combustion engine. Additionally butanol is less corrosive than ethanol, the most preferred fuel additive to date.

The following definitions and abbreviations are to be used for the interpretation of the claims and the specification.

The term “invention” or “present invention” as used herein is meant to apply generally to all embodiments of the invention as described in the claims as presented or as later amended and supplemented, or in the specification.

The term “isobutanol biosynthetic pathway” refers to the enzymatic pathway to produce isobutanol. Preferred isobutanol biosynthetic pathways are illustrated in FIG. 1 and described herein.

The term “NADPH consumption assay” refers to an enzyme assay for the determination of the specific activity of the KARI enzyme, involving measuring the disappearance of the KARI cofactor, NADPH, from the enzyme reaction.

“KARI” is the abbreviation for the enzyme ketol-acid reducto-isomerase.

The term “close proximity” when referring to the position of various amino acid residues of a KARI enzyme with respect to the adenosyl 2'-phosphate of NADPH means amino acids in the three-dimensional model for the structure of the enzyme that are within about 4.5 Å of the phosphorus atom of the adenosyl 2'-phosphate of NADPH bound to the enzyme.

The term “ketol-acid reducto-isomerase” (abbreviated “KARI”), and “acetohydroxy acid isomero-reductase” will be used interchangeably and refer to the enzyme having the EC number, EC 1.1.1.86 (*Enzyme Nomenclature* 1992, Academic Press, San Diego). Ketol-acid reducto-isomerase catalyzes the reaction of (S)-acetolactate to 2,3-dihydroxyisovalerate, as more fully described below. These enzymes are available from a number of sources, including, but not limited to *E. coli* GenBank Accession Number NC-000913

## 11

REGION: 3955993.3957468, *Vibrio cholerae* GenBank Accession Number NC-002505 REGION: 157441.158925, *Pseudomonas aeruginosa*, GenBank Accession Number NC-002516, (SEQ ID NO: 16) REGION: 5272455.5273471, and *Pseudomonas fluorescens* GenBank Accession Number NC-004129 (SEQ ID NO: 17) REGION: 6017379.6018395. As used herein the term “Class I ketol-acid reductoisomerase enzyme” means the short form that typically has between 330 and 340 amino acid residues, and is distinct from the long form, called class II, that typically has approximately 490 residues.

The term “acetolactate synthase” refers to an enzyme that catalyzes the conversion of pyruvate to acetolactate and CO<sub>2</sub>. Acetolactate has two stereoisomers ((R) and (S)); the enzyme prefers the (S)-isomer, which is made by biological systems. Preferred acetolactate synthases are known by the EC number 2.2.1.6.9 (Enzyme Nomenclature 1992, Academic Press, San Diego). These enzymes are available from a number of sources, including, but not limited to, *Bacillus subtilis* (GenBank Nos: CAB15618, Z99122, NCBI (National Center for Biotechnology Information) amino acid sequence, NCBI nucleotide sequence, respectively), *Klebsiella pneumoniae* (GenBank Nos: AAA25079, M73842 and *Lactococcus lactis* (GenBank Nos: AAA25161, L16975).

The term “acetohydroxy acid dehydratase” refers to an enzyme that catalyzes the conversion of 2,3-dihydroxyisovalerate to α-ketoisovalerate. Preferred acetohydroxy acid dehydratases are known by the EC number 4.2.1.9. These enzymes are available from a vast array of microorganisms, including, but not limited to, *E. coli* (GenBank Nos: YP\_026248, NC\_000913, *S. cerevisiae* (GenBank Nos: NP\_012550, NC\_001142), *M. maripaludis* (GenBank Nos: CAF29874, BX957219), and *B. subtilis* (GenBank Nos: CAB14105, Z99115).

The term “branched-chain α-keto acid decarboxylase” refers to an enzyme that catalyzes the conversion of α-ketoisovalerate to isobutyraldehyde and CO<sub>2</sub>. Preferred branched-chain α-keto acid decarboxylases are known by the EC number 4.1.1.72 and are available from a number of sources, including, but not limited to, *Lactococcus lactis* (GenBank Nos: AAS49166, AY548760; CAG34226, AJ746364, *Salmonella typhimurium* (GenBank Nos: NP-461346, NC-003197), and *Clostridium acetobutylicum* (GenBank Nos: NP-149189, NC-001988).

The term “branched-chain alcohol dehydrogenase” refers to an enzyme that catalyzes the conversion of isobutyraldehyde to isobutanol. Preferred branched-chain alcohol dehydrogenases are known by the EC number 1.1.1.265, but may also be classified under other alcohol dehydrogenases (specifically, EC 1.1.1.1 or 1.1.1.2). These enzymes utilize NADH (reduced nicotinamide adenine dinucleotide) and/or NADPH as electron donor and are available from a number of sources, including, but not limited to, *S. cerevisiae* (GenBank Nos: NP-010656, NC-001136; NP-014051, NC-001145), *E. coli* (GenBank Nos: NP-417484, and *C. acetobutylicum* (GenBank Nos: NP-349892, NC\_003030).

The term “branched-chain keto acid dehydrogenase” refers to an enzyme that catalyzes the conversion of α-ketoisovalerate to isobutyryl-CoA (isobutyryl-cofactor A), using NAD<sup>+</sup> (nicotinamide adenine dinucleotide) as electron acceptor. Preferred branched-chain keto acid dehydrogenases are known by the EC number 1.2.4.4. These branched-chain keto acid dehydrogenases comprise four subunits, and sequences from all subunits are available from a vast array of microorganisms, including, but not limited to, *B. subtilis* (GenBank Nos: CAB14336, Z99116; CAB14335, Z99116; CAB14334, Z99116; and CAB14337, Z99116) and *Pseudomonas putida*

## 12

(GenBank Nos: AAA65614, M57613; AAA65615, M57613; AAA65617, M57613; and AAA65618, M57613).

The terms “k<sub>cat</sub>” and “K<sub>M</sub>” are known to those skilled in the art and are described in Enzyme Structure and Mechanism, 2<sup>nd</sup> ed. (Ferst; W.H. Freeman Press, NY, 1985; pp 98-120). The term “k<sub>cat</sub>”, often called the “turnover number”, is defined as the maximum number of substrate molecules converted to products per active site per unit time, or the number of times the enzyme turns over per unit time. K<sub>M</sub>=Vmax/[E], where [E] is the enzyme concentration (Ferst, supra). The terms “total turnover” and “total turnover number” are used herein to refer to the amount of product formed by the reaction of a KARI enzyme with substrate.

The term “catalytic efficiency” is defined as the K<sub>cat</sub>/K<sub>M</sub> of an enzyme. Catalytic efficiency is used to quantify the specificity of an enzyme for a substrate.

The term “isolated nucleic acid molecule”, “isolated nucleic acid fragment” and “genetic construct” will be used interchangeably and will mean a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

The term “amino acid” refers to the basic chemical structural unit of a protein or polypeptide. The following abbreviations are used herein to identify specific amino acids:

Amino Acid	Three-Letter Abbreviation	One-Letter Abbreviation
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

The term “gene” refers to a nucleic acid fragment that is capable of being expressed as a specific protein, optionally including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of a microorganism. A “foreign” gene refers to a gene not normally found in the host microorganism, but that is introduced into the host microorganism by gene transfer.

## 13

Foreign genes can comprise native genes inserted into a non-native microorganism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

As used herein the term “coding sequence” refers to a DNA sequence that encodes for a specific amino acid sequence. “Suitable regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing site, effector binding site and stem-loop structure.

The term “promoter” refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of effecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

As used herein the term “transformation” refers to the transfer of a nucleic acid fragment into the genome of a host microorganism, resulting in genetically stable inheritance. Host microorganisms containing the transformed nucleic acid fragments are referred to as “transgenic” or “recombinant” or “transformed” microorganisms.

The terms “plasmid”, “vector” and “cassette” refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. “Transformation cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular

## 14

host cell. “Expression cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

5 The term “site-saturation library” refers to a library which contains random substitutions at a specific amino acid position with all 20 possible amino acids at once.

10 The term “error-prone PCR” refers to adding random copying errors by imposing imperfect or ‘sloppy’ PCR reaction conditions which generate randomized libraries of mutations in a specific nucleotide sequence.

15 As used herein the term “codon degeneracy” refers to the nature in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency 20 of codon usage approaches the frequency of preferred codon usage of the host cell.

25 The term “codon-optimized” as it refers to genes or coding regions of nucleic acid molecules for transformation of various hosts, refers to the alteration of codons in the gene or coding regions of the nucleic acid molecules to reflect the typical codon usage of the host microorganism without altering the polypeptide encoded by the DNA.

## Molecular Techniques

30 Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Sambrook et al. (Sambrook, Fritsch and Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) (hereinafter “Maniatis”); and by Silhavy et al. (*Experiments with Gene Fusions*, Cold Spring Harbor Laboratory Press Cold Spring Harbor, N.Y., 1984); and by Ausubel, F. M. et al., (*Current Protocols in Molecular Biology*, published by Greene Publishing Assoc. and Wiley-Interscience, 1987).

35 The present invention addresses a need that arises in the microbial production of isobutanol where the ketol-acid reductoisomerase enzyme performs a vital role. Wild type ketol-acid reductoisomerase enzymes typically use NADPH as their cofactor. However, in the formation of isobutanol an excess of NADH is produced by ancillary metabolic pathways. The invention provides mutant Class I KARI enzymes that have been evolved to utilize NADH as a cofactor, overcoming the cofactor problem and increasing the efficiency of the isobutanol biosynthetic pathway.

40 Production of isobutanol utilizes the glycolysis pathway present in the host microorganism. During the production of two molecules of pyruvate from glucose during glycolysis, there is net production of two molecules of NADH from NAD<sup>+</sup> by the glyceraldehyde-3-phosphate dehydrogenase reaction. During the further production of one molecule of 45 isobutanol from two molecules of pyruvate, there is net consumption of one molecule of NADPH, by the KARI reaction, and one molecule of NADH by the isobutanol dehydrogenase reaction. The overall reaction of glucose to isobutanol thus leads to net production of one molecule of NADH and net 50 consumption of one molecule of NADPH. The interconversion of NADH with NADPH is generally slow and inefficient; thus, the NADPH consumed is generated by metabolism (for example, by the pentose phosphate pathway) consuming substrate in the process. Meanwhile, the cell strives to maintain homeostasis in the NAD<sup>+</sup>/NADH ratio, leading to the excess NADH produced in isobutanol production being consumed in wasteful reduction of other metabolic intermediates; e.g., by

the production of lactate from pyruvate. Thus, the imbalance between NADH produced and NADPH consumed by the isobutanol pathway leads to a reduction in the molar yield of isobutanol produced from glucose in two ways: 1) unnecessary operation of metabolism to produce NADPH, and 2) wasteful reaction of metabolic intermediates to maintain NAD<sup>+</sup>/NADH homeostasis. The solution to this problem is to invent a KARI that is specific for NADH as its cofactor, so that both molecules of NADH produced in glycolysis are consumed in the synthesis of isobutanol from pyruvate.

#### Keto Acid Reductoisomerase (KARI) Enzymes

Acetohydroxy acid isomeroreductase or ketol-acid reducto-isomerase (KARI; EC 1.1.1.86) catalyzes two steps in the biosynthesis of branched-chain amino acids and is a key enzyme in their biosynthesis. KARI is found in a variety of microorganisms and amino acid sequence comparisons across species have revealed that there are 2 types of this enzyme: a short form (class I) found in fungi and most bacteria, and a long form (class II) typical of plants.

Class I KARIs typically have between 330-340 amino acid residues. The long form KARI enzymes have about 490 amino acid residues. However, some bacteria such as *Escherichia coli* possess a long form, where the amino acid sequence differs appreciably from that found in plants. KARI is encoded by the *ilvC* gene and is an essential enzyme for growth of *E. coli* and other bacteria in a minimal medium. Typically KARI uses NADPH as cofactor and requires a divalent cation such as Mg<sup>++</sup> for its activity. In addition to utilizing acetolactate in the valine pathway, KARI also converts acetohydroxybutanoate to dihydroxymethylpentanoate in the isoleucine production pathway.

Class II KARIs generally consist of a 225-residue N-terminal domain and a 287-residue C-terminal domain. The N-terminal domain, which contains the NADPH-binding site, has an α/β structure and resembles domains found in other pyridine nucleotide-dependent oxidoreductases. The C-terminal domain consists almost entirely of helices and is of a previously unknown topology.

The crystal structure of the *E. coli* KARI enzyme at 2.6 Å resolution has been solved (Tyagi, et al., Protein Sci., 14: 3089-3100, 2005). This enzyme consists of two domains, one with mixed α/β structure which is similar to that found in other pyridine nucleotide-dependent dehydrogenases. The second domain is mainly α-helical and shows strong evidence of internal duplication. Comparison of the active sites of KARI of *E. coli*, *Pseudomonas aeruginosa*, and spinach showed that most residues in the active site of the enzyme occupy conserved positions. While the *E. coli* KARI was crystallized as a tetramer, which is probably the likely biologically active unit, the *P. aeruginosa* KARI (Ahn, et al., J. Mol. Biol., 328: 505-515, 2003) formed a dodecamer, and the enzyme from spinach formed a dimer. Known KARIs are slow enzymes with a reported turnover number (*k<sub>cat</sub>*) of 2 s<sup>-1</sup> (Aulabaugh et al.; Biochemistry, 29: 2824-2830, 1990) or 0.12 s<sup>-1</sup> (Rane et al., Arch. Biochem. Biophys. 338: 83-89, 1997) for acetolactate. Studies have shown that genetic control of isoleucine-valine biosynthesis in *E. coli* is different than that in *Ps. aeruginosa* (Marinus, et al., Genetics, 63: 547-56, 1969).

#### Identification of Amino Acid Target Sites for Cofactor Switching

It was reported that phosphate p2' oxygen atoms of NADPH form hydrogen bonds with side chains of Arg162, Ser165 and Ser167 of spinach KARI (Biou V., et al. The EMBO Journal, 16: 3405-3415, 1997). Multiple sequence alignments were performed, using vector NTI (Invitrogen Corp. Carlsbad, Calif.), with KARI enzymes from spinach,

*Pseudomonas aeruginosa* (PAO-KARI) and *Pseudomonas fluorescens* (PF5-KARI). The NADPH binding sites are shown in FIG. 2A. The amino acids, arginine, threonine and serine appear to play similar roles in forming hydrogen bonds with phosphate p2' oxygen atoms of NADPH in KARI enzymes. Studies by Ahn et al., (J. Mol. Biol., 328: 505-515, 2003) had identified three NADPH phosphate binding sites (Arg47, Ser50 and Thr52) for *Pseudomonas aeruginosa* (PAO-KARI) following comparing its structure with that of the spinach KARI. Hypothesizing that these three NADPH phosphate binding sites of the three KARI enzymes used in the disclosure were conserved, Arg47, Ser50 and Thr52 of PF5-KARI were targeted as the phosphate binding sites for this enzyme. This hypothesis was further confirmed through homology modeling.

Multiple sequence alignment among PF5-ilvC and several other KARI enzymes with promiscuous nucleotide specificity was also performed. As shown in FIG. 2B, the amino acids of glycine (G50) and tryptophan (W53), in other KARI enzymes in FIG. 2B, always appear together as a pair in the sequences of those enzymes. It was therefore assumed that the tryptophan 53 bulky residue was important in determining nucleotide specificity and by reducing the size of nucleotide binding pocket one could favor binding of the smaller nucleotide, NADH. Position 53 of PF5-ilvC was therefore chosen as a target for mutagenesis.

Several site-saturation gene libraries were prepared containing genes encoding KARI enzymes by commercially available kits for the generation of mutants. Clones from each library were screened for improved KARI activity using the NADH consumption assay described herein. Screening resulted in the identification of a number of genes having mutations that can be correlated to KARI activity. The location of the mutations were identified using the amino acid sequence of the *Pseudomonas fluorescens* PF5 ilvC protein (SEQ ID NO:17). Mutants with improved KARI activity had mutations at one or more positions at amino acids: 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, 165, and 170. More specifically desirable mutations included the following substitutions:

- a) the residue at position 47 has an amino acid substitution selected from the group consisting of A, C, D, F, G, I, L, N, P, and Y;
- b) the residue at position 50 has an amino acid substitution selected from the group consisting of A, C, D, E, F, G, M, N, V, W;
- c) the residue at position 52 has an amino acid substitution selected from the group consisting of A, C, D, G, H, N, S;
- d) the residue at position 53 has an amino acid substitution selected from the group consisting of A, H, I, W;

In another embodiment, additional mutagenesis, using error prone PCR, performed on the mutants listed above identified suitable mutation positions as: 156, 165, 61, 170, 115 and 24. More specifically the desirable mutants with lower K<sub>M</sub> for NADH contained the following substitutions:

- e) the residue at position 156 has an amino acid substitution of V;
- f) the residue at position 165 has an amino acid substitution of M;
- g) the residue at position 61 has an amino acid substitution of F;
- h) the residue at position 170 has an amino acid substitution of A;
- i) the residue at position 24 has an amino acid substitution of F; and
- j) the residue at position 115 has an amino acid substitution of L.

## 17

In another embodiment, multiple sequence alignment of *Pseudomonas fluorescens* PF5-ilvC and *Bacillus cereus* ilvC1 and ilvC2 and spinach KARI was performed which allowed identification of positions 24, 33, 47, 50, 52, 53, 61, 80, 156 and 170 for further mutagenesis. More specifically mutants with much lower  $K_M$  for NADH were obtained. These mutations are also based on the *Pseudomonas fluorescens*, KARI enzyme (SEQ ID NO:17) as a reference sequence wherein the reference sequence comprises at least one amino acid substitution selected from the group consisting of:

- k) the residue at position 24 has an amino acid substitution of phenylalanine;
- l) the residue at position 50 has an amino acid substitution of alanine;
- m) the residue at position 52 has an amino acid substitution of aspartic acid;
- n) the residue at position 53 has an amino acid substitution of alanine;
- o) the residue at position 61 has an amino acid substitution of phenylalanine;
- p) the residue at position 156 has an amino acid substitution of valine;
- q) the residue at position 33 has an amino acid substitution of leucine;
- r) the residue at position 47 has an amino acid substitution of tyrosine;
- s) the residue at position 80 has an amino acid substitution of isoleucine;
- and
- t) the residue at position 170 has an amino acid substitution of alanine.

The present invention includes a mutant polypeptide having KARI activity, said polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 24, 25, 26, 27 and 28.

A consensus sequence for the mutant ilvC was generated from the multiple sequence alignment and is provided as SEQ ID NO: 29 which represents all experimentally verified mutations of the KARI enzyme based on the amino acid sequence of the KARI enzyme isolated from *Pseudomonas fluorescens*, (SEQ ID NO:17)

Additionally the present invention describes mutation positions identified using a profile Hidden Markov Model (HMM) built based on sequences of 25 functionally verified Class I and Class II KARI enzymes. Profile HMM identified mutation positions 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, and 170 (the numbering is based on the sequences of *Pseudomonas fluorescens* PF5 KARI). Thus, it will be appreciated by the skilled person that mutations at these positions, as well as those discussed above that have been experimentally verified will also give rise to KARI enzymes having the ability to bind NADH.

Furthermore, applicants have discovered that the ketol-acid reductoisomerase enzyme has two functionally related domains: one domain affecting nucleotide specificity and the other domain impacting the  $K_M$  for the cofactor (FIGS. 11A, 11B, and 12A-12D). To examine whether this characteristic could be exploited to engineer the desired KARI mutants (i.e., mutants with high NADH activity ( $K_M < 20 \mu\text{M}$ ) and substantially decreased NADPH activity ( $K_M > 100 \mu\text{M}$ )), two libraries were created.

One library was a four-site saturation library targeting the NADH or NADPH binding positions, i.e., amino acids at positions 47, 50, 52 and 53 (FIGS. 11A and 11B). To build this library, mutants which possessed both NADH and NADPH activities and  $K_M \sim 10-20 \mu\text{M}$  for NADH, were

## 18

selected from a group consisting of SEQ ID NOs: 28, 67, 68, 69, 70 and 84, as templates. Further saturation mutagenesis generated new mutants (i.e., mutants with SEQ ID NOs: 75-78) that possessed mainly NADH activity with very low NADPH activity.

The desirable mutants with higher NADH activity, following site saturation mutagenesis, comprised the following substitutions:

- u) the residue at position 24 has an amino acid substitution of phenylalanine;
- v) the residue at position 50 has an amino acid substitution of aspartic acid or valine or isoleucine or phenylalanine;
- w) the residue at position 52 has an amino acid substitution of tyrosine or aspartic acid;
- x) the residue at position 53 has an amino acid substitution of tyrosine or glycine, or arginine, or alanine;
- y) the residue at position 61 has an amino acid substitution of phenylalanine;
- z) the residue at position 156 has an amino acid substitution of valine;
- aa) the residue at position 33 has an amino acid substitution of leucine;
- bb) the residue at position 47 has an amino acid substitution of histidine, or proline, or threonine, or glutamic acid; and
- cc) the residue at position 80 has an amino acid substitution of isoleucine.

The  $K_M$  for NADH in the above mutants was still slightly high (e.g., JB1C6, SEQ ID NO: 74, has  $K_M$  of 22  $\mu\text{M}$  for NADH). To further improve the NADH  $K_M$  of the mutant KARIs, a “domain swapping library”, which combined the nucleotide switching mutations and mutations with improved  $K_M$  for NADH, was created (FIG. 12A-12D). More specifically, the beneficial mutations at positions 47, 50, 52 and 53 obtained in the site saturation experiment (see Tables 3 and 4), were transferred into mutants that possessed  $K_M \sim 4-40 \mu\text{M}$  for NADH (SEQ ID NOs: 24-28 and 67-70 and 84, see Tables 6 and 7). The resultant new mutants accepted NADH as cofactor with very low  $K_M \sim 10 \mu\text{M}$  and greatly reduced NADPH activity. Examples of these mutants include: JEA1 (SEQ ID NO: 79), JEG2 (SEQ ID NO: 80), JEG4 (SEQ ID NO: 81), JEA7 (SEQ ID NO: 82) and JED1 (SEQ ID NO: 83).

Following domain swapping experiments, the mutants that possessed very low  $K_M$  for NADH had the following substitutions:

- dd) the residue at position 24 has an amino acid substitution of phenylalanine;
- ee) the residue at position 50 has an amino acid substitution of alanine, asparagine, or phenylalanine;
- ff) the residue at position 52 has an amino acid substitution of aspartic acid;
- gg) the residue at position 53 has an amino acid substitution of alanine;
- hh) the residue at position 61 has an amino acid substitution of phenylalanine;
- ii) the residue at position 156 has an amino acid substitution of valine;
- jj) the residue at position 33 has an amino acid substitution of leucine;
- kk) the residue at position 47 has an amino acid substitution of asparagine, proline; and phenylalanine;
- ll) the residue at position 80 has an amino acid substitution of isoleucine.

In one embodiment the present method includes a mutant polypeptide having KARI activity, said polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 24-28, 67-70, and 75-98,

In another embodiment the method provides an NADH utilizing KARI mutant with a  $K_M$  for NADH<15  $\mu\text{M}$ .

In a preferred embodiment, the mutant KARI JEA1 (SEQ ID NO: 79) has the following substitutions: Y24F/C33L/R47P/S50F/T52D/L61F/T80I/A156V

In another preferred embodiment, the mutant KARI JEG2 (SEQ ID NO: 80) has the following substitutions: (Y24F/C33L/R47F/S50A/T52D/V53A/L61F/T80I/A156V)

In another preferred embodiment, the mutant KARI JEG4 (SEQ ID NO: 81), has the following substitutions: (Y24F/C33L/R47P/S50N/T52D/V53A/L61F/T80I/A156V)

In another preferred embodiment, the mutant KARI JEA7 (SEQ ID NO: 82), has the following substitutions: (Y24F/C33L/R47P/S50N/T52D/V53A/L61F/T80I/A156V)

In another preferred embodiment, the mutant KARI JED1 (SEQ ID NO: 83) has the following substitutions: (C33L/R47N/S50N/T52D/V53A/L61F/T80I/A156V)

In another embodiment the method provides an NADH accepting KARI mutant wherein the ratio of NADH/NADPH activity is greater than one. A consensus sequence for the mutant ilvC was generated from the multiple sequence alignment and is provided as SEQ ID NO: 29 which represents all experimentally verified mutations of the KARI enzyme based on the amino acid sequence of the KARI enzyme isolated from *Pseudomonas fluorescens* (SEQ ID NO:17).

#### The Host Strains for KARI Engineering

Two host strains, *E. coli* TOP10 from Invitrogen and *E. coli* Bw25113 ( $\Delta$ ilvC, an ilvC gene-knockout), were used for making constructs over-expressing the KARI enzyme in this disclosure. In the Bw25113 strain, the entire ilvC gene of the *E. coli* chromosome was replaced by a Kanamycin cassette using the Lambda red homology recombination technology described by Kirill et al., (Kirill A. Datsenko and Barry L. Wanner, Proc. Natl. Acad. Sci. USA, 97: 6640-6645, 2000). Homology Modeling of PF5 KARI with Bound Substrates

The structure of PF5-KARI with bound NADPH, acetolactate and magnesium ions was built based on the crystal structure of *P. aeruginosa* PAO1-KARI (PDB ID 1NP3, Ahn H. J. et al., J. Mol. Biol., 328: 505-515, 2003) which has 92% amino acid sequence homology to PF5 KARI. PAO1-KARI structure is a homo-dodecamer and each dodecamer consists of six homo-dimers with extensive dimer interface. The active site of KARI is located in this dimer interface. The biological assembly is formed by six homo-dimers positioned on the edges of a tetrahedron resulting in a highly symmetrical dodecamer of 23 point group symmetry. For simplicity, only the dimeric unit (monomer A and monomer B) was built for the homology model of PF5-KARI in this study because the active site is in the homo-dimer interface.

The model of PF5-KARI dimer was built based on the coordinates of monomer A and monomer B of PAO1-KARI and sequence of PF5-KARI using DeepView/Swiss PDB viewer (Guex, N. and Peitsch, M. C., Electrophoresis, 18: 2714-2723, 1997). This model was then imported to program O (Jones, T. A. et al, Acta Crystallogr. A 47: 110-119, 1991) on a Silicon Graphics system for further modification.

The structure of PAO1-KARI has no NADPH, substrate or inhibitor or magnesium in the active site. Therefore, the spinach KARI structure (PDB ID 1yve, Biou V. et al., The EMBO Journal, 16: 3405-3415, 1997), which has magnesium ions, NADPH and inhibitor (N-Hydroxy-N-isopropylxamate) in the acetolactate binding site, was used to model these molecules in the active site. The plant KARI has very little sequence homology to either PF5- or PAO1 KARI (<20% amino acid identity), however the structures in the active site region of these two KARI enzymes are very similar. To overlay the active site of these two KARI structures, commands

LSQ\_ext, LSQ\_improve, LSQ\_mol in the program O were used to line up the active site of monomer A of spinach KARI to the monomer A of PF5 KARI model. The coordinates of NADPH, two magnesium ions and the inhibitor bound in the active site of spinach KARI were extracted and incorporated to molecule A of PF5 KARI. A set of the coordinates of these molecules were generated for monomer B of PF5 KARI by applying the transformation operator from monomer A to monomer B calculated by the program.

Because there is no NADPH in the active site of PAO1 KARI crystal structure, the structures of the phosphate binding loop region in the NADPH binding site (residues 44-45 in PAO1 KARI, 157-170 in spinach KARI) are very different between the two. To model the NADPH bound form, the model of the PF5-KARI phosphate binding loop (44-55) was replaced by that of 1yve (157-170). Any discrepancy of side chains between these two was converted to those in the PF5-KARI sequence using the mutate\_replace command in program O, and the conformations of the replaced side-chains were manually adjusted. The entire NADPH/Mg/inhibitor bound dimeric PF5-KARI model went through one round of energy minimization using program CNX (ACCELRYSS San Diego Calif., Burnger, A. T. and Warren, G. L., Acta Crystallogr., D 54: 905-921, 1998) after which the inhibitor was replaced by the substrate, acetolactate (AL), in the model. The conformation of AL was manually adjusted to favor hydride transfer of C4 of the nicotinamine of NADPH and the substrate. No further energy minimization was performed on this model (coordinates of the model created for this study are attached in a separate word file). The residues in the phosphate binding loop and their interactions with NADPH are illustrated in FIG. 3.

Application of a "Profile Hidden Markov Model" for Identification of Residue Positions Involved in Cofactor Switching in KARI Enzymes

Applicants have developed a method for identifying KARI enzymes and the residue positions that are involved in cofactor switching from NADPH to NADH. To structurally characterize KARI enzymes, a Profile Hidden Markov Model (HMM) was prepared as described in Example 5 using amino acid sequences of 25 KARI proteins with experimentally verified function as outlined in Table 6. These KARIs were from [*Pseudomonas fluorescens* Pf-5 (SEQ ID NO: 17), *Sulfolobus solfataricus* P2 (SEQ ID NO: 13), *Pyrobaculum aerophilum* str. IM2 (SEQ ID NO: 14), *Natronomonas pharaonis* DSM 2160 (SEQ ID NO: 30), *Bacillus subtilis* subsp. *subtilis* str. 168 (SEQ ID NO: 31), *Corynebacterium glutamicum* ATCC 13032 (SEQ ID NO: 32), *Phaeospirillum molischianum* (SEQ ID NO: 33), *Ralstonia solanacearum* GMI1000 (SEQ ID NO: 15), *Zymomonas mobilis* subsp. *mobilis* ZM4 (SEQ ID NO: 34), *Alkalilimnicola ehrlichei* MLHE-1 (SEQ ID NO: 35), *Campylobacter lari* RM2100 (SEQ ID NO: 36), *Marinobacter aquaeolei* VT8 (SEQ ID NO: 37), *Psychrobacter arcticus* 273-4 (SEQ ID NO: 38), *Hahella chejuensis* KCTC 2396 (SEQ ID NO: 39), *Thiobacillus denitrificans* ATCC 25259 (SEQ ID NO: 40), *Azotobacter vinelandii* AvOP (SEQ ID NO: 41), *Pseudomonas syringae* pv. *syringae* B728a (SEQ ID NO: 42), *Pseudomonas syringae* pv. *tomato* str. DC3000 (SEQ ID NO: 43), *Pseudomonas putida* KT2440 (Protein SEQ ID NO: 44), *Pseudomonas entomophila* L48 (SEQ ID NO: 45), *Pseudomonas mendocina* ymp (SEQ ID NO: 46), *Pseudomonas aeruginosa* PAO1 (SEQ ID NO: 16), *Bacillus cereus* ATCC 10987 (SEQ ID NO: 47), *Bacillus cereus* ATCC 10987 (SEQ ID NO: 48), and *Spinacia oleracea* (SEQ ID NO: 18).

In addition using methods disclosed in this application, sequences of Class II KARI enzymes such as *E. coli* (SEQ ID

NO: 63—GenBank Accession Number P05793), marine gamma *Proteobacterium* HTCC2207 (SEQ ID NO: 64—GenBank Accession Number ZP\_01224863.1), *Desulfuromonas acetoxidans* (SEQ ID NO: 65—GenBank Accession Number ZP\_01313517.1) and *Pisum sativum* (pea) (SEQ ID NO: 66—GenBank Accession Number 082043) could be mentioned.

This Profile HMM for KARIs may be used to identify any KARI related proteins. Any protein that matches the Profile HMM with an E value of <10<sup>-3</sup> using hmmsearch program in the HMMER package is expected to be a functional KARI, which can be either a Class I and Class II KARI. Sequences matching the Profile HMM given herein are then analyzed for the location of the 12 positions in *Pseudomonas fluorescens* Pf-5 that switches the cofactor from NADPH to NADH. The eleven nodes, as defined in the section of Profile HMM building, in the profile HMM representing the columns in the alignment which correspond to the eleven co-factor switching positions in *Pseudomonas fluorescens* Pf-5 KARI are identified as node 24, 33, 47, 50, 52, 53, 61, 80, 115, 156 and 170. The lines corresponding to these nodes in the model file are identified in Table 9. One skilled in the art will readily be able to identify these 12 positions in the amino acid sequence of a KARI protein from the alignment of the sequence to the profile HMM using hmm search program in HMMER package.

The KARI enzymes identified by this method, include both Class I and Class II KARI enzymes from either microbial or plant natural sources. Any KARI identified by this method may be used for heterologous expression in microbial cells.

For example each of the KARI encoding nucleic acid fragments described herein may be used to isolate genes encoding homologous proteins. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to: 1) methods of nucleic acid hybridization; 2) methods of DNA and RNA amplification, as exemplified by various uses of nucleic acid amplification technologies [e.g., polymerase chain reaction (PCR) (Mullis et al., U.S. Pat. No. 4,683,202); ligase chain reaction (LCR) (Tabor, S. et al., Proc. Acad. Sci. USA 82:1074, 1985); or strand displacement amplification (SDA) (Walker, et al., Proc. Natl. Acad. Sci. U.S.A., 89: 392, 1992); and 3) methods of library construction and screening by complementation.

Although the sequence homology between Class I and Class II KARI enzymes is low, the three dimensional structure of both Classes of the enzymes, particularly around the active site and nucleotide binding domains is highly conserved (Tygai, R., et al., Protein Science, 34: 399-408, 2001). The key amino acid residues that make up the substrate binding pocket are highly conserved between these two Classes even though they may not align well in a simple sequence comparison. It can therefore be concluded that the residues affecting cofactor specificity identified in Class I KARI (e.g., positions 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, and 170 of PF5 KARI) can be extended to Class II KARI enzymes.

#### Isobutanol Biosynthetic Pathways

Carbohydrate utilizing microorganisms employ the Embden-Meyerhof-Parnas (EMP) pathway, the Entner and Doudoroff pathway (EDP) and the pentose phosphate pathway (PPP) as the central, metabolic routes to provide energy and cellular precursors for growth and maintenance. These pathways have in common the intermediate glyceraldehyde-3-phosphate and, ultimately, pyruvate is formed directly or in combination with the EMP pathway. Subsequently, pyruvate is transformed to acetyl-cofactor A (acetyl-CoA) via a variety of means. Acetyl-CoA serves as a key intermediate, for

example, in generating fatty acids, amino acids and secondary metabolites. The combined reactions of sugar conversion to pyruvate produce energy (e.g., adenosine-5'-triphosphate, ATP) and reducing equivalents (e.g., reduced nicotinamide adenine dinucleotide, NADH, and reduced nicotinamide adenine dinucleotide phosphate, NADPH). NADH and NADPH must be recycled to their oxidized forms (NAD<sup>+</sup> and NADP<sup>+</sup>, respectively). In the presence of inorganic electron acceptors (e.g. O<sub>2</sub>, NO<sub>3</sub><sup>-</sup> and SO<sub>4</sub><sup>2-</sup>), the reducing equivalents may be used to augment the energy pool; alternatively, a reduced carbon byproduct may be formed.

There are four potential pathways for production of isobutanol from carbohydrate sources with recombinant microorganisms as shown in FIG. 1. All potential pathways for conversion of carbohydrates to isobutanol have been described in the commonly owned U.S. patent application Ser. No. 11/586,315, which is incorporated herein by reference.

The preferred pathway for conversion of pyruvate to isobutanol consists of enzymatic steps “a”, “b”, “c”, “d”, and “e” (FIGS. 1A and 1B) and includes the following substrate to product conversions:

- a) pyruvate to acetolactate, as catalyzed for example by acetolactate synthase,
- b) (S)-acetolactate to 2,3-dihydroxyisovalerate, as catalyzed for example by acetohydroxy acid isomeroreductase,
- c) 2,3-dihydroxyisovalerate to  $\alpha$ -ketoisovalerate, as catalyzed for example by acetohydroxy acid dehydratase,
- d)  $\alpha$ -ketoisovalerate to isobutyraldehyde, as catalyzed for example by a branched-chain keto acid decarboxylase, and
- e) isobutyraldehyde to isobutanol, as catalyzed for example by a branched-chain alcohol dehydrogenase.

This pathway combines enzymes involved in well-characterized pathways for valine biosynthesis (pyruvate to  $\alpha$ -ketoisovalerate) and valine catabolism ( $\alpha$ -ketoisovalerate to isobutanol). Since many valine biosynthetic enzymes also catalyze analogous reactions in the isoleucine biosynthetic pathway, substrate specificity is a major consideration in selecting the gene sources. For this reason, the primary genes of interest for the acetolactate synthase enzyme are those from *Bacillus* (alsS) and *Klebsiella* (budB). These particular acetolactate synthases are known to participate in butanediol fermentation in these microorganisms and show increased affinity for pyruvate over ketobutyrate (Gollop et al., J. Bacteriol., 172: 3444-3449, 1990); and (Holtzclaw et al., J. Bacteriol., 121: 917-922, 1975). The second and third pathway steps are catalyzed by acetohydroxy acid reductoisomerase and dehydratase, respectively. These enzymes have been characterized from a number of sources, such as for example, *E. coli* (Chunduru et al., Biochemistry, 28: 486-493, 1989); and (Flint et al., J. Biol. Chem., 268: 14732-14742, 1993). The final two steps of the preferred isobutanol pathway are known to occur in yeast, which can use valine as a nitrogen source and, in the process, secrete isobutanol.  $\alpha$ -Ketoisovalerate can be converted to isobutyraldehyde by a number of keto acid decarboxylase enzymes, such as for example pyruvate decarboxylase. To prevent misdirection of pyruvate away from isobutanol production, a decarboxylase with decreased affinity for pyruvate is desired. So far, there are two such enzymes known in the art (Smit et al., Appl. Environ. Microbiol., 71: 303-311, 2005); and (de la Plaza et al., FEMS Microbiol. Lett., 238: 367-374, 2004). Both enzymes are from strains of *Lactococcus lactis* and have a 50-200-fold preference for ketoisovalerate over pyruvate. Finally, a number of aldehyde reductases have been identified in yeast, many with overlapping substrate specificity. Those known to

decreased affinity for pyruvate is desired. So far, there are two such enzymes known in the art (Smit et al., Appl. Environ. Microbiol., 71: 303-311, 2005); and (de la Plaza et al., FEMS Microbiol. Lett., 238: 367-374, 2004). Both enzymes are from strains of *Lactococcus lactis* and have a 50-200-fold preference for ketoisovalerate over pyruvate. Finally, a number of aldehyde reductases have been identified in yeast, many with overlapping substrate specificity. Those known to

prefer branched-chain substrates over acetaldehyde include, but are not limited to, alcohol dehydrogenase VI (ADH6) and Ypr1p (Larroy et al., *Biochem. J.*, 361: 163-172, 2002); and (Ford et al., *Yeast*, 19: 1087-1096, 2002), both of which use NADPH as electron donor. An NADPH-dependent reductase, YqhD, active with branched-chain substrates has also been recently identified in *E. coli* (Sulzenbacher et al., *J. Mol. Biol.*, 342: 489-502, 2004).

Two of the other potential pathways for isobutanol production also contain the initial three steps of "a", "b" and "c" (FIG. 1A). One pathway consists of enzymatic steps "a", "b", "c", "f", "g", "e" (FIGS. 1A and 1B). Step "f" containing a "branched-chain keto acid dehydrogenase" (EC1.2.4.4). Step "g" containing an "acylating aldehyde dehydrogenase" (EC1.2.1.10) and 1.2.1.57 in addition to step "e" containing the "branched chain alcohol dehydrogenase". The other potential pathway consists of steps "a", "b", "c", "h", "i", "j", "e" (FIGS. 1A and 1B). The term "transaminase" (step "h") EC numbers 2.6.1.42 and 2.6.1.66. Step "h" consists of either a "valine dehydrogenase" (EC1.4.1.8 and EC1.4.1.9) or step "i", a "valine decarboxylase" with an EC number 4.1.1.14. Finally step "j" will use an "omega transaminase" (EC2.6.1.18) to generate isobutyraldehyde which will be reduced by step "e" to produce isobutanol. All potential pathways for conversion of pyruvate to isobutanol are depicted in FIGS. 1A and 1B.

Additionally, a number of microorganisms are known to produce butyrate and/or butanol via a butyryl-CoA intermediate (Dürre, et al., *FEMS Microbiol. Rev.*, 17: 251-262, 1995); and (Abbad-Andaloussi et al., *Microbiology*, 142: 1149-1158, 1996). Therefore isobutanol production in these microorganisms will take place using steps "k", "g" and "e" shown in FIG. 1B. Step "k" will use an "isobutyryl-CoA mutase" (EC5.4.99.13). The next step will involve using the "acylating aldehyde dehydrogenase" (EC 1.2.1.10 and EC1.2.1.57) to produce isobutyraldehyde followed by enzymatic step "e" to produce isobutanol. All these pathways are fully described in the commonly owned patent application Ser. No. 11/586,315, herein incorporated by reference.

Thus, in providing multiple recombinant pathways from pyruvate to isobutanol, there exist a number of choices to fulfill the individual conversion steps, and the person of skill in the art will be able to use publicly available sequences to construct the relevant pathways.

#### Microbial Hosts for Isobutanol Production

Microbial hosts for isobutanol production may be selected from bacteria, cyanobacteria, filamentous fungi and yeasts. The microbial host used for isobutanol production should be tolerant to isobutanol so that the yield is not limited by butanol toxicity. Microbes that are metabolically active at high titer levels of isobutanol are not well known in the art. Although butanol-tolerant mutants have been isolated from solventogenic *Clostridia*, little information is available concerning the butanol tolerance of other potentially useful bacterial strains. Most of the studies on the comparison of alcohol tolerance in bacteria suggest that butanol is more toxic than ethanol (de Cavalho, et al., *Microsc. Res. Tech.*, 64: 215-22, 2004) and (Kabelitz, et al., *FEMS Microbiol. Lett.*, 220: 223-227, 2003, Tomas, et al., *J. Bacteriol.*, 186: 2006-2018, 2004) report that the yield of 1-butanol during fermentation in *Clostridium acetobutylicum* may be limited by 1-butanol toxicity. The primary effect of 1-butanol on *Clostridium acetobutylicum* is disruption of membrane functions (Hermann et al., *Appl. Environ. Microbiol.*, 50: 1238-1243, 1985).

The microbial hosts selected for the production of isobutanol should be tolerant to isobutanol and should be able to convert carbohydrates to isobutanol. The criteria for selection

of suitable microbial hosts include the following: intrinsic tolerance to isobutanol, high rate of glucose utilization, availability of genetic tools for gene manipulation, and the ability to generate stable chromosomal alterations.

Suitable host strains with a tolerance for isobutanol may be identified by screening based on the intrinsic tolerance of the strain. The intrinsic tolerance of microbes to isobutanol may be measured by determining the concentration of isobutanol that is responsible for 50% inhibition of the growth rate ( $IC_{50}$ ) when grown in a minimal medium. The  $IC_{50}$  values may be determined using methods known in the art. For example, the microbes of interest may be grown in the presence of various amounts of isobutanol and the growth rate monitored by measuring the optical density at 600 nanometers. The doubling time may be calculated from the logarithmic part of the growth curve and used as a measure of the growth rate. The concentration of isobutanol that produces 50% inhibition of growth may be determined from a graph of the percent inhibition of growth versus the isobutanol concentration. Preferably, the host strain should have an  $IC_{50}$  for isobutanol of greater than about 0.5%.

The microbial host for isobutanol production should also utilize glucose at a high rate. Most microbes are capable of metabolizing carbohydrates. However, certain environmental microbes cannot metabolize carbohydrates to high efficiency, and therefore would not be suitable hosts.

The ability to genetically modify the host is essential for the production of any recombinant microorganism. The mode of gene transfer technology may be by electroporation, conjugation, transduction or natural transformation. A broad range of host conjugative plasmids and drug resistance markers are available. The cloning vectors are tailored to the host microorganisms based on the nature of antibiotic resistance markers that can function in that host.

The microbial host also has to be manipulated in order to inactivate competing pathways for carbon flow by deleting various genes. This requires the availability of either transposons to direct inactivation or chromosomal integration vectors. Additionally, the production host should be amenable to chemical mutagenesis so that mutations to improve intrinsic isobutanol tolerance may be obtained.

Based on the criteria described above, suitable microbial hosts for the production of isobutanol include, but are not limited to, members of the genera *Clostridium*, *Zymomonas*, *Escherichia*, *Salmonella*, *Rhodococcus*, *Pseudomonas*, *Bacillus*, *Vibrio*, *Lactobacillus*, *Enterococcus*, *Alcaligenes*, *Klebsiella*, *Paenibacillus*, *Arthrobacter*, *Corynebacterium*, *Brevibacterium*, *Pichia*, *Candida*, *Hansenula* and *Saccharomyces*. Preferred hosts include: *Escherichia coli*, *Alcaligenes eutrophus*, *Bacillus licheniformis*, *Paenibacillus macerans*, *Rhodococcus erythropolis*, *Pseudomonas putida*, *Lactobacillus plantarum*, *Enterococcus faecium*, *Enterococcus gallinarium*, *Enterococcus faecalis*, *Bacillus subtilis* and *Saccharomyces cerevisiae*.

#### Construction of Production Host

Recombinant microorganisms containing the necessary genes that will encode the enzymatic pathway for the conversion of a fermentable carbon substrate to isobutanol may be constructed using techniques well known in the art. In the present invention, genes encoding the enzymes of one of the isobutanol biosynthetic pathways of the invention, for example, acetolactate synthase, acetohydroxy acid isomerase, acetohydroxy acid dehydratase, branched-chain  $\alpha$ -keto acid decarboxylase, and branched-chain alcohol dehydrogenase, may be isolated from various sources, as described above.

Methods of obtaining desired genes from a bacterial genome are common and well known in the art of molecular biology. For example, if the sequence of the gene is known, suitable genomic libraries may be created by restriction endonuclease digestion and may be screened with probes complementary to the desired gene sequence. Once the sequence is isolated, the DNA may be amplified using standard primer-directed amplification methods such as polymerase chain reaction (U.S. Pat. No. 4,683,202) to obtain amounts of DNA suitable for transformation using appropriate vectors. Tools for codon optimization for expression in a heterologous host are readily available. Some tools for codon optimization are available based on the GC content of the host microorganism.

Once the relevant pathway genes are identified and isolated they may be transformed into suitable expression hosts by means well known in the art. Vectors or cassettes useful for the transformation of a variety of host cells are common and commercially available from companies such as EPICENTRE® (Madison, Wis.), Invitrogen Corp. (Carlsbad, Calif.), Stratagene (La Jolla, Calif.), and New England Biolabs, Inc. (Beverly, Mass.). Typically the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. Both control regions may be derived from genes homologous to the transformed host cell, although it is to be understood that such control regions may also be derived from genes that are not native to the specific species chosen as a production host.

Initiation control regions or promoters, which are useful to drive expression of the relevant pathway coding regions in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genetic elements is suitable for the present invention including, but not limited to, CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI (useful for expression in *Saccharomyces*); AOX1 (useful for expression in *Pichia*); and lac, ara, tet, trp, IP<sub>L</sub>, IP<sub>R</sub>, T7, tac, and trc (useful for expression in *Escherichia coli*, *Alcaligenes*, and *Pseudomonas*) as well as the amy, apr, npr promoters and various phage promoters useful for expression in *Bacillus subtilis*, *Bacillus licheniformis*, and *Paenibacillus macerans*.

Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary, however, it is most preferred if included.

Certain vectors are capable of replicating in a broad range of host bacteria and can be transferred by conjugation. The complete and annotated sequence of pRK404 and three related vectors-pRK437, pRK442, and pRK442(H) are available. These derivatives have proven to be valuable tools for genetic manipulation in Gram-negative bacteria (Scott et al., Plasmid, 50: 74-79, 2003). Several plasmid derivatives of broad-host-range Inc P4 plasmid RSF1010 are also available with promoters that can function in a range of Gram-negative bacteria. Plasmid pAYC36 and pAYC37, have active promoters along with multiple cloning sites to allow for the heterologous gene expression in Gram-negative bacteria.

Chromosomal gene replacement tools are also widely available. For example, a thermosensitive variant of the broad-host-range replicon pWV101 has been modified to construct a plasmid pVE6002 which can be used to effect gene replacement in a range of Gram-positive bacteria (Maguin et al., J. Bacteriol., 174: 5633-5638, 1992). Addi-

tionally, in vitro transposomes are available to create random mutations in a variety of genomes from commercial sources such as EPICENTRE®.

The expression of an isobutanol biosynthetic pathway in various preferred microbial hosts is described in more detail below.

#### Expression of an Isobutanol Biosynthetic Pathway in *E. coli*

Vectors or cassettes useful for the transformation of *E. coli* are common and commercially available from the companies listed above. For example, the genes of an isobutanol biosynthetic pathway may be isolated from various sources, cloned into a modified pUC19 vector and transformed into *E. coli* NM522.

#### Expression of an Isobutanol Biosynthetic Pathway in *Rhodococcus erythropolis*

A series of *E. coli-Rhodococcus* shuttle vectors are available for expression in *R. erythropolis*, including, but not limited to, pRhBR17 and pDA71 (Kostichka et al., Appl. Microbiol. Biotechnol., 62: 61-68, 2003). Additionally, a series of promoters are available for heterologous gene expression in *R. erythropolis* (Nakashima et al., Appl. Environ. Microbiol., 70: 5557-5568, 2004 and Tao et al., Appl. Microbiol. Biotechnol., 68: 346-354, 2005). Targeted gene disruption of chromosomal genes in *R. erythropolis* may be created using the method described by Tao et al., supra, and Brans et al. (Appl. Environ. Microbiol., 66: 2029-2036, 2000).

The heterologous genes required for the production of isobutanol, as described above, may be cloned initially in pDA71 or pRhBR71 and transformed into *E. coli*. The vectors may then be transformed into *R. erythropolis* by electroporation, as described by Kostichka et al., supra. The recombinants may be grown in synthetic medium containing glucose and the production of isobutanol can be followed using methods known in the art.

#### Expression of an Isobutanol Biosynthetic Pathway in *B. subtilis*

Methods for gene expression and creation of mutations in *B. subtilis* are also well known in the art. For example, the genes of an isobutanol biosynthetic pathway may be isolated from various sources, cloned into a modified pUC19 vector and transformed into *Bacillus subtilis* BE1010. Additionally, the five genes of an isobutanol biosynthetic pathway can be split into two operons for expression. The three genes of the pathway (bubB, ilvD, and kivD) can be integrated into the chromosome of *Bacillus subtilis* BE1010 (Payne, et al., J. Bacteriol., 173, 2278-2282, 1991). The remaining two genes (ilvC and bdhB) can be cloned into an expression vector and transformed into the *Bacillus* strain carrying the integrated isobutanol genes.

#### Expression of an Isobutanol Biosynthetic Pathway in *B. licheniformis*

Most of the plasmids and shuttle vectors that replicate in *B. subtilis* may be used to transform *B. licheniformis* by either protoplast transformation or electroporation. The genes required for the production of isobutanol may be cloned in plasmids pBE20 or pBE60 derivatives (Nagarajan et al., Gene, 114: 121-126, 1992). Methods to transform *B. licheniformis* are known in the art (Fleming et al. Appl. Environ. Microbiol., 61: 3775-3780, 1995). The plasmids constructed for expression in *B. subtilis* may be transformed into *B. licheniformis* to produce a recombinant microbial host that produces isobutanol.

#### Expression of an Isobutanol Biosynthetic Pathway in *Paenibacillus macerans*

Plasmids may be constructed as described above for expression in *B. subtilis* and used to transform *Paenibacillus*

*macerans* by protoplast transformation to produce a recombinant microbial host that produces isobutanol.

Expression of the Isobutanol Biosynthetic Pathway in *Alcaligenes (Ralstonia) eutrophus*

Methods for gene expression and creation of mutations in *Alcaligenes eutrophus* are known in the art (Taghavi et al., Appl. Environ. Microbiol., 60: 3585-3591, 1994). The genes for an isobutanol biosynthetic pathway may be cloned in any of the broad host range vectors described above, and electroporated to generate recombinants that produce isobutanol. The poly(hydroxybutyrate) pathway in *Alcaligenes* has been described in detail, a variety of genetic techniques to modify the *Alcaligenes eutrophus* genome is known, and those tools can be applied for engineering an isobutanol biosynthetic pathway.

Expression of an Isobutanol Biosynthetic Pathway in *Pseudomonas putida*

Methods for gene expression in *Pseudomonas putida* are known in the art (see for example Ben-Bassat et al., U.S. Pat. No. 6,586,229, which is incorporated herein by reference). The butanol pathway genes may be inserted into pPCU18 and this ligated DNA may be electroporated into electrocompetent *Pseudomonas putida* DOT-T1 C5aAR1 cells to generate recombinants that produce isobutanol.

Expression of an Isobutanol Biosynthetic Pathway in *Saccharomyces cerevisiae*

Methods for gene expression in *Saccharomyces cerevisiae* are known in the art (e.g., *Methods in Enzymology*, Volume 194, *Guide to Yeast Genetics and Molecular and Cell Biology*, Part A, 2004, Christine Guthrie and Gerald R. Fink, eds., Elsevier Academic Press, San Diego, Calif.). Expression of genes in yeast typically requires a promoter, followed by the gene of interest, and a transcriptional terminator. A number of yeast promoters can be used in constructing expression cassettes for genes encoding an isobutanol biosynthetic pathway, including, but not limited to constitutive promoters FBA, GPD, ADH1, and GPM, and the inducible promoters GAL1, GAL10, and CUP1. Suitable transcriptional terminators include, but are not limited to FBAt, GPDt, GPMt, ERG10t, GAL1t, CYC1, and ADH1. For example, suitable promoters, transcriptional terminators, and the genes of an isobutanol biosynthetic pathway may be cloned into *E. coli*-yeast shuttle vectors.

Expression of an Isobutanol Biosynthetic Pathway in *Lactobacillus plantarum*

The *Lactobacillus* genus belongs to the Lactobacillales family and many plasmids and vectors used in the transformation of *Bacillus subtilis* and *Streptococcus* may be used for *lactobacillus*. Non-limiting examples of suitable vectors include pAMβ1 and derivatives thereof (Renault et al., Gene 183:175-182, 1996); and (O'Sullivan et al., Gene, 137: 227-231, 1993); pMBB1 and pHW800, a derivative of pMBB1 (Wyckoff et al., Appl. Environ. Microbiol., 62: 1481-1486, 1996); pMG1, a conjugative plasmid (Tanimoto et al., J. Bacteriol., 184: 5800-5804, 2002); pNZ9520 (Kleerebezem et al., Appl. Environ. Microbiol., 63: 4581-4584, 1997); pAM401 (Fujimoto et al., Appl. Environ. Microbiol., 67: 1262-1267, 2001); and pAT392 (Arthur et al., Antimicrob. Agents Chemother., 38: 1899-1903, 1994). Expression vectors for *E. faecalis* using the nisA gene from *Lactococcus* may also be used (Eichenbaum et al., Appl. Environ. Microbiol., 64: 2763-2769, 1998). Additionally, vectors for gene replacement in the *E. faecium* chromosome may be used (Nallaapareddy et al., Appl. Environ. Microbiol., 72: 334-345, 2006).

Fermentation Media

10 Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated. In addition to one and two carbon substrates methylotrophic microorganisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., *Microb. Growth Cl-Compd.*, [Int. Symp.], 7th (1993), 415-32. (eds): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al., Arch. Microbiol., 153: 485-489, 1990). Hence it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon containing substrates and will only be limited by the choice of microorganism.

15 20 25 30 35 40 45 50 55 60 65

Although it is contemplated that all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are glucose, fructose, and sucrose.

In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for growth of the cultures and promotion of the enzymatic pathway necessary for isobutanol production.

Culture Conditions

Typically cells are grown at a temperature in the range of about 25° C. to about 40° C. in an appropriate medium. Suitable growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast Medium (YM) broth. Other defined or synthetic growth media may also be used, and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 2',3'-monophosphate (cAMP), may also be incorporated into the fermentation medium.

Expression of an Isobutanol Biosynthetic Pathway in Various *Enterococcus* Species (*E. faecium*, *E. gallinarum*, and *E. faecalis*)

The *Enterococcus* genus belongs to the Lactobacillales family and many plasmids and vectors used in the transfor-

29

Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred for the initial condition.

Fermentations may be performed under aerobic or anaerobic conditions, where anaerobic or microaerobic conditions are preferred.

#### Industrial Batch and Continuous Fermentations

The present process employs a batch method of fermentation. A classical batch fermentation is a closed system where the composition of the medium is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the medium is inoculated with the desired microorganism or microorganisms, and fermentation is permitted to occur without adding anything to the system. Typically, however, a "batch" fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems the metabolite and biomass compositions of the system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk of production of end product or intermediate.

A variation on the standard batch system is the Fed-Batch system. Fed-Batch fermentation processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the medium. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO<sub>2</sub>. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Thomas D. Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, Mass., or Deshpande, Mukund (Appl. Biochem. Biotechnol., 36: 227, 1992), herein incorporated by reference.

Although the present invention is performed in batch mode it is contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

Continuous fermentation allows for modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth may be altered continuously while the cell concentration, measured by medium turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to the medium being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for

30

maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, *supra*.

It is contemplated that the present invention may be practiced using either batch, fed-batch or continuous processes and that any known mode of fermentation would be suitable. Additionally, it is contemplated that cells may be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for isobutanol production.

#### 10 Methods for Isobutanol Isolation from the Fermentation Medium

The biologically produced isobutanol may be isolated from the fermentation medium using methods known in the art for Acetone-butanol-ethanol (ABE) fermentations (see for example, Durre, Appl. Microbiol. Biotechnol. 49: 639-648, 1998), and (Groot et al., Process. Biochem. 27: 61-75, 1992 and references therein). For example, solids may be removed from the fermentation medium by centrifugation, filtration, decantation and isobutanol may be isolated from the fermentation medium using methods such as distillation, azeotropic distillation, liquid-liquid extraction, adsorption, gas stripping, membrane evaporation, or pervaporation.

## EXAMPLES

The present invention is further defined in the following Examples.

It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various uses and conditions.

#### General Methods:

Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., *40 Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, by T. J. Silhavy, M. L. Bennan, and L. W. Enquist, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1984, and by Ausubel, F. M. et al., *45 Current Protocols in Molecular Biology*, Greene Publishing Assoc. and Wiley-Interscience, N.Y., 1987. Materials and Methods suitable for the maintenance and growth of bacterial cultures are also well known in the art. Techniques suitable for use in the following Examples may be found in *Manual of Methods for General Bacteriology*, Phillip Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds., American Society for Microbiology, Washington, D.C., 1994, or by Thomas D. Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition, Sinauer Associates, Inc., Sunderland, Mass., 1989. All reagents, restriction enzymes and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, Wis.), BD Diagnostic Systems (Sparks, Md.), Life Technologies (Rockville, Md.), or Sigma Chemical Company (St. Louis, Mo.), unless otherwise specified.

The meaning of abbreviations used is as follows: "Å" means Angstrom, "min" means minute(s), "h" means hour(s), "µl" means microliter(s), "ng/µl" means nano gram per microliter, "pmol/µl" means pico mole per microliter, "ml" means milliliter(s), "L" means liter(s), "g/L" mean gram per liter, "ng" means nano gram, "sec" means second(s), "ml/

31

“min” means milliliter per minute(s), “w/v” means weight per volume, “v/v” means volume per volume, “nm” means nanometer(s), “mm” means millimeter(s), “cm” means centimeter(s), “mM” means millimolar, “M” means molar, “mmol” means millimole(s), “μmole” means micromole(s), “g” means gram(s), “μg” means microgram(s), “mg” means milligram(s), “g” means the gravitation constant, “rpm” means revolutions per minute, “HPLC” means high performance liquid chromatography, “MS” means mass spectrometry, “HPLC/MS” means high performance liquid chromatography/mass spectrometry, “EDTA” means ethylenediamine-tetraacetic acid, “dNTP” means deoxynucleotide triphosphate, “° C.” means degrees Celsius, and “V” means voltage.

The oligonucleotide primers used in the following Examples have been described herein (see Table 1).

#### High Throughput Screening Assay of Gene Libraries

High throughput screening of the gene libraries of mutant KARI enzymes was performed as described herein: 10× freezing medium containing 554.4 g/L glycerol, 68 mM of  $(\text{NH}_4)_2\text{SO}_4$ , 4 mM  $\text{MgSO}_4$ , 17 mM sodium citrate, 132 mM  $\text{KH}_2\text{PO}_4$ , 36 mM  $\text{K}_2\text{HPO}_4$  was prepared with molecular pure water and filter-sterilized. Freezing medium was prepared by diluting the 10× freezing medium with the LB medium. An aliquot (200 μl) of the freezing medium was used for each well of the 96-well archive plates (cat #3370, Corning Inc. Corning, N.Y.).

Clones from the LB agar plates were selected and inoculated into the 96-well archive plates containing the freezing medium and grown overnight at 37° C. without shaking. The archive plates were then stored at -80° C. *E. coli* strain Bw25113 transformed with pBAD-H isB (Invitrogen) was always used as the negative control. For libraries C, E, F and G, mutant T52D of (PF5-ilvC) was used as the positive control. The mutant T52D was a mutant of PF5-ilvC in which the threonine at position 52 was changed to aspartic acid. For library H, mutant C3B11 (R47F/S50A/T52D/v53W of PF5-ilvC) was used as the positive control.

Clones from archive plates were inoculated into the 96-deep well plates. Each well contained 3.0 μl of cells from thawed archive plates, 300 μl of the LB medium containing 100 μg/ml ampicillin and 0.02% (w/v) arabinose as the inducer. Cells were grown overnight at 37° C. with 80% humidity while shaking (900 rpm), harvested by centrifugation (4000 rpm, 5 min at 25° C.). (Eppendorf centrifuge, Brinkmann Instruments, Inc. Westbury, N.Y.) and the cell pellet was stored at -20° C. for later analysis.

The assay substrate, (R,S)-acetolactate, was synthesized as described by Aulabaugh and Schloss (Aulabaugh and Schloss, Biochemistry, 29: 2824-2830, 1990): 1.0 g of 2-acetoxy-2-methyl-3-oxobutyric acid ethyl ester (Aldrich, Milwaukee, Wis.) was mixed with 10 ml NaOH (1.0 M) and stirred at room temperature. When the solution's pH became neutral, additional NaOH was slowly added until pH~8.0 was maintained. All other chemicals used in the assay were purchased from Sigma.

The enzymatic conversion of acetolactate to αβ-dihydroxyisovalerate by KARI was followed by measuring the disappearance of the cofactor, NADPH or NADH, from the reaction at 340 nm using a plate reader (Molecular Device, Sunnyvale, Calif.). The activity was calculated using the molar extinction coefficient of 6220  $\text{M}^{-1} \text{ cm}^{-1}$  for either NADPH or NADH. The stock solutions used were:  $\text{K}_2\text{HPO}_4$  (0.2 M);  $\text{KH}_2\text{PO}_4$  (0.2 M); EDTA (0.5 M);  $\text{MgCl}_2$  (1.0 M); NADPH (2.0 mM); NADH (2.0 mM) and acetolactate (45

32

mM). The 100 ml reaction buffer mix stock containing: 4.8 ml  $\text{K}_2\text{HPO}_4$ , 0.2 ml  $\text{KH}_2\text{PO}_4$ , 4.0 ml  $\text{MgCl}_2$ , 0.1 ml EDTA and 90.9 ml water was prepared.

Frozen cell pellet in deep-well plates and BugBuster were warmed up at room temperature for 30 min at the same time. Each well of 96-well assay plates was filled with 120 μl of the reaction buffer and 20 μl of NADH (2.0 mM), 150 μl of BugBuster was added to each well after 30 min warm-up and cells were suspended using Genmate (Tecan Systems Inc. San Jose, Calif.) by pipetting the cell suspension up and down (x5). The plates were incubated at room temperature for 20 min and then heated at 60° C. for 10 min. The cell debris and protein precipitates were removed by centrifugation at 4,000 rpm for 5 min at 25° C. An aliquot (50 μl) of the supernatant was transferred into each well of 96-well assay plates, the solution was mixed and the bubbles were removed by centrifugation at 4,000 rpm at 25° C. for 1 min. Absorbance at 340 nm was recorded as background, 20 μl of acetolactate (4.5 mM, diluted with the reaction buffer) was added to each well and mixed with shaking by the plate reader. Absorbance at 340 nm was recorded at 0, and 60 minutes after substrate addition. The difference in absorbance (before and after substrate addition) was used to determine the activity of the mutants. Mutants with higher KARI activity compared to the wild type were selected for re-screening.

About 5,000 clones were screened for library C and 360 top performers were selected for re-screen. About 92 clones were screened for library E and 16 top performers were selected for re-screening. About 92 clones were screened for library F and 30 top performers were selected for re-screening. About 92 clones were screened for library G and 20 top performers were selected for re-screening. About 8,000 clones were screened for library H and 62 top performers were selected for re-screening. The re-screening was described below as secondary assay.

#### Secondary Assay of Active Mutants

Cells containing pBad-ilvC and its mutants identified by high throughput screening were grown overnight, at 37° C., in 3.0 ml of the LB medium containing 100 μg/ml ampicillin and 0.02% (w/v) arabinose as the inducer while shaking at 250 rpm. The cells were then harvested by centrifugation at 18,000×g for 1 min at room temperature (Sigma micro-centrifuge model 1-15, Laurel, MD). The cell pellets were resuspended in 300 μl of BugBuster Master Mix (EMD Chemicals). The reaction mixture was first incubated at room temperature for 20 min and then heated at 60° C. for 10 min. The cell debris and protein precipitate were removed by centrifugation at 18,000×g for 5 min at room temperature.

The reaction buffer (120 μl) prepared as described above was mixed with either NADH or NADPH (20 μl) stock and cell extract (20 μl) in each well of a 96-well assay plate. The absorbance at 340 nm at 25° C. was recorded as background. Then 20 μl of acetolactate (4.5 mM, diluted with reaction buffer) was added each well and mixed with shaking by the plate reader. The absorbance at 340 nm at 0 min, 2 min and 5 min after adding acetolactate was recorded. The absorbance difference before and after adding substrate was used to determine the activity of the mutants. The mutants with high activity were selected for sequencing.

Five top performers from “Library C” were identified and sequenced (FIG. 4). The best performer was mutant R47F/S50A/T52D/V53W, which completely reversed the nucleotide specificity. The best performers from “Libraries E, F and G” were R47P, S50D and T52D respectively (FIG. 5). For “Library H”, 5 top performers were identified and sequenced (FIG. 6) and the best performer was R47P/S50G/T52D, which also completely reversed the nucleotide specificity.

Enzymes containing activities higher than the background were considered positive.

#### KARI Enzyme Assay

KARI enzyme activity can be routinely measured by NADH or NADPH oxidation as described above, however to measure formation of the 2,3-dihydroxyisovalerate product directly, analysis of the reaction was performed using HPLC/MS.

Protein concentration of crude cell extract from Bugbuster lysed cells (as described above) was measured using the Bio-Rad protein assay reagent (BioRad Laboratories, Inc., Hercules, Calif. 94547). A total of 0.5 micrograms of crude extract protein was added to a reaction buffer consisting of 100 mM HEPES-KOH, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM glucose-6-phosphate (Sigma-Aldrich), 0.2 Units of *Leuconostoc mesenteroides* glucose-6-phosphate dehydrogenase (Sigma-Aldrich), and various concentrations of NADH or NADPH, to a volume of 96 µL. The reaction was initiated by the addition of 4 µL of acetolactate to a final concentration of 4 mM and a final volume of 100 µL. After timed incubations at 30° C., typically between 2 and 15 min, the reaction was quenched by the addition of 10 µL of 0.5 M EDTA, pH 8.0 (Life Technologies, Grand Island, N.Y. 14072). To measure the K<sub>M</sub> of NADH, the concentrations used were 0.03, 0.1, 0.3, 1, 3, and 10 mM.

To analyze for 2,3-dihydroxyisovalerate, the sample was diluted 10x with water, and 8.0 µL was injected into a Waters Acquity HPLC equipped with Waters SQD mass spectrometer (Waters Corporation, Milford, Mass.). The chromatography conditions were: flow rate (0.5 ml/min), on a Waters Acquity HSS T3 column (2.1 mm diameter, 100 mm length). Buffer A consisted of 0.1% (v/v) in water, Buffer B was 0.1% formic acid in acetonitrile. The sample was analyzed using 1% buffer B (in buffer A) for 1 min, followed by a linear gradient from 1% buffer B at 1 min to 75% buffer B at 1.5 min. The reaction product, 2,3-dihydroxyisovalerate, was detected by ionization at m/z=133, using the electrospray ionization devise at -30 V cone voltage. The amount of product 2,3-dihydroxyisovalerate was calculated by comparison to an authentic standard.

To calculate the K<sub>M</sub> for NADH, the rate data for DHIV formation was plotted in Kaleidagraph (Synergy Software, Reading, Pa.) and fitted to the single substrate Michaelis-Menton equation, assuming saturating acetolactate concentration.

#### Example 1

##### Construction of Site-Saturation Gene Libraries to Identify Mutants Accepting NADH as Cofactor

Seven gene libraries were constructed (Table 2) using two steps: 1) synthesis of Megaprimer using commercially synthesized oligonucleotides described in Table 1; and 2) construction of mutated genes using the Megaprimer obtained in step 1. These primers were prepared using high fidelity pfu-ultra polymerase (Stratagene, La Jolla, Calif.) for one pair of primer containing one forward and one reverse primer. The templates for libraries C, E, F, G and H were the wild type of PF5\_ilvc. The DNA templates for library N were those mutants having detectable NADH activity from library C while those for library O were those mutants having detectable NADH activity from library H. A 50 µL reaction mixture contained: 5.0 µL of 10x reaction buffer supplied with the pfu-ultra polymerase (Stratagene), 1.0 µL of 50 ng/µL template, 1.0 µL each of 10 pmol/µL forward and reverse primers,

1.0 µL of 40 mM dNTP mix (Promega, Madison, Wis.), 1.0 µL pfu-ultra DNA polymerase (Stratagene) and 39 µL water. The mixture was placed in a thin well 200 µL tube for the PCR reaction in a Mastercycler gradient equipment (Brinkmann Instruments, Inc. Westbury, N.Y.). The following conditions were used for the PCR reaction: The starting temperature was 95° C. for 30 sec followed by 30 heating/cooling cycles. Each cycle consisted of 95° C. for 30 sec, 54° C. for 1 min, and 70° C. for 2 min. At the completion of the temperature cycling, the samples were kept at 70° C. for 4 min more, and then held awaiting sample recovery at 4° C. The PCR product was cleaned up using a DNA cleaning kit (Cat #D4003, Zymo Research, Orange, Calif.) as recommended by the manufacturer.

TABLE 2

Gene Libraries			
Library name	Templates	Targeted position(s) of Pf5_ilvc	Primers used
C	PF5_ilvc	47, 50, 52 and 53	SEQ ID No: 1 and 2
E	PF5_ilvc	47	SEQ ID No: 1 and 3
F	PF5_ilvc	50	SEQ ID No: 1 and 4
G	PF5_ilvc	52	SEQ ID No: 1 and 5
H	PF5_ilvc	47, 50, and 52	SEQ ID No: 1 and 6
N	Good mutants from library C	53	SEQ ID NO: 20 and 21
O	Good mutants from library H	53	SEQ ID NO: 20 and 21

The Megaprimer were then used to generate gene libraries using the QuickChange II XL site directed mutagenesis kit (Catalog #200524, Stratagene, La Jolla Calif.). A 50 µL reaction mixture contained: 5.0 µL of 10x reaction buffer, 1.0 µL of 50 ng/µL template, 42 µL Megaprimer, 1.0 µL of 40 mM dNTP mix, 1.00 pfu-ultra DNA polymerase. Except for the Megaprimer and the templates, all reagents used here were supplied with the kit indicated above. This reaction mixture was placed in a thin well 200 µL-capacity PCR tube and the following reactions were used for the PCR: The starting temperature was 95° C. for 30 sec followed by 25 heating/cooling cycles. Each cycle consisted of 95° C. for 30 sec, 55° C. for 1 min, and 68° C. for 6 min. At the completion of the temperature cycling, the samples were kept at 68° C. for 8 min more, and then held at 4° C. for later processing. Dpn I restriction enzyme (1.0 µL) (supplied with the kit above) was directly added to the finished reaction mixture, enzyme digestion was performed at 37° C. for 1 h and the PCR product was cleaned up using a DNA cleaning kit (Zymo Research). The cleaned PCR product (10 µL) contained mutated genes for a gene library.

The cleaned PCR product was transformed into an electro-competent strain of *E. coli* Bw25113 (Δilvc) using a BioRad Gene Pulser II (Bio-Rad Laboratories Inc., Hercules, Calif.). The transformed clones were streaked on agar plates containing the LB medium and 100 µg/ml ampicillin (Cat #L1004, Teknova Inc. Hollister, Calif.) and incubated at 37° C. overnight. Dozens of clones were randomly chosen for DNA sequencing to confirm the quality of the library.

35

TABLE 3

List of some mutants having NADH activity identified from saturation libraries				
Mutant	Position 47	Position 50	Position 52	Position 53
SD2	R47Y	S50A	T52H	V53W
SB1	R47Y	S50A	T52G	V53W
SE1	R47A	S50W	T52G	V53W
SH2	R47N	S50W	T52N	V53W
SB2	R47I		T52G	V53W
SG1	R47Y		T52G	V53W
SB3	R47G	S50W	T52G	V53W
SE2	R47P	S50E	T52A	V53W
SD3	R47L	S50W	T52G	V53W
C2A6	R47I	S50G	T52D	V53W
C3E11	R47A	S50M	T52D	V53W
C3A7	R47Y	S50A	T52D	V53W
C3B11	R47F	S50A	T52D	V53W
C4A5	R47Y	S50A	T52S	V53W
C3B12	R47I		T52D	V53W
C4H7	R47I		T52S	V53W
C1D3	R47G	S50M	T52D	V53W
C4D12	R47C	S50W	T52G	V53W
C1G7	R47P	S50G	T52D	V53W
C2F6	R47P	S50V	T52D	V53W
C1C4	R47P	S50E	T52S	V53W
6924F9	R47P	S50G	T52D	
6881E11	R47P	S50N	T52C	
6868F10	R47P		T52S	
6883G10	R47P	S50D	T52S	
6939G4	R47P	S50C	T52D	
11463D8	R47P	S50F	T52D	
9667A11	R47N	S50N	T52D	V53A
9675C8	R47Y	S50A	T52D	V53A
9650E5	R47N	S50W	T52G	V53H
9875B9	R47N	S50N	T52D	V53W
9862B9	R47D	S50W	T52G	V53W
9728G11	R47N	S50W	T52G	V53W
11461D8	R47F	S50A	T52D	V53A
11461A2	R47P	S50F	T52D	V53I

## Example 2

## Construction of Error Prone pcr Librar

Mutants obtained in Example 1, with mutations in their cofactor binding sites which exhibited relatively good NADH activities, were used as the DNA template to prepare the error prone (ePCR) libraries using the GeneMorph II kit (Stratagene) as recommended by the manufacturer. All the epPCR libraries target the N-terminal (which contains the NADPH binding site) of PF5\_KARI. The forward primer (SED ID No: 20) and the reverse primer (SED ID No: 22) were used for all ePCR libraries.

The DNA templates for the  $n^{th}$  epPCR library were mutants having good NADH activity from the  $(n-1)^{th}$  epPCR library. The templates of the first epPCR library were mutants having relatively good NADH activity from libraries N and O. The mutations rate of library made by this kit was controlled by the amount of template added in the reaction mixture and the number of amplification cycles. Typically, 1.0 ng of each DNA template was used in 100  $\mu$ l of reaction mixture. The number of amplification cycles was 70. The following conditions were used for the PCR reaction: The starting temperature was 95° C. for 30 sec followed by 70 heating/cooling cycles. Each cycle consisted of 95° C. for 30 sec, 55° C. for 30

36

min, and 70° C. for 2 min. After the first 35 heating/cooling cycles finished, more dNTP and Mutazyme II DNA polymerase were added. The PCR product was cleaned up using a DNA cleaning kit (Cat #D4003, Zymo Research, Orange, Calif.) as recommended by the manufacturer. The cleaned PCR product was treated as Megaprimer and introduced into the vector using the Quickchange kit as described in Example 1. Table 4 below lists the KARI mutants obtained and the significant improvement observed in their NADH binding ability. The  $K_M$  was reduced from 1100  $\mu$ M for mutant C3B11 to 50  $\mu$ M for mutant 12957G9.

TABLE 4

List of some mutants with their measured $K_M$ values		
Mutant	Mutation Locations	NADH $K_M$ ( $\mu$ M)
C3B11	R47F/S50A/T52D/V53W	1100
SB3	R47G/S50W/T52G/V53W	500
11518B4	R47N/S50N/T52D/V53A/A156V	141
11281G2	R47N/S50N/T52D/V53A/A156V/L165M	130
12985F6	R47Y/S50A/T52D/V53A/L61F/A156V	100
13002D8	R47Y/S50A/T52D/V53A/L61F/A156V/G170A	68
12957G9	Y24F/R47Y/S50A/T52D/V53A/L61F/G170A	50
12978D9	R47Y/S50A/T52D/V53A/L61F/Q115L/A156V	114

## Example 3

## Identification of Amino Acids for Cofactor Specificity Switching Using Bioinformatic Tools

To discover if naturally existing KARI sequences could provide clues for amino acid positions that should be targeted for mutagenesis, multiple sequence alignment (MSA) using PF5\_KARI, its close homolog PAO1\_KARI and three KARI sequences with measurable NADH activity, i.e., *B. Cereus* ilvC1 and ilvC2 and spinach KARI were performed (FIG. 8). Based on the multiple sequence alignment, positions 33, 43, 59, 61, 71, 80, 101, and 119 were chosen for saturation mutagenesis. Saturation mutagenesis on all of these positions was performed simultaneously using the QuickChange II XL site directed mutagenesis kit (Catalog #200524, Stratagene, La Jolla Calif.) with the manufacturer's suggested protocol. Starting material for this mutagenesis was a mixed template consisting of the mutants already identified in Example 2, Table 4. The primers used are listed in Table 5. The library of mutants thus obtained were named "library Z". Mutants with good NADH activity from this library were identified using high throughput screening and their KARI activity and the  $K_M$  for NADH were measured as described above. These mutants (Table 6) possess much lower  $K_M$ 's for NADH compared to the parent templates (Table 4). A Megaprimer, using primers (SEQ ID Nos. 20 and 58), was created and mutations at positions 156 and 170 were eliminated. Further screening of this set of mutants identified mutant 3361 G8 (SEQ ID NO: 67)(Table 7). The hits from library Z were further subjected to saturation mutagenesis at position 53 using primers (SEQ ID Nos. 20 and 21), and subsequent screening identified the remaining mutants in Table 7. As shown in Table 7 the new mutants possessed much lower  $K_M$  for NADH (e.g., 4.0 to 5.5  $\mu$ M) compared to mutants listed in Table 6 (e.g., 14-40  $\mu$ M).

TABLE 5

Primers for Example 5	
Targeted position(s) of Pf5_iLvC	Primers
33	pBAD-405-C33_090808f: GCTCAAGCANNKAACCTGAAGG (SEQ ID NO: 49) pBAD-427-C33_090808r: CCTTCAGGTTKNNTGCTTGAGC (SEQ ID NO: 50)
43	pBAD-435-T43_090808f: GTAGACGTGNNKGGTGGCCTG (SEQ ID NO: 51) pBAD-456-T43_090808r: CAGGCCAACNNCACGTCTAC (SEQ ID NO: 52)
59 and 61	pBAD-484-H59L61_090808f: CTGAAGCCNNKGGCNKAAAGTGAC (SEQ ID NO: 53) pBAD-509-H59L61_090808r: GTCACTTKNNGCCKNNGGCTTCAG (SEQ ID NO: 54)
71	pBAD-519-A71_090808f: GCAGCCGTTNNKGGTGCCGACT (SEQ ID NO: 55) pBAD-541-A71_090808r: AGTCGGCACCKNNAACGGCTGC (SEQ ID NO: 56)
80	pBAD-545-T80_090808f: CATGATCCTGNNKCCGGACGAG (SEQ ID NO: 57) pBAD-567-T80_090808r: CTCGTCCGGKNNCAGGATCATG (SEQ ID NO: 58)
101	pBAD-608-A101_090808f: CAAGAAGGGCNNKACTCTGGCCT (SEQ ID NO: 59) pBAD-631-A101_090808r: AGGCCAGAGTKNNGCCCTTCTTG (SEQ ID NO: 60)
119	pBAD-663-R119_090808f: GTTGTGCCTNNKGCCGACCTCG (SEQ ID NO: 61) pBAD-685-R119_090808r: CGAGGTCGGCKNNAGGCACAAC (SEQ ID NO: 62)

35

TABLE 6

List of some mutants with their measured $K_M$ values (positions to be mutated in this library were identified by bioinformatic tools)		
Mutant	Mutation Locations	NADH $K_M$ ( $\mu\text{M}$ )
ZB1	Y24F/R47Y/S50A/T52D/V53A/L61F/A156V (SEQ ID NO: 24)	40
ZF3	Y24F/C33L/R47Y/S50A/T52D/V53A/L61F (SEQ ID NO: 25)	21
ZF2	Y24F/C33L/R47Y/S50A/T52D/V53A/L61F/A156V (SEQ ID NO: 26)	17
ZB3	Y24F/C33L/R47Y/S50A/T52D/V53A/L61F/G170A (SEQ ID NO: 27)	17
Z4B8	C33L/R47Y/S50A/T52D/V53A/L61F/T80I/A156V (SEQ ID NO: 28)	14

TABLE 7

Mutants further optimized for improved $K_M$ (for NADH)		
Mutant	Mutation Locations	NADH $K_m$ ( $\mu\text{M}$ )
3361G8	C33L/R47Y/S50A/T52D/V53A/L61F/T80I (SEQ ID NO: 67)	5.5
2H10	Y24F/C33L/R47Y/S50A/T52D/V53I/L61F/T80I/ A156V (SEQ ID NO: 68)	5.3
1D2	Y24F/R47Y/S50A/T52D/V53A/L61F/T80I/ A156V (SEQ ID NO: 69)	4.1
3F12	Y24F/C33L/R47Y/S50A/T52D/V53A/L61F/T80I/ A156V (SEQ ID NO: 70)	4.0

TABLE 7-continued

Mutants further optimized for improved $K_M$ (for NADH)			
40	Mutant	Mutation Locations	NADH $K_m$ ( $\mu\text{M}$ )
	3361E1	Y24F/R47Y/S50A/T52D/V53I/L61F (SEQ ID NO: 84)	4.5

45 Further analyses using bioinformatic tools were therefore performed to expand the mutational sites to other KARI sequences as described below.

#### Sequence Analysis

50 Members of the protein family of ketol-acid reducoisomerase (KARI) were identified through BlastP searches of publicly available databases using amino acid sequence of *Pseudomonas fluorescens* PF5 KARI (SEQ ID NO:17) with the following search parameters: E value=10, word size=3,

55 Matrix=Blosum62, and Gap opening=11 and gap extension=1, E value cutoff of  $10^{-3}$ . Identical sequences and sequences that were shorter than 260 amino acids were removed. In addition, sequences that lack the typical GxGXX (G/A) motif involved in the binding of NAD(P)H in the N-terminal domain were also removed. These analyses resulted in a set of 692 KARI sequences.

60 A profile HMM was generated from the set of the experimentally verified Class I and Class II KARI enzymes from various sources as described in Table 8. Details on building, calibrating, and searching with this profile HMM are provided below. Any sequence that can be retrieved by HMM search using the profile HMM for KARI at E-value above

$1E^{-3}$  is considered a member of the KARI family. Positions in a KARI sequence aligned to the following in the profile HMM nodes (defined below in the section of profile HMM building) are claimed to be responsible for NADH utilization: 24, 33, 47, 50, 52, 53, 61, 80, 115, 156, and 170 (the numbering is based on the sequences of *Pseudomonas fluorescens* Pf5 KARI).

#### Preparation of Profile HMM

A group of KARI sequences were expressed in *E. coli* and have been verified to have KARI activity. These KARIs are listed in Table 6. The amino acid sequences of these experimentally verified functional KARIs were analyzed using the HMMER software package (The theory behind profile HMMs is described in R. Durbin, S. Eddy, A. Krogh, and G. Mitchison, Biological sequence analysis: probabilistic models of proteins and nucleic acids, Cambridge University Press, 1998; Krogh et al., J. Mol. Biol. 235:1501-1531, 1994), following the user guide which is available from HMMER (Janelia Farm Research Campus, Ashburn, Va.). The output of the HMMER software program is a profile Hidden Markov Model (profile HMM) that characterizes the input sequences. As stated in the user guide, profile HMMs are statistical descriptions of the consensus of a multiple sequence alignment. They use position-specific scores for amino acids (or nucleotides) and position specific scores for opening and extending an insertion or deletion. Compared to other profile based methods, HMMs have a formal probabilistic basis. Profile HMMs for a large number of protein families are publicly available in the PFAM database (Janelia Farm Research Campus, Ashburn, Va.).

The profile HMM was built as follows:

#### Step 1. Build a Sequence Alignment

The 25 sequences for the functionally verified KARIs listed above were aligned using Clustal W (Thompson, J. D., Higgins, D. G., and Gibson T. J., Nuc. Acid Res. 22: 4673 4680, 1994) with default parameters. The alignment is shown in FIG. 9.

TABLE 8

25 Experimentally verified KARI enzymes			
GI Number	Accession	SEQ ID NO:	Microorganism
70732562	YP_262325.1	17	<i>Pseudomonas fluorescens</i> Pf-5
15897495	NP_342100.1	13	<i>Sulfolobus solfataricus</i> P2
18313972	NP_560639.1	14	<i>Pyrococcus aerophilum</i> str. IM2
76801743	YP_326751.1	30	<i>Natronomonas pharaonis</i> DSM 2160
16079881	NP_390707.1	31	<i>Bacillus subtilis</i> subsp. <i>subtilis</i> str. 168
19552493	NP_600495.1	32	<i>Corynebacterium glutamicum</i> ATCC 13032
6225553	O32414	33	<i>Phaeospirillum molischianum</i>
17546794	NP_520196.1	15	<i>Ralstonia solanacearum</i> GMI1000
56552037	YP_162876.1	34	<i>Zymomonas mobilis</i> subsp. <i>mobilis</i> ZM4
114319705	YP_741388.1	35	<i>Alkalilimnicola ehrlichei</i> MLHE-1
57240359	ZP_00368308.1	36	<i>Campylobacter lari</i> RM2100
120553816	YP_958167.1	37	<i>Marinobacter aquaeolei</i> VT8
71065099	YP_263826.1	38	<i>Psychrobacter arcticus</i> 273-4
83648555	YP_436990.1	39	<i>Hahella chejuensis</i> KCTC 2396
74318007	YP_315747.1	40	<i>Thiobacillus denitrificans</i> ATCC 25259
67159493	ZP_00420011.1	41	<i>Azotobacter vinelandii</i> AvOP
66044103	YP_233944.1	42	<i>Pseudomonas syringae</i> pv. <i>syringae</i> B728a

TABLE 8-continued

25 Experimentally verified KARI enzymes			
GI Number	Accession	SEQ ID NO:	Microorganism
28868203	NP_790822.1	43	<i>Pseudomonas syringae</i> pv. <i>tomato</i> str. DC3000
26991362	NP_746787.1	44	<i>Pseudomonas putida</i> KT2440
104783656	YP_610154.1	45	<i>Pseudomonas entomophila</i> L48
146306044	YP_001186509.1	46	<i>Pseudomonas mendocina</i> ymp
15599888	NP_253382.1	16	<i>Pseudomonas aeruginosa</i> PAO1
42780593	NP_977840.1	47	<i>Bacillus cereus</i> ATCC 10987
42781005	NP_978252.1	48	<i>Bacillus cereus</i> ATCC 10987
266346	Q01292	18	<i>Spinacia oleracea</i>

#### Step 2. Build a Profile HMM

The hmmbuild program was run on the set of aligned sequences using default parameters. hmmbuild reads the multiple sequence alignment file, builds a new profile HMM, and saves the profile HMM to file. Using this program an uncalibrated profile was generated from the multiple sequence alignment for twenty-four experimentally verified KARIs as described above.

The following information based on the HMMER software user guide gives some description of the way that the hmmbuild program prepares a profile HMM. A profile HMM is a linear state machine consisting of a series of nodes, each of which corresponds roughly to a position (column) in the multiple sequence alignment from which it is built. If gaps are ignored, the correspondence is exact, i.e., the profile HMM has a node for each column in the alignment, and each node can exist in one state, a match state. The word “match” here implies that there is a position in the model for every position in the sequence to be aligned to the model. Gaps are modeled using insertion (I) states and deletion (D) states. All columns that contain more than a certain fraction x of gap characters will be assigned as an insert column. By default, x is set to 0.5. Each match state has an I and a D state associated with it. HMMER calls a group of three states (M/D/I) at the same consensus position in the alignment a “node”.

A profile HMM has several types of probabilities associated with it. One type is the transition probability—the probability of transitioning from one state to another. There are also emissions probabilities associated with each match state, based on the probability of a given residue existing at that position in the alignment. For example, for a fairly well-conserved column in an alignment, the emissions probability for the most common amino acid may be 0.81, while for each of the other 19 amino acids it may be 0.01.

A profile HMM is completely described in a HMMER2 profile save file, which contains all the probabilities that are used to parameterize the HMM. The emission probabilities of a match state or an insert state are stored as log-odds ratio relative to a null model:  $\log_2(p_x)/(\text{null}_x)$ . Where  $p_x$  is the probability of an amino acid residue, at a particular position in the alignment, according to the profile HMM and  $\text{null}_x$  is the probability according to the Null model. The Null model is a simple one state probabilistic model with pre-calculated set of emission probabilities for each of the 20 amino acids derived from the distribution of amino acids in the SWISS-PROT release 24. State transition scores are also stored as log odds parameters and are proportional to  $\log_2(t_x)$ . Where  $t_x$  is the transition probability of transiting from one state to another state.

## Step 3. Calibrate the Profile HMM

The profile HMM was read using `hmmpcalibrate` which scores a large number of synthesized random sequences with the profile (the default number of synthetic sequences used is 5,000), fits an extreme value distribution (EVD) to the histogram of those scores, and re-saves the HMM file now including the EVD parameters. These EVD parameters ( $\mu$  and  $\lambda$ ) are used to calculate the E-values of bit scores when the profile is searched against a protein sequence database. `hmmpcalibrate` writes two parameters into the HMM file on a line labeled "EVD": these parameters are the  $\mu$  (location) and  $\lambda$  (scale) parameters of an extreme value distribution (EVD) that best fits a histogram of scores calculated on randomly generated sequences of about the same length and residue composition as SWISS-PROT. This calibration was done once for the profile HMM.

The calibrated profile HMM for the set of KARI sequences is provided appended hereto as a profile HMM Excel chart (Table 9). In the main model section starting from the HMM flag line, the model has three lines per node, for M nodes (where M is the number of match states, as given by the LENG line). The first line reports the match emission log-odds scores: the log-odds ratio of emitting each amino acid from that state and from the Null model. The first number if the node number (1..M). The next K numbers for match emission scores, one per amino acid. The highest scoring amino acid is indicated in the parenthesis after the node number. These log-odds scores can be converted back to HMM probabilities using the null model probability. The last number on the line represents the alignment column index for this match state. The second line reports the insert emission scores, and the third line reports on state transition scores: M→M, M→I, M→D; I→M, I→I; D→M, D→D; B→M; M→E.

## Step 4. Test the Specificity and Sensitivity of the Built Profile HMMs

The Profile HMM was evaluated using `hmmpsearch`, which reads a Profile HMM from `hmmfile` and searches a sequence file for significantly similar sequence matches. The sequence file searched contained 692 sequences (see above). During the search, the size of the database (Z parameter) was set to 1 billion. This size setting ensures that significant E-values against the current database will remain significant in the foreseeable future. The E-value cutoff was set at 10.

An `hmmersearch`, using `hmmpsearch`, with the profile HMM generated from the alignment of the twenty-five KARIs with experimentally verified function, matched all 692 sequences with an E value  $<10^{-3}$ . This result indicates that members of the KARI family share significant sequence similarity. A `hmmersearch` with a cutoff of E value  $10^{-3}$  was used to separate KARIs from other proteins.

## Step 5. Identify Positions that are Relevant for NAD(P)H Utilization.

Eleven positions have been identified in KARI of *Pseudomonas fluorescens* Pf-5 that switches the cofactor from NADPH to NADH. Since the KARI sequences share significant sequence similarity (as described above), it can be reasoned that the homologous positions in the alignment of KARI sequences should contribute to the same functional specificity. The profile HMM for KARI enzymes has been generated from the multiple sequence alignment which contains the sequence of *Pseudomonas fluorescens* Pf-5 KARI. The eleven positions in the profile HMM representing the columns in the alignment which correspond to the eleven cofactor switching positions in *Pseudomonas fluorescens* Pf-5 KARI are identified as positions 24, 33, 47, 50, 52, 53,

61, 80, 115, 156, and 170. The lines corresponding to these positions in the model file are highlighted in yellow in Table 9.

For any query sequence, `hmmpsearch` is used to search the profile HMM for KARI against the query sequence and the alignment of the query to the HMM is recorded in the output file. In the alignment section of the output, the top line is the HMM consensus. The amino acid shown for the consensus is the highest probability amino acid at that position according to the HMM (not necessarily the highest scoring amino acid). The center line shows letters for "exact" matches to the highest probability residue in the HMM, or a "+" when the match has a positive score. The third line shows the sequence itself. The positions in the query sequence that are deemed as relevant for cofactor switching are identified as those that are aligned to these eleven nodes in the profile HMM as described above. An example of the alignment of *Pseudomonas fluorescens* Pf-5 KARI to the profile HMM of KARI is shown in FIG. 10 and the eleven positions that are responsible for cofactor switching are shaded in grey.

## Example 4

## Construction of a Site-Saturation Gene Library for Complete Cofactor Switching to NADH

To construct the site-saturation gene library for KARI mutants, mutants 3361E1, 3361G8, 1D2, 2H10, 3F12, & Z4B8 (see Example 3, Tables 6 and 7) were used as templates. The library was constructed using QuickChange kit (Cat #200524, Stratagene, La Jolla, Calif.). The concentration of each mutant in the template mixture was 5.0 ng/ $\mu$ l. The two primers (2.5 nM) introducing saturation mutagenesis at positions 47, 50, 52 and 53, were PF5\_4Mt111008.f (SEQ ID NO: 71) and PF5\_4Mt111008.r (SEQ ID NO: 72).

## The PCR Reaction Mixture Contained:

40	10 x reaction buffer	5.0 $\mu$ l
	PF5_4Mt111008.f	2.0 $\mu$ l
	PF5_4Mt111008.r	2.0 $\mu$ l
	50 x dNTP	1.0 $\mu$ l
	DNA Template	1.0 $\mu$ l
	PfuUltra	1.0 $\mu$ l
	Water	38 $\mu$ l

## The PCR Reaction Program was:

50	1) 95° C.	30 sec
	2) 95° C.	30 sec
	3) 55° C.	1.0 min
	4) 68° C.	6.0 min
	5) Go to step (2)	Repeat 35 times
	6) 68° C.	8.0 min
	7) 4° C.	press Enter

The mixture was placed in a thin well 200  $\mu$ l tube for the PCR reaction in a Mastercycler gradient equipment (Brinkmann Instruments, Inc. Westbury, N.Y.). After the PCR reaction, 1.0  $\mu$ l Dpn I restriction enzyme (supplied with the kit above) was directly added into the PCR reaction mixture, which was then incubated at 37° C. for 1 h to remove the DNA templates. The Dpn I digested PCR product was cleaned up by the Zymo DNA clearance kit (Cat #D4003, Zymo Research, Orange, Calif.) as recommended by the manufacturer.

65 The cleaned PCR product was transformed into an electro-competent strain of *E. coli* Bw25113 (AilvC) using a BioRad Gene Pulser II (Bio-Rad Laboratories Inc., Hercules, Calif.).

The transformed clones were streaked on agar plates containing the LB medium and 100 µg/ml ampicillin (Cat #L1004, Teknova Inc. Hollister, Calif.) and incubated at 37° C. overnight. Dozens of clones were randomly chosen for DNA sequencing to confirm the quality of the library. Several mutants identified in this library (Table 10 and FIGS. 11A and 11B) had very low NADPH activity while they had good NADH activity. Their cofactor consumption is listed in Table 11 (The data was based on three parallel measurements). “Negative” in the following Tables refers to an empty pBAD vector without the KARI gene.

TABLE 10

List of some of the mutants identified in Example 1	
Mutant	Mutation Locations
JB1C6	Y24F/C33L/R47H/S50D/T52Y/V53Y/L61F/T80I/A156V
16445E4	C33L/R47P/S50V/T52D/V53G/L61F/T80I/A156V
16468D7	Y24F/C33L/R47T/S50I/T52D/V53R/L61F/T80I/A156V
16469F3	C33L/R47E/S50A/T52D/V53A/L61F/T80I

TABLE 11

The cofactor consumption of some mutants following a 5 min reaction (decrease in OD <sub>340 nm</sub> )				
Mutants	0.2 mM NADH		0.2 mM NADPH	
	average	stdev	average	stdev
JB1C6	-0.232	0.127	-0.019	0.009
16445E4	-0.152	0.057	-0.013	0.001
16468D7	-0.153	0.012	-0.039	0.020
16469F3	-0.054	0.069	-0.025	0.016
Z4B8	-0.178	0.042	-0.170	0.013
PF5_WT	-0.078	0.014	-0.320	0.024
Negative	-0.061	0.029	-0.015	0.014

## Example 5

## Construction of a Domain Swapping Library

In this Example the beneficial mutations outside the cofactor binding sites and the beneficial mutations within the cofactor binding sites were combined to create a domain swapping library.

Mutants, which had mutations in the cofactor binding site and exhibited only NADH activity (SE1, SB3, SE2, SD3, C2F6, C3B11, C4D12, 9650E5, 9667A11, 9862B9, 9875B9, 11461D8, 11463D8, 11518B4, SEQ ID NOs: 85-98), were used to obtain additional beneficial mutations in the cofactor binding site. Two primers, pBAD\_230f (SEQ ID NO: 73) and pBAD\_601\_021308r (SEQ ID NO: 74), were used to amplify the mutants listed in Table 12. PCR reagents used were from Invitrogen (Cat #10572-014, Invitrogen, Carlsbad, Calif.).

The PCR Reaction Mixture Contained:

5	PCR SuperMix	180 µl
	pBAD_230f (18 nM)	5.0 µl
	pBAD_601_021308r (10 nM)	9.0 µl
	Template mix (5.0 ng/µl)	6.0 µl

The PCR Reaction Program was:

15	(1) 95° C.	30 sec
	(2) 95° C.	20 sec
	(3) 55° C.	20 sec
	(4) 72° C.	60 sec
	(5) Go to step (2)	repeat 35 times
	(6) 72° C.	4 min
20	(7) 4° C.	press enter

After the PCR reaction, 1.0 µl Dpn I restriction enzyme (supplied with the kit above) was directly added into the PCR reaction mixture, which was then incubated at 37° C. for 1 h to remove the DNA templates. The Dpn I digested PCR product was cleaned up by the Zymo DNA clearance kit (Cat #D4003, Zymo Research, Orange, Calif.) as recommended by the manufacturer and 42 µl cleaned DNA product containing beneficial mutations in the cofactor binding sites obtained was designated as Megaprimer.

The Megaprimers thus obtained were then used to generate the domain swapping library using the QuickChange II XL site directed mutagenesis kit (Catalog #200524, Stratagene, La Jolla Calif.). The templates used in Example 4 were also used in this experiment. A 50 µl reaction mixture containing: 5.0 µl of 10× reaction buffer, 1.0 µl of 5.0 ng/µl template, 42 µl Megaprimer, 1.0 µl of 40 mM dNTP mix, 1.0 µl pfu-ultra DNA polymerase was prepared. Except for the Megaprimer and the templates, all reagents used here were supplied with the purchased kit. This reaction mixture was placed in a thin well 200 µl-capacity PCR tube and the following reactions were used for the PCR. The starting temperature was 95° C. for 30 sec followed by 30 heating/cooling cycles. Each cycle consisted of 95° C. for 30 sec, 55° C. for 1 min, and 68° C. for 6 min. At the completion of the temperature cycling, the samples were kept at 68° C. for 8 min, and then stored at 4° C. for later processing. Dpn I restriction enzyme (1.0 µl) (supplied with the kit above) was directly added to the finished reaction mixture, enzyme digestion was performed at 37° C. for 1 h and the PCR product was cleaned up using a DNA cleaning kit (Zymo Research). The cleaned PCR product (10 µl) contained mutated genes for a gene library.

The mutated genes were transformed into an electro-competent strain of *E. coli* Bw25113 (ΔilvC) using a BioRad Gene Pulser II (Bio-Rad Laboratories Inc., Hercules, Calif.). The transformed clones were streaked on LB agar plates containing 100 µg/ml ampicillin (Cat #L1004, Teknova Inc. Hollister, Calif.) and incubated at 37° C. overnight. Dozens of clones were randomly chosen for DNA sequencing to confirm the quality of the library.

45

This library yielded many mutants with high NADH activity (low  $K_M$  for NADH), which also had very low NADPH activity. (Table 12 and FIGS. 12A-12D). Their cofactor consumption is also shown in Table 13 (The data was based on three parallel measurements).

TABLE 12

		Mutants with improved $K_M$ (for NADH) obtained from the domain swapping library	NADH $K_M$ ( $\mu\text{M}$ )
Mutant	Mutation Locations		
JEA1	Y24F/C33L/R47P/S50F/T52D/L61F/T80I/A156V	9.1	
JEG2	Y24F/C33L/R47F/S50A/T52D/V53A/L61F/T80I/A156V	9.4	
JEG4	Y24F/C33L/R47N/S50N/T52D/V53A/L61F/T80I/A156V	9.6	
JEA7	Y24F/C33L/R47P/S50N/T52D/V53A/L61F/T80I/A156V	10.6	
JED1	C33L/R47N/S50N/T52D/V53A/L61F/T80I/A156V	11.0	

TABLE 13

The cofactor consumption of some mutants after 5 min reaction (decrease in OD <sub>340 nm</sub> )				
Mutants	0.2 mM NADH		0.2 mM NADPH	
	average	stdev	average	stdev
JEA1	-0.285	0.030	-0.110	0.025
JED1	-0.287	0.032	-0.074	0.014
JEG2	-0.261	0.009	-0.078	0.009
JEG4	-0.227	0.016	-0.050	0.016
JEA7	-0.205	0.079	-0.038	0.009
Z4B8	-0.178	0.042	-0.170	0.013
PF5_WT	-0.078	0.014	-0.320	0.024
Negative	-0.061	0.029	-0.015	0.014

## Example 6

## Thermostability of PF5-Ilvc and its Mutants

The wildtype PF5-ILVC and various cells containing mutated pBad-ilvC were grown overnight at 37° C. in 25 ml of the LB medium containing 100  $\mu\text{g}/\text{ml}$  ampicillin and 0.02% (w/v) arabinose inducer while shaking at 250 rpm. The cells were then harvested by centrifugation at 18,000×g for 1 min at room temperature and the cell pellets were re-suspended in 300  $\mu\text{l}$  of BugBuster Master Mix (EMD Chemicals). The reaction mixture was first incubated at room temperature for 20 min and aliquots of this cell mixture (e.g. 50

46

$\mu\text{l}$ ) were incubated at different temperatures (from room temperature to 75° C.) for 10 min. The precipitate was removed by centrifugation at 18,000×g for 5 min at room temperature. The remaining activity of the supernatant was analyzed as described above. As shown in FIG. 7, pBad-ilvC was very stable with  $T_{50}$  at 68° C. ( $T_{50}$  is the temperature, at which 50% of protein lost its activity after 10 min incubation).

The thermostability of PF5-ilvC allowed destruction of most of the other non-KARI NADH oxidation activity within these cells, reducing the NADH background consumption and thus facilitating the KARI activity assays. This heat treatment protocol was used in all screening and re-screening assays. The mutants thus obtained were all thermostable which allowed easier selection of the desirable mutants.

## Example 7

## Stoichiometric Production of 2,3-Dihydroxyisovalerate by KARI During Consumption of NADH or NADPH as Cofactors

Screening and routine assays of KARI activity rely on the 340 nm absorption decrease associated with oxidation of the pyridine nucleotides NADPH or NADH. To insure that this metric was coupled to the formation of the reaction product (i.e., 2,3-dihydroxyisovalerate), oxidation of both pyridine nucleotide and formation of 2,3-dihydroxyisovalerate were measured in the same samples.

The oxidation of NADH or NADPH was measured at 340 nm in a 1 cm path length cuvette on a Agilent model 8453 spectrophotometer (Agilent Technologies, Wilmington Del.). Crude cell extract (0.1 ml) prepared as described above containing either wild type PF5 KARI or the C3B11 mutant, was added to 0.9 ml of K-phosphate buffer (10 mM, pH 7.6), containing 10 mM MgCl<sub>2</sub>, and 0.2 mM of either NADPH or NADH. The reaction was initiated by the addition of acetolactate to a final concentration of 0.4 mM. After 10-20% decrease in the absorption (about 5 min), 50  $\mu\text{l}$  of the reaction mixture was rapidly withdrawn and added to a 1.5 ml Eppendorf tube containing 10  $\mu\text{l}$  0.5 mM EDTA to stop the reaction and the actual absorption decrease for each sample was accurately recorded. Production of 2,3-dihydroxyisovalerate was measured and quantitated by HPLC/MS as described above.

The coupling ratio is defined by the ratio between the amount of 2,3-dihydroxyisovalerate (DHIV) produced and the amount of either NADH or NADPH consumed during the experiment. The coupling ratio for the wild type enzyme (PF5-ilvC), using NADPH, was 0.98 DHIV/NADPH, while that for the mutant (C3B11), using NADH, was on average around 1.10 DHIV/NADPH underlining the high activity of the mutant enzyme to consume NADH and produce DHIV.

TABLE 9

US 9,238,801 B2

49

50

TABLE 9-continued

US 9,238,801 B2

51

52

TABLE 9-continued

-	-	16(L)	-1268	-1113	-3338	-540	-1057	-2827	-1716	569	-2409	2299	-236	-2381	-2862	-2089	-2316	-232	-1213	-1306	-1645	-1304	10000%
-	-	16(M)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	-45	96	359	117	-369	-294	-249	-249
-	-	17(S)	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	17(S)	-1350	-2877	-588	1045	-3189	-496	-920	-2963	-628	-2901	-2011	1860	-2289	-489	-1184	2139	190	-2503	-3077	-2343	10100%
-	-	18(G)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249
-	-	18(G)	-2336	-8139	-325	-894	-1115	-701	-1378	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	19(H)	-454	-8332	-968	-1110	-2112	3143	-1211	-2091	-1317	-2264	-1691	-978	-1499	-1202	-1421	-646	-774	-1550	-1916	-1919	10200%
-	-	19(H)	-898	-1313	-545	-482	-320	-1336	4297	-1552	-160	-1493	-1035	-579	-1675	-363	-322	-934	-951	-1354	-725	107	10300%
-	-	20(D)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249
-	-	20(D)	-872	-1812	3234	432	-2215	-967	-433	-2172	-569	-2269	-1704	99	-1453	-184	-1141	-728	-973	-1814	-2146	-1646	10400%
-	-	21(E)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249
-	-	22(Y)	-38	-5840	-6882	-894	-1115	-3098	-179	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	23(I)	-766	-1695	521	2831	-2050	-1029	-293	-1804	-118	-1919	-1331	69	-1441	-4	-527	-653	-814	-1512	-1988	-1505	10500%
-	-	23(I)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249
-	-	24(I)	-38	-5840	-6882	-894	-1115	-3098	-179	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	24(I)	-2294	-1931	-4749	-4227	-1724	-4227	-3220	2306	-3952	1990	-634	-3878	94	-3538	-3812	-3411	-2247	1576	-2891	-2629	10700%
-	-	24(I)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249
-	-	25(K)	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	25(K)	-2801	-2299	-5406	-5003	-2108	-5164	-4649	3051	-4886	1593	-869	-4829	-4788	-4454	-4829	-4493	-2764	1435	-3781	-3585	10800%
-	-	25(K)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249
-	-	26(G)	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	26(G)	-2184	-3900	796	392	-4174	2903	-1580	-4030	-1636	-3937	-3173	-967	-2810	-1	-2362	1069	-2220	-3530	-4130	-3229	11000%
-	-	27(K)	-149	-501	233	42	-375	399	104	-625	210	-463	-722	-276	396	44	96	358	116	-371	-296	-251	-251
-	-	27(K)	-155	-3318	-9181	-3674	-118	-701	-1378	*	*	*	*	*	*	*	*	*	*	*	*	*	*
-	-	27(K)	-3243	-3775	-4129	-2558	-4750	-3647	-1490	-4021	3681	-3617	-2982	-2368	-3580	-1076	1318	-3119	-2876	-3817	-3395	-3374	12600%
-	-	27(K)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	-275	394	45	96	359	117	-369	-294	-249	-249

US 9,238,801 B2

53

54

TABLE 9-continued

TABLE 9-continued

38(G)	677	-2128	-3838	-4171	-4647	-3536	-3816	-4506	-4340	-4749	-3857	-3009	-3149	-3871	-4137	-1784	-2005	-3297	-4725	-4735	13700%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3782	-445	-3553	-2886	-2112	866	-1265	1506	-2614	-2557	-3469	-3282	-2908 13800%
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-4781	-4818	-5025	-4365	-3727	-3728	-4477	-4545	-2567	-2762	-3852	-4724	-4942 13900%
40(A)	3631	-2768	-4492	-4815	-4888	-2992	-4271	-4781	-4818	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3407	-1372	-3071	-2715	-2454	-3764	2546	-1428	-2990	-2976	-3308	2269	-295 14000%
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3549	-4035	-4024	-3192	-2817	-2900	-3608	-3823	217	-1660	-276	-4363	-4211 14100%
42(A)	3357	-1795	-4134	-4277	-4057	-2118	-3548	-3549	-4035	-4024	-3192	-2817	-2900	-3608	-3823	217	-1660	-276	-4363	-4211	14100%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3116	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
43(Q)	96	1930	2644	4475	4236	2322	1154	739	4118	1062	1121	342	2446	2895	-2441	392	1005	693	1678	278	14200%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3116	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
44(N)	-4000	-4117	-3389	-3749	-5073	-3911	-4123	-6022	-4503	-5797	-5419	-4397	-4479	-4255	-4592	-4115	-4312	-5371	-4650	-4731	14300%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3116	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
45(L)	-4414	-3800	-5638	-5628	-2290	-4980	-4628	-1886	-5423	3316	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3116	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
46(R)	-1731	-3015	275	-931	-3487	-2518	-973	-3116	2321	-2955	-2123	224	-2603	256	2808	-1596	-1613	-2730	-2995	-2515	14500%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3116	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
47(D)	-2896	-4843	3855	944	-5037	-2600	-2082	-5082	-4903	-4373	-1209	-3196	-1786	-3536	-2501	-3007	-4517	-5004	-3956	14600%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3116	-1236	-5514	-4997	-4750	-5002	-5379	-4399	-4399	-2629	-3665	-3690 14400%	
48(S)	-1556	-2212	-2863	-2679	-4293	-2279	-3082	-4365	-3311	-4524	-3676	288	-3026	-2967	-3497	3508	-1962	-3259	-4477	-4066	14700%	
-	-148	-500	232	44	-381	398	105	-627	211	-465	-721	275	393	45	95	360	118	-370	-295	-250		
-	-155	-3318	-9181	-2405	-302	-701	-1378	*	*	-4854	-2555	-4752	-4136	-53	-3115	-1836	-3440	-2284	-2716	-4157	-4880	-3914 15400%
49(G)	-2521	-3968	1232	-911	-4849	3373	-2126	-4884	-2555	-4752	-4136	-53	-3115	-1836	-3440	-2284	-2716	-4157	-4880	-3914 15400%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-4854	-2555	-4752	-4136	-53	-3115	-1836	-3440	-2284	-2716	-4157	-4880	-3914 15400%
50(V)	-2767	-2324	-5232	-4770	396	-4827	-3784	-36	-4546	848	-611	-4472	-4518	-3980	-4367	-4081	-2716	3323	-3037	-2660	15500%	
-	-148	-500	233	43	-381	399	106	-626	211	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-148	-3381	-9181	-203	-2928	-701	-1378	*	*	-4854	-2555	-4752	-4136	-53	-3115	-1836	-3440	-2284	-2716	-4157	-4880	-3914 15400%
51(D)	-1684	-3285	2735	2014	-3554	-2196	-1177	-3350	92	-3279	-2427	692	-2505	-770	-1595	-1483	-1666	332	-3460	-2676	15700%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-4854	-2555	-4752	-4136	-53	-3115	-1836	-3440	-2284	-2716	-4157	-4880	-3914 15400%

US 9,238,801 B2

TABLE 9-continued

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

TABLE 9-continued

144(G)	2167	-1833	-3963	-4199	-4430	2715	-3642	-4236	-4146	-4489	-3540	-2795	-2898	-3661	-3939	910	-1682	-2994	-4647	-4556	25500%			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3533	-3912	-3066	2095	-3659	4036	-3912	-3822	-2883	-2963	-3249	-4027	-3787	25600%	
-	-149	-2604	-2948	-4094	-4235	-5544	-3267	-3353	-3767	-399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-6627	-5765	-6297	-5970	-5141	-4804	-5546	-5385	-4727	-4815	-5862	-4924	-5849	25700%	
-	-149	-4203	-5092	-5462	-5893	3834	-5028	-6627	-5765	-399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3830	634	-3639	-2963	-1838	1551	-1305	-748	-2470	-2510	-3482	-3434	-2990	25800%	
-	-147(H)	-2569	-3440	-1867	-1702	-3820	-2996	4731	-3830	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-2747	-2399	-2634	-1430	-2330	-2747	-2399	-2684	567	2687	-1484	-2682	-2351	25900%	
-	-149(T)	194	-1498	-3255	-2899	-2240	-2226	-2291	-1754	-2632	1634	-2626	-2570	-4662	-4579	-4940	-4923	-4013	-3297	3796	-4414	-4190	26000%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-5946	-2789	-5502	-5118	-4521	-4754	-3672	-4219	-4989	-4832	-5644	-4538	-4993	26100%	
-	-149(Y)	-3122	-2888	-5092	-5160	-3522	-4180	-4687	-905	-5060	-2626	-2570	-4662	-4579	-4940	-4923	-4013	-3297	3796	-4414	-4190	26000%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-2459	-142	-2413	-1501	-560	-2018	-128	2308	1224	-66	-2023	-2585	-1919	26200%	
-	-149(R)	-962	-2395	-777	1012	-2721	76	1031	-2459	-142	-2413	-1501	-560	-2018	-128	2308	1224	-66	-2023	-2585	-1919	26200%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3703	-5127	-3017	-3111	-3732	-4959	-3668	-4500	-4356	-4679	-3867	-565	4052	26400%	
-	-149(E)	-902	-2032	-899	2078	-2228	-1934	-611	-1897	-259	-221	-1156	520	-2024	816	-736	-736	-858	1303	-287	-2295	537	26300%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3703	-5127	-3017	-3111	-3732	-4959	-3668	-4500	-4356	-4679	-3867	-565	4052	26400%	
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-153(Y)	-4820	-3765	-5219	-5565	3303	-5093	-1317	-3703	-5127	-3017	-3111	-3732	-4959	-3668	-4500	-4356	-4679	-3867	-565	4052	26400%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-155(Q)	576	-2355	344	1156	-2675	-1856	-515	-508	1502	-2370	-1444	571	-1949	1878	419	-764	-822	-1976	-2538	-1856	26600%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-154(V)	129	-1901	-989	821	-2060	-1969	-654	-1704	498	-52	-1037	-703	-2057	695	-796	443	-344	1871	-2192	-1626	26500%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-156(G)	-3239	-3889	516	-2361	-5355	3646	-3337	-5629	-3818	-5498	-4951	-2619	-3905	-3187	-4377	-3211	-3532	-4837	-4895	-4826	26700%		
-	-149	-500	232	44	-381	399	105	-627	211	-466	-721	277	393	45	95	359	117	-368	-295	-250				
-	-155	-3318	-9181	-2159	-366	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249		

TABLE 9-continued

157(G)	753	-2516	-789	488	-2848	2300	-672	-2582	596	-2529	-1627	481	-2112	-224	471	962	-1024	-2149	-2694	-2033	27300%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3216	-3901	-4170	-1874	-2095	-3384	-4734	-4766	27400%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-4648	-4554	-4752	-4115	825	2986	-4159	-3678	27500%					
159(V)	-2845	-2030	-5123	-4769	-2667	-4797	-4593	2349	-4661	-1545	-1424	-4502	-395	45	96	359	117	-369	-294	-249	-249					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-5058	-4393	1199	4031	-3244	-3757	-2911	-4148	-4583	-4362	27600%			
160(P)	-2541	-3139	-2413	-2753	-4726	-2991	-3342	-5055	-3527	-4674	-3911	-2991	-466	-720	275	394	45	96	359	117	-369	-294	-249			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-2359	-617	-2434	-1576	-891	-2199	-345	-1093	872	-1043	-1946	-2701	-2102	27700%
161(C)	1577	3078	1357	-656	-2664	-219	891	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3626	-3433	-3567	480	-2414	-1973	-3145	-2755	27800%					
162(L)	-2140	-2404	-3995	-3997	-2053	-3121	-3283	-1687	-3689	3041	-1200	-3360	-394	45	96	359	117	-369	-294	-249	-249					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-4439	-4023	-4320	-3916	-2488	2176	-3342	-3040	27900%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3728	-5577	-4545	-2547	-2762	-3852	-4724	-4942	28000%					
164(A)	3631	-2768	-4492	-4815	-4888	-2992	-4271	-4781	-4818	-5025	-4365	-3727	-394	45	96	359	117	-369	-294	-249	-249					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3330	-1815	-2362	-2318	-2233	-2272	-981	3315	28200%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
165(V)	-2623	-2122	-5301	-4990	-2770	-5102	-5132	-2426	-4946	-1532	-1474	-4791	-4869	-4891	-5102	-4483	-2619	3200	-4506	-3991	28100%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-4693	4575	-3826	-4704	-4772	-5612	-4577	-4751	28300%					
-	-149	-2631	903	-2051	722	-3242	3753	-2386	-2056	-2342	-1863	-2047	-394	45	96	359	117	-369	-294	-249	-249					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3235	-1872	-3575	-2522	-3009	-4491	-4932	-3946	28400%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-1212	-538	-3033	-3056	-384	125	-958	635	28500%					
167(Q)	-4589	-4392	-3927	-4146	-5099	-4221	-4099	-5973	-3840	-5564	-5304	-4230	-4693	4575	-3826	-4704	-4772	-5612	-4577	-4751	28300%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3330	-1815	-2362	-2318	-2233	-2272	-981	3315	28200%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-4693	4575	-3826	-4704	-4772	-5612	-4577	-4751	28300%					
-	-149	-4605	-3943	-902	-4948	-2633	-2157	-5087	-2604	-4922	-4387	428	-3235	-1872	-3575	-2522	-3009	-4491	-4932	-3946	28400%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-1212	-538	-3033	-3056	-384	125	-958	635	28500%					
169(X)	1776	-6612	1224	138	698	2992	816	1295	350	-326	780	943	-1212	-538	-3033	-3056	-384	125	-958	635	28500%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	9181	894	1115	-701	1378	*	*	*	*	*	-1212	-538	-3033	-3056	-384	125	-958	635	28500%					

US 9,238,801 B2

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

TABLE 9-continued

TABLE 9-continued

220(K)	-1633	-2905	-1573	706	-3375	-2487	-900	-3003	-2925	2849	-2008	-1128	-2541	1714	784	-1509	-105	-2617	-2894	-2418	3360%								
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-832	714	-1817	-2498	-1493	-1792	-1483	274	453	-1419	501	3370%								
221(A)	2352	2066	-2593	-2000	-947	-2434	-1271	-486	-32	-832	714	-1817	-2498	-1493	-1792	-1483	274	453	-1419	501	3370%								
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-3220	-3625	81	-2886	-2733	-2977	-3326	-3545	-1606	-1763	-2574	-4068	-3810	3380%						
222(G)	224	-1905	-3562	-3696	-3684	3361	-3297	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249									
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-5070	-1342	-3653	-5111	-2971	-3065	-3743	-4949	-3874	-4496	-4351	-4650	-3829	-591	1725	3390%				
223(F)	4781	-3756	-5207	-5542	-4341	-5068	-1342	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-3139	-2645	-2483	-2136	-1734	-1646	-2359	-1761	-2298	-2936	-1995	920	-1748	3354	967	-2989	-2654	3410%	
224(E)	-2413	-4114	221	3465	-4392	-2485	-1689	-4248	-1608	-4112	-3396	-1094	-2951	-1336	871	-2119	-2441	-3763	-4239	-3395	3400%								
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-1864	-3139	-2645	-2483	-2136	-1734	-1646	-2359	-1761	-2298	-2936	-1995	920	-1748	3354	967	-2989	-2654	3410%	
225(T)	-1461	-1864	-3139	-2645	-2483	-2136	-1734	-1646	-2359	-1761	-2298	-2936	-1995	920	-1748	3354	967	-2989	-2654	3410%									
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-5314	-5148	-673	-5068	-2476	-1443	-4706	3059	-789	-4359	-4756	-3864	-4314	-4462	-3729	-2115	-1672	1736	3420%	
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-9181	-894	-1115	-701	-1378	*	*	-2145	-1909	-3451	-3600	-3879	-4011	-2397	2510	2999	-3974	-3608	34300%	
227(V)	-1819	-1960	-4426	-4359	-2977	-3037	-3800	-439	-4098	-2145	-1909	-3451	-3600	-3879	-4011	-2397	2510	2999	-3974	-3608	34300%								
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-1440	-1916	-275	-2529	-292	-1240	-2176	-998	-2345	1183	-1184	-2355	-905	-1425	512	-1158	-1817	-2697	-2174	3450%
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
228(E)	-2863	-4790	1397	3563	-4990	-2594	-2061	-5021	-2476	-4848	-4298	-1204	-3182	-1761	-3454	-2476	-2968	-4462	-4951	-3920	34400%								
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-1440	-1916	-275	-2529	-292	-1240	-2176	-998	-2345	1183	-1184	-2355	-905	-1425	512	-1158	-1817	-2697	-2174	3450%
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
230(G)	-4435	-4203	-5092	-5462	-5893	3834	-5028	-6627	-5765	-6297	-5970	-5141	-4804	-5546	-5385	-4727	-4815	-5862	-4924	-5849	34600%								
-	-149	-500	233	43	-381	-1115	-701	-1378	*	*	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249						
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	-8139	-9181	-894	-1115	-701	-1378	*	*	-2145	-1909	-3451	-3600	-3879	-4011	-2397	2510	2999	-3974	-3608	34300%

US 9,238,801 B2

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

-	-	24244(L)	-85	-1333	-3893	-3280	-1111	-3185	-2083	1066	-2910	2310	1961	-2823	-3170	-2501	-2721	-2289	-113	436	-1859	-1558	36000%
-	-	24245(K)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24246(L)	-149	-500	233	43	-381	400	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24247(I)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24248(V)	-1685	-1668	-4095	-3732	-2081	-3082	-2893	-227	-3402	-1488	1383	-3123	-3419	-3145	-3320	367	-1807	3332	-2874	-2504	36500%
-	-	24249(D)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24250(L)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24251(M)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24252(Y)	-4562	-3630	-5142	-5401	1516	-4992	-1300	-3544	-4968	-2963	-2986	-3671	-4868	-3786	-4393	381	-4432	-3662	2413	4375	36900%
-	-	24253(E)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24254(G)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249
-	-	24255(G)	-4435	-4203	-5092	-5462	-5893	3834	-5028	-6627	-5765	-6297	-5970	-5141	-4804	-5546	-5385	-4727	-4815	-5862	-4924	-5849	37200%
-	-	24256(I)	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249

US 9,238,801 B2

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

TABLE 9-continued

282(E)	-166	-2372	859	1835	-2692	-1861	1182	-2444	490	-2388	-1462	590	478	1356	-620	116	-837	-1994	-2555	-1871	39900%			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-281	-2916	-3214	2251	2366	1397	-3549	-3270	40000%			
-	-149	228	-1688	-3655	-3444	-3179	-2145	-2891	-2611	-3215	-3076	-2328	-2557	-394	45	96	359	117	-369	-294	-249			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	-394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-3430	-937	2705	-2874	-2650	-3556	-3267	-3189	40100%			
-	-149	-3623	-3848	-2331	-4472	-3512	-1356	-3763	2942	-2385	-1460	-498	-1960	1120	437	106	-836	-1992	-2552	-1869	40200%			
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-466	-720	275	394	45	96	359	117	-369	-294		
-	-149	-443	-2370	732	1690	-2691	-1863	-526	-2422	1639	-2650	-3214	-394	45	96	359	117	-369	-294	-249				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	-394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-2279	-1391	-586	-2019	-136	1056	-62	-881	-1889	-2488	-1849	40300%
-	-149	-2286	-843	814	-2570	-1928	-578	269	1096	-626	-2466	-720	275	394	45	96	359	117	-369	-294	-249			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	-394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-4838	-4039	-4539	-4860	-3558	-1557	-3044	-3030	40400%			
-	-149	-3656	-5816	-5350	-1349	-5621	-4248	-822	-4288	948	4920	-5248	-2554	-472	1762	-1527	-1524	-2597	-2885	1245	40500%			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-2832	-1997	-1146	-1975	663	831	-795	72	-2015	-2577	-1891	40600%
-	-149	-1646	-2891	-1591	287	-3346	-526	-912	-2971	2831	-2832	-1997	-1146	-2554	-472	1762	-1527	-1524	-2597	-2885	1245	40500%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-2409	-1485	1305	-1975	663	831	-795	72	-2015	-2577	-1891	40600%
-	-149	-2394	367	2205	-2713	-487	-545	-2465	-134	-626	-210	-466	-720	275	394	45	96	359	117	-369	-294	-249		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-1406	-1109	-3691	-3957	-3613	-3805	-3144	-2046	2342	-3118	-2720	40700%
-	-149	-3024	-4584	-4122	-2155	-3932	-3330	1746	-3870	-1406	-1109	-3691	-3957	-3613	-3805	-3144	-2046	2342	-3118	-2720	40700%			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-2362	917	-492	-1949	889	-603	-763	783	-1968	-2532	1851	40900%
-	-149	-187	-2175	-4307	-3889	-898	-3779	-2344	-944	-3485	2855	-476	-3390	-3782	-3025	-3298	-2972	-2345	-1269	-1846	1565	40800%		
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-1462	-1130	-3691	-3957	-3613	-3805	-3144	-2046	2342	-3118	-2720	40700%
-	-149	-2714	2790	1765	-4119	-2356	-1511	-3962	-1467	-3852	-3075	24	-2782	-1139	2142	-1879	-2163	-3473	-4024	-3155	40100%			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249				
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-495	-1447	-4789	-4862	-4869	-5086	-4473	-2627	-2071	-4467	-3968	41100%
-	-149	-2630	-2131	-5302	-4991	-2737	-5092	-5106	3464	-4941	-1495	-1447	-4789	-4862	-4869	-5086	-4473	-2627	-2071	-4467	-3968	41100%		
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	*	-466	-720	275	394	45	96	359	117	-369	-294	-249	

US 9,238,801 B2

TABLE 9-continued

US 9,238,801 B2

TABLE 9-continued

TABLE 9-continued

318(A)	2474	-2397	-816	-367	-2797	-273	-722	-2529	555	-2507	-1610	592	-2110	837	-805	-138	-1006	-2092	-2699	-2039	43500%					
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	325	-1232	867	1235	-1752	-2474	-1419	1020	-1455	670	-411	831	535	43600%	
-	-149	-154	-986	-2485	-337	1024	-375	-1232	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249				
-	-149	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-2361	613	-644	1079	976	597	-382	2908	-1246	-1219	-2044	-2579	-2061	43700%
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-149	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-2405	1293	2366	1485	-575	-2020	-117	2045	95	-893	-1984	-2543	-1892	43800%
-	-149	-833	-2364	-833	905	-2678	-1930	-568	-2405	1293	2366	1485	-575	-2020	-117	2045	95	-893	-1984	-2543	-1892	43800%				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-2266	1474	1478	-1963	682	-629	-781	12	-279	-2472	476	44000%			
-	-149	505	-2300	-750	523	-2598	121	-525	-594	485	95	-1395	1720	-1957	348	224	551	-821	-1910	-2497	-1828	43900%				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-2276	889	-2266	1474	1478	-1963	682	-629	-781	12	-279	-2472	476	44000%	
-	-149	444	-2266	-766	1488	-2551	-1871	533	-2276	889	-2266	1474	1478	-1963	682	-629	-781	12	-279	-2472	476	44000%				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-2121	-1133	1769	-1827	1398	447	-748	-766	-1713	-1779	-1595	44100%			
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-3124	-2254	2158	-2417	-657	-1430	-1361	197	-2727	-3303	-2540	44200%			
-	-149	1053	-3109	1756	1735	-3404	-2143	-1074	-3191	-846	-3124	-2254	2158	-2417	-657	-1430	-1361	197	-2727	-3303	-2540	44200%				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-284	-1781	426	282	601	-2121	-1133	1769	-1827	1398	447	44100%			
-	-149	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-284	-1781	426	282	601	-2121	-1133	1769	-1827	1398	447	44100%		
-	-149	-1245	-2064	-3071	-1267	-3262	-2570	4711	-3611	-1060	-3528	-2812	-1479	-2961	1288	-1287	670	-2133	-3161	-3310	-2601	44300%				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-2316	-131	-138	-1391	-518	1404	2021	-634	-785	619	-561	-2495	-1830	44400%	
-	-149	-500	332	948	-2585	-739	-537	-2316	-131	-138	-1391	-518	1404	2021	-634	-785	619	-561	-2495	-1830	44400%					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-3240	-1327	-191	-722	-2160	-3016	-1615	822	-2097	-1556	-560	-2157	-1805	44500%	
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-8	-8139	-9181	-894	-1115	-701	-1378	*	*	*	*	-984	-1115	-701	-1378	*	*	*	*	*	*	*	*	*		
-	-149	-2734	-3605	-1382	3593	-3624	-2086	-2317	-3317	-2175	-3167	1983	-1898	-3440	-2054	-2556	-2649	-2820	-3234	-3920	-3370	44600%				
-	-149	-500	233	43	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249					
-	-2336	-8139	-325	-894	-1115	-701	-1378	*	*	*	*	-1941	-611	-307	2031	-1189	-636	-2030	1425	-709	-864	-350	1337	-2323	-1722	44800%
-	-38	-5840	-6882	-894	-1115	-109	-3775	*	*	*	*	-1941	-611	-307	2031	-1189	-636	-2030	1425	-709	-864	-350	1337	-2323	-1722	44800%
-	-149	8	-2067	-905	437	-2275	-1941	-381	399	106	-626	210	-466	-720	275	394	45	96	359	117	-369	-294	-249	-249		

US 9,238,801 B2

TABLE 9-continued

TABLE 9-continued

## SEQUENCE LISTING

&lt;160&gt; NUMBER OF SEQ ID NOS: 98

<210> SEQ ID NO 1  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer

&lt;400&gt; SEQUENCE: 1

tgatgaacat cttcgcgtat tcgccgtct

30

<210> SEQ ID NO 2  
<211> LENGTH: 68  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: forward primer for library C  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (24)..(25)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (33)..(34)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (39)..(40)  
<223> OTHER INFORMATION: n is a, c, g, or t

&lt;400&gt; SEQUENCE: 2

gcgttagacgt gactgttggc ctgnntaaag gcnnngctnn ctgggccaag gctgaagccc

60

acggcattg

68

<210> SEQ ID NO 3  
<211> LENGTH: 68  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: forward primer for library E  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (24)..(25)  
<223> OTHER INFORMATION: n is a, c, g, or t

&lt;400&gt; SEQUENCE: 3

gcgttagacgt gactgttggc ctgnntaaag gctcggtcac cgttgccaag gctgaagccc

60

acggcattg

68

<210> SEQ ID NO 4  
<211> LENGTH: 68  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: forward primer for library F  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (33)..(34)  
<223> OTHER INFORMATION: n is a, c, g, or t

&lt;400&gt; SEQUENCE: 4

gcgttagacgt gactgttggc ctgcgtaaag gcnnngctac cgttgccaag gctgaagccc

60

acggcattg

68

<210> SEQ ID NO 5  
<211> LENGTH: 68

-continued

---

```

<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: forward primer for library G
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (39)..(40)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 5
gcttagacgt gactgttggc ctgcgtaaag gtcggctnn tgttgccaag gctgaagccc      60
acggcttg                                         68

<210> SEQ ID NO 6
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: forward primer for library H
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (24)..(25)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (33)..(34)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (39)..(40)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 6
gcttagacgt gactgttggc ctgnntaaag gcnnntgctnn tgttgccaag gctgaagccc      60
acggcttg                                         68

<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequencing primer (forward)

<400> SEQUENCE: 7
aagatttagcg gatcctacct                                         20

<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequencing primer (reverse)

<400> SEQUENCE: 8
aacagccaag cttttagttc                                         20

<210> SEQ ID NO 9
<211> LENGTH: 330
<212> TYPE: PRT
<213> ORGANISM: Methanococcus maripaludis

<400> SEQUENCE: 9
Met Lys Val Phe Tyr Asp Ser Asp Phe Lys Leu Asp Ala Leu Lys Glu
1          5           10          15

Lys Thr Ile Ala Val Ile Gly Tyr Gly Ser Gln Gly Arg Ala Gln Ser
20          25           30

```

## US 9,238,801 B2

**109****110**

-continued

Leu Asn Met Lys Asp Ser Gly Leu Asn Val Val Val Gly Leu Arg Lys  
 35 40 45  
 Asn Gly Ala Ser Trp Glu Asn Ala Lys Ala Asp Gly His Asn Val Met  
 50 55 60  
 Thr Ile Glu Glu Ala Ala Glu Lys Ala Asp Ile Ile His Ile Leu Ile  
 65 70 75 80  
 Pro Asp Glu Leu Gln Ala Glu Val Tyr Glu Ser Gln Ile Lys Pro Tyr  
 85 90 95  
 Leu Lys Glu Gly Lys Thr Leu Ser Phe Ser His Gly Phe Asn Ile His  
 100 105 110  
 Tyr Gly Phe Ile Val Pro Pro Lys Gly Val Asn Val Val Leu Val Ala  
 115 120 125  
 Pro Lys Ser Pro Gly Lys Met Val Arg Arg Thr Tyr Glu Glu Gly Phe  
 130 135 140  
 Gly Val Pro Gly Leu Ile Cys Ile Glu Ile Asp Ala Thr Asn Asn Ala  
 145 150 155 160  
 Phe Asp Ile Val Ser Ala Met Ala Lys Gly Ile Gly Leu Ser Arg Ala  
 165 170 175  
 Gly Val Ile Gln Thr Thr Phe Lys Glu Glu Thr Glu Thr Asp Leu Phe  
 180 185 190  
 Gly Glu Gln Ala Val Leu Cys Gly Gly Val Thr Glu Leu Ile Lys Ala  
 195 200 205  
 Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210 215 220  
 Phe Glu Thr Cys His Glu Leu Lys Leu Ile Val Asp Leu Ile Tyr Gln  
 225 230 235 240  
 Lys Gly Phe Lys Asn Met Trp Asn Asp Val Ser Asn Thr Ala Glu Tyr  
 245 250 255  
 Gly Gly Leu Thr Arg Arg Ser Arg Ile Val Thr Ala Asp Ser Lys Ala  
 260 265 270  
 Ala Met Lys Glu Ile Leu Lys Glu Ile Gln Asp Gly Arg Phe Thr Lys  
 275 280 285  
 Glu Phe Val Leu Glu Lys Gln Val Asn His Ala His Leu Lys Ala Met  
 290 295 300  
 Arg Arg Ile Glu Gly Asp Leu Gln Ile Glu Glu Val Gly Ala Lys Leu  
 305 310 315 320  
 Arg Lys Met Cys Gly Leu Glu Lys Glu Glu  
 325 330

&lt;210&gt; SEQ ID NO 10

&lt;211&gt; LENGTH: 330

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Methanococcus maripaludis

&lt;400&gt; SEQUENCE: 10

Met Lys Val Phe Tyr Asp Ser Asp Phe Lys Leu Asp Ala Leu Lys Glu  
 1 5 10 15  
 Lys Thr Ile Ala Val Ile Gly Tyr Gly Ser Gln Gly Arg Ala Gln Ser  
 20 25 30  
 Leu Asn Met Lys Asp Ser Gly Leu Asn Val Val Val Gly Leu Arg Lys  
 35 40 45  
 Asn Gly Ala Ser Trp Asn Asn Ala Lys Ala Asp Gly His Asn Val Met  
 50 55 60  
 Thr Ile Glu Glu Ala Ala Glu Lys Ala Asp Ile Ile His Ile Leu Ile  
 65 70 75 80

-continued

Pro Asp Glu Leu Gln Ala Glu Val Tyr Glu Ser Gln Ile Lys Pro Tyr  
 85 90 95

Leu Lys Glu Gly Lys Thr Leu Ser Phe Ser His Gly Phe Asn Ile His  
 100 105 110

Tyr Gly Phe Ile Val Pro Pro Lys Gly Val Asn Val Val Leu Val Ala  
 115 120 125

Pro Lys Ser Pro Gly Lys Met Val Arg Arg Thr Tyr Glu Glu Gly Phe  
 130 135 140

Gly Val Pro Gly Leu Ile Cys Ile Glu Ile Asp Ala Thr Asn Asn Ala  
 145 150 155 160

Phe Asp Ile Val Ser Ala Met Ala Lys Gly Ile Gly Leu Ser Arg Ala  
 165 170 175

Gly Val Ile Gln Thr Thr Phe Lys Glu Glu Thr Glu Thr Asp Leu Phe  
 180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Val Thr Glu Leu Ile Lys Ala  
 195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210 215 220

Phe Glu Thr Cys His Glu Leu Lys Leu Ile Val Asp Leu Ile Tyr Gln  
 225 230 235 240

Lys Gly Phe Lys Asn Met Trp Asn Asp Val Ser Asn Thr Ala Glu Tyr  
 245 250 255

Gly Gly Leu Thr Arg Arg Ser Arg Ile Val Thr Ala Asp Ser Lys Ala  
 260 265 270

Ala Met Lys Glu Ile Leu Arg Glu Ile Gln Asp Gly Arg Phe Thr Lys  
 275 280 285

Glu Phe Leu Leu Glu Lys Gln Val Ser Tyr Ala His Leu Lys Ser Met  
 290 295 300

Arg Arg Leu Glu Gly Asp Leu Gln Ile Glu Glu Val Gly Ala Lys Leu  
 305 310 315 320

Arg Lys Met Cys Gly Leu Glu Lys Glu Glu  
 325 330

<210> SEQ ID NO 11  
 <211> LENGTH: 330  
 <212> TYPE: PRT  
 <213> ORGANISM: Methanococcus vannielii

<400> SEQUENCE: 11

Met Lys Val Phe Tyr Asp Ala Asp Ile Lys Leu Asp Ala Leu Lys Ser  
 1 5 10 15

Lys Thr Ile Ala Val Ile Gly Tyr Gly Ser Gln Gly Arg Ala Gln Ser  
 20 25 30

Leu Asn Met Lys Asp Ser Gly Leu Asn Val Val Val Gly Leu Arg Lys  
 35 40 45

Asn Gly Ala Ser Trp Glu Asn Ala Lys Asn Asp Gly His Glu Val Leu  
 50 55 60

Thr Ile Glu Glu Ala Ser Lys Lys Ala Asp Ile Ile His Ile Leu Ile  
 65 70 75 80

Pro Asp Glu Leu Gln Ala Glu Val Tyr Glu Ser Gln Ile Lys Pro Tyr  
 85 90 95

Leu Thr Glu Gly Lys Thr Leu Ser Phe Ser His Gly Phe Asn Ile His  
 100 105 110

Tyr Gly Phe Ile Ile Pro Pro Lys Gly Val Asn Val Val Leu Val Ala

-continued

115	120	125
Pro Lys Ser Pro Gly Lys Met Val Arg Lys Thr Tyr Glu Glu Gly Phe		
130	135	140
Gly Val Pro Gly Leu Ile Cys Ile Glu Val Asp Ala Thr Asn Thr Ala		
145	150	155
Phe Glu Thr Val Ser Ala Met Ala Lys Gly Ile Gly Leu Ser Arg Ala		
165	170	175
Gly Val Ile Gln Thr Thr Phe Arg Glu Glu Thr Glu Thr Asp Leu Phe		
180	185	190
Gly Glu Gln Ala Val Leu Cys Gly Gly Val Thr Glu Leu Ile Lys Ala		
195	200	205
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ser Pro Glu Met Ala Tyr		
210	215	220
Phe Glu Thr Cys His Glu Leu Lys Leu Ile Val Asp Leu Ile Tyr Gln		
225	230	235
Lys Gly Phe Lys Asn Met Trp His Asp Val Ser Asn Thr Ala Glu Tyr		
245	250	255
Gly Gly Leu Thr Arg Arg Ser Arg Ile Val Thr Ala Asp Ser Lys Ala		
260	265	270
Ala Met Lys Glu Ile Leu Lys Glu Ile Gln Asp Gly Arg Phe Thr Lys		
275	280	285
Glu Phe Val Leu Glu Asn Gln Ala Lys Met Ala His Leu Lys Ala Met		
290	295	300
Arg Arg Leu Glu Gly Glu Leu Gln Ile Glu Glu Val Gly Ser Lys Leu		
305	310	315
Arg Lys Met Cys Gly Leu Glu Lys Asp Glu		
325	330	

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 349

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 12

Met Leu Lys Gln Ile Asn Phe Gly Gly Thr Val Glu Thr Val Tyr Glu		
1	5	10
15		
Arg Ala Asp Trp Pro Arg Glu Lys Leu Leu Asp Tyr Phe Lys Asn Asp		
20	25	30
30		
Thr Phe Ala Leu Ile Gly Tyr Gly Ser Gln Gly Tyr Gly Gln Gly Leu		
35	40	45
45		
Asn Leu Arg Asp Asn Gly Leu Asn Val Ile Ile Gly Val Arg Lys Asp		
50	55	60
60		
Gly Ala Ser Trp Lys Ala Ala Ile Glu Asp Gly Trp Val Pro Gly Lys		
65	70	75
80		
Asn Leu Phe Thr Val Glu Asp Ala Ile Lys Arg Gly Ser Tyr Val Met		
85	90	95
95		
Asn Leu Leu Ser Asp Ala Ala Gln Ser Glu Thr Trp Pro Ala Ile Lys		
100	105	110
110		
Pro Leu Leu Thr Lys Gly Lys Thr Leu Tyr Phe Ser His Gly Phe Ser		
115	120	125
125		
Pro Val Phe Lys Asp Leu Thr His Val Glu Pro Pro Lys Asp Leu Asp		
130	135	140
140		
Val Ile Leu Val Ala Pro Lys Gly Ser Gly Arg Thr Val Arg Ser Leu		
145	150	155
155		
160		

-continued

---

Phe Lys Glu Gly Arg Gly Ile Asn Ser Ser Tyr Ala Val Trp Asn Asp  
165 170 175

Val Thr Gly Lys Ala His Glu Lys Ala Gln Ala Leu Ala Val Ala Ile  
180 185 190

Gly Ser Gly Tyr Val Tyr Gln Thr Thr Phe Glu Arg Glu Val Asn Ser  
195 200 205

Asp Leu Tyr Gly Glu Arg Gly Cys Leu Met Gly Gly Ile His Gly Met  
210 215 220

Phe Leu Ala Gln Tyr Asp Val Leu Arg Glu Asn Gly His Ser Pro Ser  
225 230 235 240

Glu Ala Phe Asn Glu Thr Val Glu Ala Thr Gln Ser Leu Tyr Pro  
245 250 255

Leu Ile Gly Lys Tyr Gly Met Asp Tyr Met Tyr Asp Ala Cys Ser Thr  
260 265 270

Thr Ala Arg Arg Gly Ala Leu Asp Trp Tyr Pro Ile Phe Lys Asn Ala  
275 280 285

Leu Lys Pro Val Phe Gln Asp Leu Tyr Glu Ser Thr Lys Asn Gly Thr  
290 295 300

Glu Thr Lys Arg Ser Leu Glu Phe Asn Ser Gln Pro Asp Tyr Arg Glu  
305 310 315 320

Lys Leu Glu Lys Glu Leu Asp Thr Ile Arg Asn Met Glu Ile Trp Lys  
325 330 335

Val Gly Lys Glu Val Arg Lys Leu Arg Pro Glu Asn Gln  
340 345

&lt;210&gt; SEQ\_ID NO 13

&lt;211&gt; LENGTH: 335

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Sulfolobus solfataricus

&lt;400&gt; SEQUENCE: 13

Met Lys Cys Thr Ser Lys Ile Tyr Thr Asp Asn Asp Ala Asn Leu Asp  
1 5 10 15

Leu Ile Lys Gly Lys Arg Ile Ala Val Leu Gly Tyr Gly Ser Gln Gly  
20 25 30

Arg Ala Trp Ala Gln Asn Leu Arg Asp Ser Gly Leu Asn Val Val Val  
35 40 45

Gly Leu Glu Arg Glu Gly Lys Ser Trp Glu Leu Ala Lys Ser Asp Gly  
50 55 60

Ile Thr Pro Leu His Thr Lys Asp Ala Val Lys Asp Ala Asp Ile Ile  
65 70 75 80

Ile Phe Leu Val Pro Asp Met Val Gln Arg Thr Leu Trp Leu Glu Ser  
85 90 95

Val Gln Pro Tyr Met Lys Lys Gly Ala Asp Leu Val Phe Ala His Gly  
100 105 110

Phe Asn Ile His Tyr Lys Leu Ile Asp Pro Pro Lys Asp Ser Asp Val  
115 120 125

Tyr Met Ile Ala Pro Lys Gly Pro Gly Pro Thr Val Arg Glu Tyr Tyr  
130 135 140

Lys Ala Gly Gly Val Pro Ala Leu Val Ala Val His Gln Asp Val  
145 150 155 160

Ser Gly Thr Ala Leu His Lys Ala Leu Ala Ile Ala Lys Gly Ile Gly  
165 170 175

Ala Thr Arg Ala Gly Val Ile Pro Thr Thr Phe Lys Glu Glu Thr Glu  
180 185 190

-continued

Thr Asp Leu Phe Gly Glu Gln Val Ile Leu Val Gly Gly Ile Met Glu  
 195 200 205  
 Leu Met Arg Ala Ala Phe Glu Thr Leu Val Glu Gly Tyr Gln Pro  
 210 215 220  
 Glu Val Ala Tyr Phe Glu Thr Ile Asn Glu Leu Lys Met Leu Val Asp  
 225 230 235 240  
 Leu Val Tyr Glu Lys Gly Ile Ser Gly Met Leu Lys Ala Val Ser Asp  
 245 250 255  
 Thr Ala Lys Tyr Gly Gly Met Thr Val Gly Lys Phe Val Ile Asp Glu  
 260 265 270  
 Ser Val Arg Lys Arg Met Lys Glu Ala Leu Gln Arg Ile Lys Ser Gly  
 275 280 285  
 Lys Phe Ala Glu Glu Trp Val Glu Glu Tyr Gly Arg Gly Met Pro Thr  
 290 295 300  
 Val Val Asn Gly Leu Ser Asn Val Gln Asn Ser Leu Glu Glu Lys Ile  
 305 310 315 320  
 Gly Asn Gln Leu Arg Asp Leu Val Gln Lys Gly Lys Pro Lys Ser  
 325 330 335

&lt;210&gt; SEQ\_ID NO 14

&lt;211&gt; LENGTH: 328

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Pyrobaculum aerophilum

&lt;400&gt; SEQUENCE: 14

Met Ala Lys Ile Tyr Thr Asp Arg Glu Ala Ser Leu Glu Pro Leu Lys  
 1 5 10 15  
 Gly Lys Thr Ile Ala Val Ile Gly Tyr Gly Ile Gln Gly Arg Ala Gln  
 20 25 30  
 Ala Leu Asn Leu Arg Asp Ser Gly Leu Glu Val Ile Ile Gly Leu Arg  
 35 40 45  
 Arg Gly Gly Lys Ser Trp Glu Leu Ala Thr Ser Glu Gly Phe Arg Val  
 50 55 60  
 Tyr Glu Ile Gly Glu Ala Val Arg Lys Ala Asp Val Ile Leu Val Leu  
 65 70 75 80  
 Ile Pro Asp Met Glu Gln Pro Lys Val Trp Gln Glu Gln Ile Ala Pro  
 85 90 95  
 Asn Leu Lys Glu Gly Val Val Asp Phe Ala His Gly Phe Asn Val  
 100 105 110  
 His Phe Gly Leu Ile Lys Pro Pro Lys Asn Ile Asp Val Ile Met Val  
 115 120 125  
 Ala Pro Lys Ala Pro Gly Lys Ala Val Arg Glu Glu Tyr Leu Ala Gly  
 130 135 140  
 Arg Gly Val Pro Ala Leu Val Ala Val Tyr Gln Asp Tyr Ser Gly Ser  
 145 150 155 160  
 Ala Leu Lys Tyr Ala Leu Ala Leu Ala Lys Gly Ile Gly Ala Thr Arg  
 165 170 175  
 Ala Gly Val Ile Glu Thr Thr Phe Ala Glu Glu Thr Glu Thr Asp Leu  
 180 185 190  
 Ile Gly Glu Gln Ile Val Leu Val Gly Gly Leu Met Glu Leu Ile Lys  
 195 200 205  
 Lys Gly Phe Glu Val Leu Val Glu Met Gly Tyr Gln Pro Glu Val Ala  
 210 215 220  
 Tyr Phe Glu Val Leu Asn Glu Ala Lys Leu Ile Met Asp Leu Ile Trp

## US 9,238,801 B2

**119**

-continued

**120**

225	230	235	240
Gln Arg Gly Ile Tyr Gly Met Leu Asn Gly Val Ser Asp Thr Ala Lys			
245	250	255	
Tyr Gly Gly Leu Thr Val Gly Pro Arg Val Ile Asp Glu Asn Val Lys			
260	265	270	
Arg Lys Met Lys Glu Ala Ala Met Arg Val Lys Ser Gly Glu Phe Ala			
275	280	285	
Lys Glu Trp Val Glu Glu Tyr Asn Arg Gly Ala Pro Thr Leu Arg Lys			
290	295	300	
Leu Met Glu Glu Ala Arg Thr His Pro Ile Glu Lys Val Gly Glu Glu			
305	310	315	320
Met Arg Lys Leu Leu Phe Gly Pro			
325			

&lt;210&gt; SEQ\_ID NO 15

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Ralstonia solanacearum

&lt;400&gt; SEQUENCE: 15

Met Lys Val Phe Tyr Asp Lys Asp Ala Asp Leu Ser Leu Ile Lys Gly			
1	5	10	15
Lys Asn Val Thr Ile Ile Gly Tyr Ser Gln Gly His Ala His Ala			
20	25	30	
Leu Asn Leu Asn Asp Ser Gly Val Lys Val Thr Val Gly Leu Arg Lys			
35	40	45	
Asn Gly Ala Ser Trp Asn Lys Ala Val Asn Ala Gly Leu Gln Val Lys			
50	55	60	
Glu Val Ala Glu Ala Val Lys Asp Ala Asp Val Val Met Ile Leu Leu			
65	70	75	80
Pro Asp Glu Gln Ile Ala Asp Val Tyr Lys Asn Glu Val His Gly Asn			
85	90	95	
Ile Lys Gln Gly Ala Ala Leu Ala Phe Ala His Gly Phe Asn Val His			
100	105	110	
Tyr Gly Ala Val Ile Pro Arg Ala Asp Leu Asp Val Ile Met Val Ala			
115	120	125	
Pro Lys Ala Pro Gly His Thr Val Arg Gly Thr Tyr Ala Gln Gly Gly			
130	135	140	
Gly Val Pro His Leu Ile Ala Val His Gln Asp Lys Ser Gly Ser Ala			
145	150	155	160
Arg Asp Ile Ala Leu Ser Tyr Ala Thr Ala Asn Gly Gly Arg Ala			
165	170	175	
Gly Ile Ile Glu Thr Asn Phe Arg Glu Glu Thr Glu Thr Asp Leu Phe			
180	185	190	
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Ile Lys Ala			
195	200	205	
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr			
210	215	220	
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Ile Tyr Glu			
225	230	235	240
Gly Gly Ile Gly Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr			
245	250	255	
Gly Glu Tyr Val Thr Gly Pro Arg Val Val Thr Ala Glu Thr Lys Gln			
260	265	270	

-continued

---

Ala Met Lys Gln Cys Leu His Asp Ile Gln Thr Gly Glu Tyr Ala Lys  
275 280 285

Ser Phe Leu Leu Glu Asn Lys Ala Gly Ala Pro Thr Leu Ile Ser Arg  
290 295 300

Arg Arg Leu Thr Ala Asp His Gln Ile Glu Gln Val Gly Ala Lys Leu  
305 310 315 320

Arg Ala Met Met Pro Trp Ile Ala Lys Asn Lys Leu Val Asp Gln Ser  
325 330 335

Lys Asn

<210> SEQ ID NO 16

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Pseudomonas aeruginosa

<400> SEQUENCE: 16

Met Arg Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala His Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Arg Ser  
35 40 45

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Ala  
50 55 60

Asp Val Lys Thr Ala Val Ala Ala Asp Val Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Gly Arg Leu Tyr Lys Glu Glu Ile Glu Pro Asn  
85 90 95

Leu Lys Lys Gly Ala Thr Leu Ala Phe Ala His Gly Phe Ser Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Cys Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Cys Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Ala  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Thr Glu Gly Ala Ala Asn Tyr Pro Ser Met Thr Ala Tyr  
290 295 300

-continued

Arg Arg Asn Asn Ala Ala His Pro Ile Glu Gln Ile Gly Glu Lys Leu  
305 310 315 320

Arg Ala Met Met Pro Trp Ile Ala Ala Asn Lys Ile Val Asp Lys Ser  
325 330 335

Lys Asn

<210> SEQ ID NO 17

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Pseudomonas fluorescens

<400> SEQUENCE: 17

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Arg Lys  
35 40 45

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

-continued

Lys Asn

<210> SEQ ID NO 18  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: Spinacia oleracea

&lt;400&gt; SEQUENCE: 18

Met	Arg	Val	Phe	Tyr	Asp	Lys	Asp	Cys	Asp	Leu	Ser	Ile	Ile	Gln	Gly
1														15	

Lys	Lys	Val	Ala	Ile	Ile	Gly	Tyr	Gly	Ser	Gln	Gly	His	Ala	His	Ala
20														30	

Cys	Asn	Leu	Lys	Asp	Ser	Gly	Val	Asp	Val	Thr	Gly	Leu	Arg	Ser	
35														45	

Gly	Ser	Ala	Thr	Val	Ala	Lys	Ala	Glu	Ala	His	Gly	Leu	Lys	Val	Ala
50														60	

Asp	Val	Lys	Thr	Ala	Val	Ala	Ala	Asp	Val	Val	Met	Ile	Leu	Thr	
65														80	

Pro	Asp	Glu	Phe	Gln	Gly	Arg	Leu	Tyr	Lys	Glu	Glu	Ile	Glu	Pro	Asn
85														95	

Leu	Lys	Lys	Gly	Ala	Thr	Leu	Ala	Phe	Ala	His	Gly	Phe	Ser	Ile	His
100														110	

Tyr	Asn	Gln	Val	Val	Pro	Arg	Ala	Asp	Leu	Asp	Val	Ile	Met	Ile	Ala
115														125	

Pro	Lys	Ala	Pro	Gly	His	Thr	Val	Arg	Ser	Glu	Phe	Val	Lys	Gly	Gly
130														140	

Gly	Ile	Pro	Asp	Leu	Ile	Ala	Ile	Tyr	Gln	Asp	Ala	Ser	Gly	Asn	Ala
145														160	

Lys	Asn	Val	Ala	Leu	Ser	Tyr	Ala	Cys	Gly	Val	Gly	Gly	Arg	Thr	
165														175	

Gly	Ile	Ile	Glu	Thr	Thr	Phe	Lys	Asp	Glu	Thr	Glu	Thr	Asp	Leu	Phe
180														190	

Gly	Glu	Gln	Ala	Val	Leu	Cys	Gly	Gly	Cys	Val	Glu	Leu	Val	Lys	Ala
195														205	

Gly	Phe	Glu	Thr	Leu	Val	Glu	Ala	Gly	Tyr	Ala	Pro	Glu	Met	Ala	Tyr
210														220	

Phe	Glu	Cys	Leu	His	Glu	Leu	Lys	Leu	Ile	Val	Asp	Leu	Met	Tyr	Glu
225														240	

Gly	Gly	Ile	Ala	Asn	Met	Asn	Tyr	Ser	Ile	Ser	Asn	Asn	Ala	Glu	Tyr
245														255	

Gly	Glu	Tyr	Val	Thr	Gly	Pro	Glu	Val	Ile	Asn	Ala	Glu	Ser	Arg	Ala
260														270	

Ala	Met	Arg	Asn	Ala	Leu	Lys	Arg	Ile	Gln	Asp	Gly	Glu	Tyr	Ala	Lys
275														285	

Met	Phe	Ile	Thr	Glu	Gly	Ala	Ala	Asn	Tyr	Pro	Ser	Met	Thr	Ala	Tyr
290														300	

Arg	Arg	Asn	Asn	Ala	Ala	His	Pro	Ile	Glu	Gln	Ile	Gly	Glu	Lys	Leu
305														320	

Arg	Ala	Met	Met	Pro	Trp	Ile	Ala	Ala	Asn	Lys	Ile	Val	Asp	Lys	Ser
325														335	

Lys Asn

&lt;210&gt; SEQ ID NO 19

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

-continued

&lt;213&gt; ORGANISM: Pseudomonas fluorescens

&lt;400&gt; SEQUENCE: 19

Met	Lys	Val	Phe	Tyr	Asp	Lys	Asp	Cys	Asp	Leu	Ser	Ile	Ile	Gln	Gly
1														15	

Lys	Lys	Val	Ala	Ile	Ile	Gly	Phe	Gly	Ser	Gln	Gly	His	Ala	Gln	Ala
20														30	

Cys	Asn	Leu	Lys	Asp	Ser	Gly	Val	Asp	Val	Thr	Val	Gly	Leu	Tyr	Lys
35														45	

Gly	Ala	Ala	Asp	Ala	Ala	Lys	Ala	Glu	Ala	His	Gly	Phe	Lys	Val	Thr
50														60	

Asp	Val	Ala	Ala	Ala	Ala	Val	Ala	Asp	Leu	Val	Met	Ile	Leu	Thr	
65														80	

Pro	Asp	Glu	Phe	Gln	Ser	Gln	Leu	Tyr	Lys	Asn	Glu	Ile	Glu	Pro	Asn
85														95	

Ile	Lys	Lys	Gly	Ala	Thr	Leu	Ala	Phe	Ser	His	Gly	Phe	Ala	Ile	His
100														110	

Tyr	Asn	Gln	Val	Val	Pro	Arg	Ala	Asp	Leu	Asp	Val	Ile	Met	Ile	Ala
115														125	

Pro	Lys	Ala	Pro	Gly	His	Thr	Val	Arg	Ser	Glu	Phe	Val	Lys	Gly	Gly
130														140	

Gly	Ile	Pro	Asp	Leu	Ile	Ala	Ile	Tyr	Gln	Asp	Ala	Ser	Gly	Asn	Ala
145														160	

Lys	Asn	Val	Ala	Leu	Ser	Tyr	Ala	Ala	Ala	Val	Gly	Gly	Arg	Thr	
165														175	

Gly	Ile	Ile	Glu	Thr	Thr	Phe	Lys	Asp	Glu	Thr	Glu	Thr	Asp	Leu	Phe
180														190	

Gly	Glu	Gln	Ala	Val	Leu	Cys	Gly	Gly	Thr	Val	Glu	Leu	Val	Lys	Ala
195														205	

Gly	Phe	Glu	Thr	Leu	Val	Glu	Ala	Gly	Tyr	Ala	Pro	Glu	Met	Ala	Tyr
210														220	

Phe	Glu	Cys	Leu	His	Glu	Leu	Lys	Leu	Ile	Val	Asp	Leu	Met	Tyr	Glu
225														240	

Gly	Gly	Ile	Ala	Asn	Met	Asn	Tyr	Ser	Ile	Ser	Asn	Asn	Ala	Glu	Tyr
245														255	

Gly	Glu	Tyr	Val	Thr	Gly	Pro	Glu	Val	Ile	Asn	Ala	Glu	Ser	Arg	Gln
260														270	

Ala	Met	Arg	Asn	Ala	Leu	Lys	Arg	Ile	Gln	Asp	Gly	Glu	Tyr	Ala	Lys
275														285	

Met	Phe	Ile	Ser	Glu	Gly	Ala	Thr	Gly	Tyr	Pro	Ser	Met	Thr	Ala	Lys
290														300	

Arg	Arg	Asn	Asn	Ala	Ala	His	Gly	Ile	Glu	Ile	Ile	Gly	Glu	Gln	Leu
305														320	

Arg	Ser	Met	Met	Pro	Trp	Ile	Gly	Ala	Asn	Lys	Ile	Val	Asp	Lys	Ala
325														335	

Lys Asn

&lt;210&gt; SEQ ID NO 20

&lt;211&gt; LENGTH: 24

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: primer pBAD 266

&lt;400&gt; SEQUENCE: 20

-continued

ctctctactg tttctccata cccg

24

<210> SEQ ID NO 21  
<211> LENGTH: 27  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer PF5- 53Mt  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (26)..(27)  
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 21

caagccgtgg gcttcagcct tggcknn

27

<210> SEQ ID NO 22  
<211> LENGTH: 23  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer pBAD 866

&lt;400&gt; SEQUENCE: 22

cggtttcagt ctcgtccttg aag

23

<210> SEQ ID NO 23  
<211> LENGTH: 0  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Blank sequence

&lt;400&gt; SEQUENCE: 23

000

<210> SEQ ID NO 24  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic construct mutant ilcV

&lt;400&gt; SEQUENCE: 24

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly			
1	5	10	15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala		
20	25	30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys		
35	40	45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr		
50	55	60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr			
65	70	75	80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn		
85	90	95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His		
100	105	110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala		
115	120	125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly		
130	135	140

-continued

---

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ\_ID NO 25  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic construct mutant ilcV

<400> SEQUENCE: 25

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys  
35 40 45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr

## US 9,238,801 B2

133

134

-continued

---

165	170	175
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe		
180	185	190
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala		
195	200	205
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr		
210	215	220
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu		
225	230	235
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr		
245	250	255
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln		
260	265	270
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys		
275	280	285
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys		
290	295	300
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu		
305	310	315
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala		
325	330	335

Lys Asn

<210> SEQ\_ID NO 26  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic construct mutant ilcV

<400> SEQUENCE: 26

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly		
1	5	10
Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala		
20	25	30
Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys		
35	40	45
Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr		
50	55	60
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr		
65	70	75
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn		
85	90	95
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His		
100	105	110
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala		
115	120	125
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly		
130	135	140
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala		
145	150	155
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr		
165	170	175
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe		
180	185	190

-continued

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 27  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic construct mutant ilcV

<400> SEQUENCE: 27

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys  
35 40 45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

-continued

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ\_ID NO 28  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic construct mutant ilcV

<400> SEQUENCE: 28

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys  
35 40 45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu

-continued

225	230	235	240
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr			
245	250	255	
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln			
260	265	270	
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys			
275	280	285	
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys			
290	295	300	
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu			
305	310	315	320
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala			
325	330	335	
Lys Asn			

```

<210> SEQ_ID NO 29
<211> LENGTH: 338
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic construct
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Xaa = Tyr or Phe
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (33)..(33)
<223> OTHER INFORMATION: Xaa = Cys or Leu
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (47)..(47)
<223> OTHER INFORMATION: Xaa = Arg or Tyr
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (50)..(50)
<223> OTHER INFORMATION: Xaa = Ser or Ala
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (52)..(52)
<223> OTHER INFORMATION: Xaa = Thr or Asp
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (53)..(53)
<223> OTHER INFORMATION: Xaa = Val or Ala
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (61)..(61)
<223> OTHER INFORMATION: Xaa = Leu or Phe
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (80)..(80)
<223> OTHER INFORMATION: Xaa = Thr or Iso
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (156)..(156)
<223> OTHER INFORMATION: Xaa = Ala or Val
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (170)..(170)
<223> OTHER INFORMATION: Xaa = Gly or Ala

```

<400> SEQUENCE: 29

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly			
1	5	10	15

Lys Lys Val Ala Ile Ile Gly Xaa Gly Ser Gln Gly His Ala Gln Ala			
20	25	30	

Xaa Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Xaa Lys

## US 9,238,801 B2

**141****142**

-continued

35                    40                    45

Gly Xaa Ala Xaa Xaa Ala Lys Ala Glu Ala His Gly Xaa Lys Val Thr  
 50                    55                    60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Xaa  
 65                    70                    75                    80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85                    90                    95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100                  105                  110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115                  120                  125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130                  135                  140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Xaa Ser Gly Asn Ala  
 145                  150                  155                  160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Xaa Val Gly Gly Arg Thr  
 165                  170                  175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180                  185                  190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195                  200                  205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210                  215                  220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225                  230                  235                  240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245                  250                  255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260                  265                  270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275                  280                  285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290                  295                  300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305                  310                  315                  320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325                  330                  335

Lys Asn

&lt;210&gt; SEQ ID NO 30

&lt;211&gt; LENGTH: 331

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Natronomonas pharaanis

&lt;400&gt; SEQUENCE: 30

Met Thr Asp Ala Thr Ile Tyr Tyr Asp Asp Asp Ala Glu Ser Thr Val  
 1                    5                    10                    15

Leu Asp Asp Lys Thr Val Ala Val Leu Gly Tyr Gly Ser Gln Gly His  
 20                  25                  30

Ala His Ala Gln Asn Leu Asp Asp Ser Gly Val Asp Val Val Val Gly  
 35                  40                  45

Leu Arg Glu Asp Ser Ser Arg Ser Ala Ala Glu Ala Asp Gly Leu  
 50                  55                  60

Asp Val Ala Thr Pro Arg Gly Ala Ala Glu Gln Ala Asp Leu Val Ser

-continued

65	70	75	80
Val	Leu	Val	Pro
Asp	Thr	Val	Gln
Pro		Ala	Val
Tyr			Glu
Gln			Ile
Ile			Glu
His			85
Tyr			90
Gly			95
Asp	Val	Gln	Pro
Gly	Asp	Thr	Leu
Asn			Gln
Phe			100
Ala			105
His			110
Gly			
Ile			
His			
Tyr			
Gly			
Ile			
Glu			
Pro			
Ser			
Glu			
Asp			
Val			
Asn			
Val			
Thr			
Met			
Ile			
Asn			
Leu			
Arg			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			
Arg			
Asn			
Val			
Gly			
Asn			
Val			

## US 9,238,801 B2

**145**

-continued

---

Phe His Gln Ile Val Pro Pro Ala Asp Val Asp Val Phe Leu Val Ala  
115 120 125

Pro Lys Gly Pro Gly His Leu Val Arg Arg Thr Tyr Glu Gln Gly Ala  
130 135 140

Gly Val Pro Ala Leu Phe Ala Ile Tyr Gln Asp Val Thr Gly Glu Ala  
145 150 155 160

Arg Asp Lys Ala Leu Ala Tyr Ala Lys Gly Ile Gly Gly Ala Arg Ala  
165 170 175

Gly Val Leu Glu Thr Thr Phe Lys Glu Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Leu Ser Ala Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Thr Glu Ala Gly Tyr Gln Pro Glu Leu Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Glu Gly Leu Ala Gly Met Arg Tyr Ser Ile Ser Asp Thr Ala Gln Trp  
245 250 255

Gly Asp Phe Val Ser Gly Pro Arg Val Val Asp Ala Lys Val Lys Glu  
260 265 270

Ser Met Lys Glu Val Leu Lys Asp Ile Gln Asn Gly Thr Phe Ala Lys  
275 280 285

Glu Trp Ile Val Glu Asn Gln Val Asn Arg Pro Arg Phe Asn Ala Ile  
290 295 300

Asn Ala Ser Glu Asn Glu His Gln Ile Glu Val Val Gly Arg Lys Leu  
305 310 315 320

Arg Glu Met Met Pro Phe Val Lys Gln Gly Lys Lys Lys Glu Ala Val  
325 330 335

Val Ser Val Ala Gln Asn  
340

&lt;210&gt; SEQ ID NO 32

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Corynebacterium glutamicum

&lt;400&gt; SEQUENCE: 32

Met Ala Ile Glu Leu Leu Tyr Asp Ala Asp Ala Asp Leu Ser Leu Ile  
1 5 10 15

Gln Gly Arg Lys Val Ala Ile Val Gly Tyr Gly Ser Gln Gly His Ala  
20 25 30

His Ser Gln Asn Leu Arg Asp Ser Gly Val Glu Val Val Ile Gly Leu  
35 40 45

Arg Glu Gly Ser Lys Ser Ala Glu Lys Ala Lys Glu Ala Gly Phe Glu  
50 55 60

Val Lys Thr Thr Ala Glu Ala Ala Ala Trp Ala Asp Val Ile Met Leu  
65 70 75 80

Leu Ala Pro Asp Thr Ser Gln Ala Glu Ile Phe Thr Asn Asp Ile Glu  
85 90 95

Pro Asn Leu Asn Ala Gly Asp Ala Leu Leu Phe Gly His Gly Leu Asn  
100 105 110

Ile His Phe Asp Leu Ile Lys Pro Ala Asp Asp Ile Ile Val Gly Met  
115 120 125

Val Ala Pro Lys Gly Pro Gly His Leu Val Arg Arg Gln Phe Val Asp  
130 135 140

**146**

-continued

Gly Lys Gly Val Pro Cys Leu Ile Ala Val Asp Gln Asp Pro Thr Gly  
145 150 155 160

Thr Ala Gln Ala Leu Thr Leu Ser Tyr Ala Ala Ala Ile Gly Gly Ala  
165 170 175

Arg Ala Gly Val Ile Pro Thr Thr Phe Glu Ala Glu Thr Val Thr Asp  
180 185 190

Leu Phe Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Glu Glu Leu Val  
195 200 205

Lys Val Gly Phe Glu Val Leu Thr Glu Ala Gly Tyr Glu Pro Glu Met  
210 215 220

Ala Tyr Phe Glu Val Leu His Glu Leu Lys Leu Ile Val Asp Leu Met  
225 230 235 240

Phe Glu Gly Ile Ser Asn Met Asn Tyr Ser Val Ser Asp Thr Ala  
245 250 255

Glu Phe Gly Gly Tyr Leu Ser Gly Pro Arg Val Ile Asp Ala Asp Thr  
260 265 270

Lys Ser Arg Met Lys Asp Ile Leu Thr Asp Ile Gln Asp Gly Thr Phe  
275 280 285

Thr Lys Arg Leu Ile Ala Asn Val Glu Asn Gly Asn Thr Glu Leu Glu  
290 295 300

Gly Leu Arg Ala Ser Tyr Asn Asn His Pro Ile Glu Glu Thr Gly Ala  
305 310 315 320

Lys Leu Arg Asp Leu Met Ser Trp Val Lys Val Asp Ala Arg Ala Glu  
325 330 335

Thr Ala

<210> SEQ ID NO 33  
<211> LENGTH: 339  
<212> TYPE: PRT  
<213> ORGANISM: Phaeospirillum molischianum  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (310)..(310)  
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 33

Met Arg Val Tyr Tyr Asp Arg Asp Ala Asp Val Asn Leu Ile Lys Ser  
1 5 10 15

Lys Lys Val Ala Val Ile Gly Tyr Gly Ser Gln Gly His Ala His Val  
20 25 30

Leu Asn Leu Arg Asp Ser Gly Val Lys Asp Val Ala Val Ala Leu Arg  
35 40 45

Pro Gly Ser Ala Ser Ile Lys Lys Ala Glu Ala Glu Gly Leu Lys Val  
50 55 60

Leu Thr Pro Ala Glu Ala Ala Ala Trp Ala Asp Val Val Met Ile Leu  
65 70 75 80

Thr Pro Asp Glu Leu Gln Ala Asp Leu Tyr Lys Ser Glu Leu Ala Ala  
85 90 95

Asn Leu Lys Pro Gly Ala Ala Leu Val Phe Ala His Gly Leu Ala Ile  
100 105 110

His Phe Lys Leu Ile Glu Ala Arg Ala Asp Leu Asp Val Phe Met Val  
115 120 125

Ala Pro Lys Gly Pro Gly His Thr Val Arg Gly Glu Tyr Leu Lys Gly  
130 135 140

Gly Gly Val Pro Cys Leu Val Ala Val Ala Gln Asn Pro Thr Gly Asn

## US 9,238,801 B2

**149****150**

-continued

145	150	155	160
Ala Leu Glu Leu Ala Leu Ser Tyr Ala Ser Ala Ile Gly Gly Arg			
165	170	175	
Ser Gly Ile Ile Glu Thr Thr Phe Arg Glu Glu Cys Glu Thr Asp Leu			
180	185	190	
Phe Gly Glu Gln Val Val Leu Cys Gly Gly Leu Ser Lys Leu Ile Gln			
195	200	205	
Tyr Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala			
210	215	220	
Tyr Phe Glu Cys Leu His Glu Val Lys Leu Ile Val Asp Leu Ile Tyr			
225	230	235	240
Glu Gly Gly Ile Ala Asn Met Arg Tyr Ser Ile Ser Asn Thr Ala Glu			
245	250	255	
Tyr Gly Asp Tyr Val Thr Gly Ser Arg Ile Ile Thr Glu Ala Thr Lys			
260	265	270	
Ala Glu Met Lys Arg Val Leu Ala Asp Ile Gln Ser Gly Arg Phe Val			
275	280	285	
Arg Asp Trp Met Leu Glu Cys Lys Ala Gly Gln Pro Ser Phe Lys Ala			
290	295	300	
Thr Arg Arg Ile Gln Xaa Glu His Val Ile Glu Val Val Gly Glu Lys			
305	310	315	320
Leu Arg Gly Met Met Pro Trp Ile Ser Lys Asn Lys Leu Val Asp Lys			
325	330	335	

Ala Arg Asn

<210> SEQ ID NO 34  
<211> LENGTH: 339  
<212> TYPE: PRT  
<213> ORGANISM: Zymomonas mobilis

&lt;400&gt; SEQUENCE: 34

Met Lys Val Tyr Tyr Asp Ser Asp Ala Asp Leu Gly Leu Ile Lys Ser			
1	5	10	15
Lys Lys Ile Ala Ile Leu Gly Tyr Gly Ser Gln Gly His Ala His Ala			
20	25	30	
Gln Asn Leu Arg Asp Ser Gly Val Ala Glu Val Ala Ile Ala Leu Arg			
35	40	45	
Pro Asp Ser Ala Ser Val Lys Lys Ala Gln Asp Ala Gly Phe Lys Val			
50	55	60	
Leu Thr Asn Ala Glu Ala Ala Lys Trp Ala Asp Ile Leu Met Ile Leu			
65	70	75	80
Ala Pro Asp Glu His Gln Ala Ala Ile Tyr Ala Glu Asp Leu Lys Asp			
85	90	95	
Asn Leu Arg Pro Gly Ser Ala Ile Ala Phe Ala His Gly Leu Asn Ile			
100	105	110	
His Phe Gly Leu Ile Glu Pro Arg Lys Asp Ile Asp Val Phe Met Ile			
115	120	125	
Ala Pro Lys Gly Pro Gly His Thr Val Arg Ser Glu Tyr Val Arg Gly			
130	135	140	
Gly Gly Val Pro Cys Leu Val Ala Val Asp Gln Asp Ala Ser Gly Asn			
145	150	155	160
Ala His Asp Ile Ala Leu Ala Tyr Ala Ser Gly Ile Gly Gly Arg			
165	170	175	
Ser Gly Val Ile Glu Thr Thr Phe Arg Glu Glu Val Glu Thr Asp Leu			

## US 9,238,801 B2

**151**

-continued

---

180	185	190	
Phe Gly Glu Gln Ala Val Leu Cys Gly Gly	Gly Leu Thr Ala Leu Ile Thr		
195	200	205	
Ala Gly Phe Glu Thr Leu Thr Glu Ala Gly Tyr	Ala Pro Glu Met Ala		
210	215	220	
Phe Phe Glu Cys Met His Glu Met Lys Leu Ile Val Asp	Leu Ile Tyr		
225	230	235	240
Glu Ala Gly Ile Ala Asn Met Arg Tyr Ser Ile Ser Asn	Thr Ala Glu		
245	250	255	
Tyr Gly Asp Ile Val Ser Gly Pro Arg Val Ile Asn Glu	Ser Lys		
260	265	270	
Lys Ala Met Lys Ala Ile Leu Asp Asp Ile Gln Ser	Gly Arg Phe Val		
275	280	285	
Ser Lys Phe Val Leu Asp Asn Arg Ala Gly Gln Pro	Glu Leu Lys Ala		
290	295	300	
Ala Arg Lys Arg Met Ala Ala His Pro Ile Glu Gln Val	Gly Ala Arg		
305	310	315	320
Leu Arg Lys Met Met Pro Trp Ile Ala Ser Asn Lys Leu Val	Asp Lys		
325	330	335	
Ala Arg Asn			

&lt;210&gt; SEQ ID NO: 35

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Alkalalimnicola ehrlichei

&lt;400&gt; SEQUENCE: 35

Met Gln Val Tyr Tyr Asp Lys Asp Ala Asp Leu Ser Ile Ile Gln Gly			
1	5	10	15
Lys Lys Val Ala Val Ile Gly Tyr Gly Ser Gln Gly His Ala His Ala			
20	25	30	
Asn Asn Leu Lys Glu Ser Gly Val Asp Val Val Val Gly Leu Arg Glu			
35	40	45	
Gly Ser Ser Ser Ala Ala Lys Ala Gln Lys Ala Gly Leu Ala Val Ala			
50	55	60	
Ser Ile Glu Asp Ala Ala Gln Ala Asp Val Val Met Ile Leu Ala			
65	70	75	80
Pro Asp Glu His Gln Ala Val Ile Tyr His Asn Gln Ile Ala Pro Asn			
85	90	95	
Val Lys Pro Gly Ala Ala Ile Ala Phe Ala His Gly Phe Asn Ile His			
100	105	110	
Phe Gly Gln Ile Gln Pro Ala Ala Asp Leu Asp Val Ile Met Val Ala			
115	120	125	
Pro Lys Gly Pro Gly His Leu Val Arg Ser Thr Tyr Val Glu Gly Gly			
130	135	140	
Gly Val Pro Ser Leu Ile Ala Ile His Gln Asp Ala Thr Gly Lys Ala			
145	150	155	160
Lys Asp Ile Ala Leu Ser Tyr Ala Ser Ala Asn Gly Gly Arg Ala			
165	170	175	
Gly Val Ile Glu Thr Ser Phe Arg Glu Glu Thr Asp Leu Phe			
180	185	190	
Gly Glu Gln Ala Val Leu Cys Gly Gly Ile Thr Ser Leu Ile Gln Ala			
195	200	205	
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr			

## US 9,238,801 B2

**153****154**

-continued

210            215            220

Phe Glu Cys Leu His Glu Thr Lys Leu Ile Val Asp Leu Leu Tyr Gln  
 225            230            235            240

Gly Gly Ile Ala Asn Met Arg Tyr Ser Ile Ser Asn Thr Ala Glu Tyr  
 245            250            255

Gly Asp Phe Thr Arg Gly Pro Arg Val Ile Asn Glu Glu Ser Arg Glu  
 260            265            270

Ala Met Arg Glu Ile Leu Ala Glu Ile Gln Glu Gly Glu Phe Ala Arg  
 275            280            285

Glu Phe Val Leu Glu Asn Gln Ala Gly Cys Pro Thr Leu Thr Ala Arg  
 290            295            300

Arg Arg Leu Ala Ala Glu His Glu Ile Glu Val Val Gly Glu Arg Leu  
 305            310            315            320

Arg Gly Met Met Pro Trp Ile Asn Ala Asn Lys Leu Val Asp Lys Asp  
 325            330            335

Lys Asn

&lt;210&gt; SEQ ID NO 36

&lt;211&gt; LENGTH: 340

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Campylobacter lari

&lt;400&gt; SEQUENCE: 36

Met Ala Val Ser Ile Tyr Tyr Asp Lys Asp Cys Asp Ile Asn Leu Ile  
 1                5                10                15

Lys Ser Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala  
 20              25              30

His Ala Met Asn Leu Arg Asp Ser Gly Val Glu Val Ile Ile Gly Leu  
 35              40              45

Lys Glu Gly Gly Gln Ser Trp Ala Lys Ala Gln Lys Ala Asn Phe Ile  
 50              55              60

Val Lys Ser Val Lys Glu Ala Thr Lys Glu Ala Asp Leu Ile Met Ile  
 65              70              75              80

Leu Ala Pro Asp Glu Ile Gln Ser Glu Ile Phe Asn Glu Glu Ile Lys  
 85              90              95

Pro Glu Leu Lys Ala Gly Lys Thr Leu Ala Phe Ala His Gly Phe Asn  
 100            105            110

Ile His Tyr Gly Gln Ile Val Ala Pro Lys Gly Ile Asp Val Ile Met  
 115            120            125

Ile Ala Pro Lys Ala Pro Gly His Thr Val Arg His Glu Phe Ser Ile  
 130            135            140

Gly Gly Gly Thr Pro Cys Leu Ile Ala Ile His Gln Asp Glu Ser Lys  
 145            150            155            160

Asn Ala Lys Asn Leu Ala Leu Ser Tyr Ala Ser Ala Ile Gly Gly Gly  
 165            170            175

Arg Thr Gly Ile Ile Glu Thr Thr Phe Lys Ala Glu Thr Glu Thr Asp  
 180            185            190

Leu Phe Gly Glu Gln Ala Val Leu Cys Gly Gly Leu Ser Ala Leu Ile  
 195            200            205

Gln Ala Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Glu Pro Glu Met  
 210            215            220

Ala Tyr Phe Glu Cys Leu His Glu Met Lys Leu Ile Val Asp Leu Ile  
 225            230            235            240

Tyr Gln Gly Gly Ile Ala Asp Met Arg Tyr Ser Val Ser Asn Thr Ala

## US 9,238,801 B2

**155****156**

-continued

245	250	255
Glu Tyr Gly Asp Tyr Ile Thr Gly Pro Lys Ile Ile Thr Lys Glu Thr		
260	265	270
Lys Glu Ala Met Lys Gly Val Leu Lys Asp Ile Gln Asn Gly Ser Phe		
275	280	285
Ala Lys Asp Phe Ile Leu Glu Arg Arg Ala Asn Phe Ala Arg Met His		
290	295	300
Ala Glu Arg Lys Leu Met Asn Asp Ser Leu Ile Glu Lys Thr Gly Arg		
305	310	315
Glu Leu Arg Ala Met Met Pro Trp Ile Ser Ala Lys Lys Leu Val Asp		
325	330	335
Lys Asp Lys Asn		
340		

<210> SEQ\_ID NO 37  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: Marinobacter aquaeolei  
<400> SEQUENCE: 37

Met Gln Val Tyr Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly		
1	5	10
Lys Lys Val Ala Ile Leu Gly Phe Gly Ser Gln Gly His Ala His Ala		
20	25	30
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Val Val Gly Leu Arg Ala		
35	40	45
Gly Ser Ser Ser Ile Ala Lys Ala Glu Ala Tyr Gly Leu Lys Thr Ser		
50	55	60
Asp Val Ala Ser Ala Val Ala Ser Ala Asp Val Val Met Val Leu Thr		
65	70	75
Pro Asp Glu Phe Gln Ala Gln Leu Tyr Arg Glu Glu Ile Glu Pro Asn		
85	90	95
Leu Lys Gln Gly Ala Thr Leu Ala Phe Ala His Gly Phe Ala Ile His		
100	105	110
Tyr Asn Gln Ile Val Pro Arg Lys Asp Leu Asp Val Ile Met Val Ala		
115	120	125
Pro Lys Ala Pro Gly His Thr Val Arg Thr Glu Phe Thr Lys Gly Gly		
130	135	140
Gly Ile Pro Asp Leu Ile Ala Ile Phe Gln Asp Ala Ser Gly Asn Ala		
145	150	155
Lys Asn Val Ala Leu Ser Tyr Ala Ser Gly Ile Gly Gly Arg Thr		
165	170	175
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe		
180	185	190
Gly Glu Gln Ala Val Leu Cys Gly Gly Ala Val Glu Leu Val Lys Ala		
195	200	205
Gly Phe Glu Thr Leu Thr Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr		
210	215	220
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu		
225	230	235
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr		
245	250	255
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Glu Gln Ser Arg Glu		
260	265	270

## US 9,238,801 B2

**157**

-continued

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Ser Gly Glu Tyr Ala Lys  
 275                    280                    285

Met Phe Ile Ser Glu Gly Ala Leu Asn Tyr Pro Ser Met Thr Ala Arg  
 290                    295                    300

Arg Arg Gln Asn Ala Ala His Glu Ile Glu Thr Val Gly Glu Lys Leu  
 305                    310                    315                    320

Arg Ser Met Met Pro Trp Ile Ser Ala Asn Lys Ile Val Asp Lys Asp  
 325                    330                    335

Lys Asn

&lt;210&gt; SEQ\_ID NO 38

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Psychrobacter arcticus

&lt;400&gt; SEQUENCE: 38

Met Asn Val Tyr Tyr Asp Lys Asp Cys Asp Leu Ser Ile Val Gln Gly  
 1                    5                    10                    15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala His Ala  
 20                    25                    30

Leu Asn Leu Gln Asp Ser Asn Val Asp Val Thr Val Gly Leu Arg Ala  
 35                    40                    45

Asp Ser Gly Ser Trp Lys Lys Ala Glu Asn Ala Gly Leu Lys Val Ala  
 50                    55                    60

Glu Val Glu Glu Ala Val Lys Ala Ala Asp Ile Ile Met Ile Leu Thr  
 65                    70                    75                    80

Pro Asp Glu Phe Gln Lys Glu Leu Tyr Asn Asp Val Ile Glu Pro Asn  
 85                    90                    95

Ile Lys Gln Gly Ala Thr Leu Ala Phe Ala His Gly Phe Ala Ile His  
 100                    105                    110

Tyr Asn Gln Val Ile Pro Arg Ser Asp Leu Asp Val Ile Met Val Ala  
 115                    120                    125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Ala Lys Gly Gly  
 130                    135                    140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Gln Ala  
 145                    150                    155                    160

Lys Gln Leu Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Ser  
 165                    170                    175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180                    185                    190

Gly Glu Gln Ala Val Leu Cys Gly Gly Ala Val Glu Leu Val Lys Met  
 195                    200                    205

Gly Phe Glu Thr Leu Thr Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210                    215                    220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225                    230                    235                    240

Gly Gly Ile Ala Asp Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245                    250                    255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Glu Gln Ser Arg Glu  
 260                    265                    270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Ser Gly Glu Tyr Ala Lys  
 275                    280                    285

Met Phe Ile Ser Glu Gly Ala Thr Asn Tyr Pro Ser Met Thr Ala Arg  
 290                    295                    300

**158**

**159****160**

-continued

Arg Arg Asn Asn Ala Glu His Gln Ile Glu Ile Thr Gly Ala Lys Leu  
 305                   310                   315                   320

Arg Gly Met Met Pro Trp Ile Gly Gly Asn Lys Ile Ile Asp Lys Asp  
 325                   330                   335

Lys Asn

&lt;210&gt; SEQ ID NO 39

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Hahella chejuensis

&lt;400&gt; SEQUENCE: 39

Met Gln Val Tyr Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1               5               10               15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala His Ala  
 20               25               30

Asn Asn Leu Lys Asp Ser Gly Val Asp Val Cys Val Gly Leu Arg Lys  
 35               40               45

Gly Ser Gly Ser Trp Ala Lys Ala Glu Asn Ala Gly Leu Ala Val Lys  
 50               55               60

Glu Val Ala Glu Ala Val Ala Gly Ala Asp Val Val Met Ile Leu Thr  
 65               70               75               80

Pro Asp Glu Phe Gln Ala Gln Leu Tyr Lys Ser Glu Ile Glu Pro Asn  
 85               90               95

Leu Lys Ser Gly Ala Thr Leu Ala Phe Ala His Gly Phe Ser Ile His  
 100              105              110

Tyr Asn Gln Ile Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115              120              125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130              135              140

Gly Ile Pro Asp Leu Ile Ala Ile Phe Gln Asp Ala Ser Gly Ser Ala  
 145              150              155              160

Lys Asp Leu Ala Leu Ser Tyr Ala Ser Gly Val Gly Gly Arg Thr  
 165              170              175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180              185              190

Gly Glu Gln Ala Val Leu Cys Gly Gly Ala Val Glu Leu Val Lys Ala  
 195              200              205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210              215              220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225              230              235              240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245              250              255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Asp Gln Ser Arg Ala  
 260              265              270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275              280              285

Met Phe Ile Ala Glu Gly Ala His Asn Tyr Pro Ser Met Thr Ala Tyr  
 290              295              300

Arg Arg Asn Asn Ala Ala His Pro Ile Glu Gln Val Gly Glu Lys Leu  
 305              310              315              320

Arg Ser Met Met Pro Trp Ile Ala Ser Asn Lys Ile Val Asp Lys Ser  
 325              330              335

-continued

Lys Asn

<210> SEQ ID NO 40  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: Thiobacillus denitrificans

<400> SEQUENCE: 40

Met	Lys	Val	Tyr	Tyr	Asp	Lys	Asp	Ala	Asp	Leu	Ser	Leu	Ile	Lys	Gln
1															15
Arg	Lys	Val	Ala	Ile	Val	Gly	Tyr	Gly	Ser	Gln	Gly	His	Ala	His	Ala
														20	30
Asn	Asn	Leu	Lys	Asp	Ser	Gly	Val	Asp	Val	Thr	Val	Ala	Leu	Arg	Pro
														35	45
Gly	Ser	Ala	Ser	Ala	Lys	Lys	Ala	Glu	Asn	Ala	Gly	Leu	Thr	Val	Lys
														50	60
Ser	Val	Pro	Glu	Ala	Val	Ala	Gly	Ala	Asp	Leu	Val	Met	Ile	Leu	Thr
														65	80
Pro	Asp	Glu	Phe	Gln	Ser	Arg	Leu	Tyr	Arg	Asp	Glu	Ile	Glu	Pro	Asn
														85	95
Ile	Lys	Gln	Gly	Ala	Thr	Leu	Ala	Phe	Ala	His	Gly	Phe	Ser	Ile	His
														100	110
Tyr	Asn	Gln	Val	Val	Pro	Arg	Ala	Asp	Leu	Asp	Val	Ile	Met	Ile	Ala
														115	125
Pro	Lys	Ala	Pro	Gly	His	Thr	Val	Arg	Ser	Glu	Phe	Val	Lys	Gly	Gly
														130	140
Gly	Ile	Pro	Asp	Leu	Ile	Ala	Ile	Tyr	Gln	Asp	Ala	Ser	Gly	Lys	Ala
														145	160
Lys	Glu	Thr	Ala	Leu	Ser	Tyr	Ala	Ser	Ala	Ile	Gly	Gly	Gly	Arg	Thr
														165	175
Gly	Ile	Ile	Glu	Thr	Thr	Phe	Lys	Asp	Glu	Thr	Glu	Thr	Asp	Leu	Phe
														180	190
Gly	Glu	Gln	Ala	Val	Leu	Cys	Gly	Gly	Ala	Val	Glu	Leu	Val	Lys	Ala
														195	205
Gly	Phe	Asp	Thr	Leu	Val	Glu	Ala	Gly	Tyr	Ala	Pro	Glu	Met	Ala	Tyr
														210	220
Phe	Glu	Cys	Leu	His	Glu	Leu	Lys	Leu	Ile	Val	Asp	Leu	Met	Tyr	Glu
														225	240
Gly	Gly	Ile	Ala	Asn	Met	Asn	Tyr	Ser	Ile	Ser	Asn	Asn	Ala	Glu	Tyr
														245	255
Gly	Glu	Tyr	Val	Thr	Gly	Val	Lys	Val	Ile	Asn	Glu	Gln	Ser	Arg	Ala
														260	270
Ala	Met	Lys	Glu	Cys	Leu	Ala	Asn	Ile	Gln	Asn	Gly	Ala	Tyr	Ala	Lys
														275	285
Arg	Phe	Ile	Leu	Glu	Gly	Gln	Ala	Asn	Tyr	Pro	Glu	Met	Thr	Ala	Trp
														290	300
Arg	Arg	Asn	Asn	Ala	Ala	His	Gln	Ile	Glu	Val	Val	Gly	Ala	Lys	Leu
														305	320
Arg	Ser	Met	Met	Pro	Trp	Ile	Ala	Ala	Asn	Lys	Leu	Val	Asp	His	Ser
														325	335

Lys Asn

<210> SEQ ID NO 41  
<211> LENGTH: 338  
<212> TYPE: PRT

163

164

-continued

<213> ORGANISM: Azotobacter vinelandii

<400> SEQUENCE: 41

Met Lys Val Tyr Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Ser  
 1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala His Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Tyr Val Gly Leu Arg Ala  
35 40 45

Gly Ser Ala Ser Val Ala Lys Ala Glu Ala His Gly Leu Thr Val Lys  
50 55 60

Ser Val Lys Asp Ala Val Ala Ala Asp Val Val Met Ile Leu Thr

Pro Asp Glu Phe Gln Gly Arg Leu Tyr Lys Asp Glu Ile Glu Pro Asn  
65 66 67

Leu Lys Lys Gly Ala Thr Leu Ala Phe Ala His Gly Phe Ser Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Arg Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Val Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Leu Ala Leu Ser Tyr Ala Cys Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gin Ala Val Leu Cys Gly Gly Cys Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

The Gia cys Lea his Gia Lea Lys Lea lie Val Asp Lea Met The Gia  
225 230 235 240

245 250 255

260 265 270

275                    280                    285

290                    295                    300

305                    310                    315                    320

325                    330                    335

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM:

<400> SEQUENCE: 42

Met	Lys	Val	Phe	Tyr	Asp	Lys	Asp	Cys	Asp	Leu	Ser	Ile	Ile	Gln	Gly
1				5					10					15	

-continued

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Arg Lys  
35 40 45

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ser Ala Val Ala Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Val Glu Pro Asn  
85 90 95

Leu Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Thr Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Val Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ser Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Lys Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Ala Ala Asn Lys Ile Val Asp Lys Asp  
325 330 335

Lys Asn

<210> SEQ ID NO 43

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: *Pseudomonas syringae*

<400> SEQUENCE: 43

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Arg Lys  
35 40 45

## US 9,238,801 B2

**167**

-continued

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ser Ala Val Ala Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Val Glu Pro Asn  
85 90 95

Leu Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Thr Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Val Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ser Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Thr Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Glu His Gly Ile Glu Val Ile Gly Glu Lys Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Ala Ala Asn Lys Ile Val Asp Lys Asp  
325 330 335

Lys Asn

<210> SEQ ID NO 44

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Pseudomonas putida

<400> SEQUENCE: 44

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Arg Lys  
35 40 45

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Ala  
50 55 60

Asp Val Ala Thr Ala Val Ala Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

**168**

-continued

Pro Asp Glu Phe Gln Gly Ala Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ser Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ser Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Glu Glu Ser Arg Lys  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Asn Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Ser Ala Asn Lys Ile Val Asp Lys Thr  
325 330 335

Lys Asn

<210> SEQ ID NO 45

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Pseudomonas entomophila

<400> SEQUENCE: 45

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Ile Gly Leu Arg Lys  
35 40 45

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Thr Ala Val Ala Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Gly Gln Leu Tyr Lys Gln Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

-continued

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ser Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Glu Glu Ser Arg Lys  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Asn Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Ser Ala Asn Lys Ile Val Asp Lys Thr  
325 330 335

Lys Asn

<210> SEQ ID NO 46  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: Pseudomonas mendocina

<400> SEQUENCE: 46

Met Lys Val Tyr Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Ile Gly Leu Arg Lys  
35 40 45

Gly Ser Ala Thr Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ser Ala Val Ala Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Gly Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Thr Glu Phe Val Lys Gly Gly  
130 135 140

-continued

Gly Ile Pro Asp Leu Ile Ala Val Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ser Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Val Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ala Met Met Pro Trp Ile Ala Ala Asn Lys Ile Val Asp Lys Thr  
325 330 335

Lys Asn

<210> SEQ ID NO 47

<211> LENGTH: 336

<212> TYPE: PRT

<213> ORGANISM: Bacillus cereus

<400> SEQUENCE: 47

Met Ala Lys Val Tyr Tyr Glu Lys Asp Val Thr Val Asn Val Leu Lys  
1 5 10 15

Glu Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala His  
20 25 30

Ala Gln Asn Leu Arg Asp Asn Gly Phe Asp Val Val Val Gly Leu Arg  
35 40 45

Lys Gly Lys Ser Trp Asp Lys Ala Lys Glu Asp Gly Phe Ser Val Tyr  
50 55 60

Thr Val Ala Glu Ala Ala Lys Gln Ala Asp Val Val Met Ile Leu Leu  
65 70 75 80

Pro Asp Glu Leu Gln Pro Glu Val Tyr Glu Ala Glu Ile Ala Pro Asn  
85 90 95

Leu Gln Ala Gly Asn Ser Leu Val Phe Ala His Gly Phe Asn Val His  
100 105 110

Phe Asp Gln Val Lys Pro Pro Ala Asn Val Asp Val Phe Leu Val Ala  
115 120 125

Pro Lys Gly Pro Gly His Leu Val Arg Arg Thr Phe Ser Glu Gly Gly  
130 135 140

Ala Val Pro Ala Leu Phe Ala Val Tyr Gln Asp Ala Thr Gly Val Ala  
145 150 155 160

Thr Glu Lys Ala Leu Ser Tyr Ala Asp Gly Ile Gly Ala Thr Arg Ala  
165 170 175

-continued

Gly Val Leu Glu Thr Thr Phe Lys Glu Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Val Thr Ala Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Asp Ala Gly Tyr Gln Pro Glu Leu Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Leu Glu Asn Met Arg Tyr Ser Val Ser Asp Thr Ala Gln Trp  
245 250 255

Gly Asp Phe Val Ser Gly Pro Arg Val Val Thr Glu Asp Thr Lys Lys  
260 265 270

Ala Met Gly Thr Val Leu Ala Glu Ile Gln Asp Gly Thr Phe Ala Arg  
275 280 285

Gly Trp Ile Ala Glu His Lys Ala Gly Arg Pro Asn Phe His Ala Thr  
290 295 300

Asn Glu Lys Glu Asn Glu His Glu Ile Glu Val Val Gly Arg Lys Leu  
305 310 315 320

Arg Glu Met Met Pro Phe Val Gln Pro Arg Val Lys Val Gly Met Lys  
325 330 335

&lt;210&gt; SEQ ID NO 48

&lt;211&gt; LENGTH: 335

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Bacillus cereus

&lt;400&gt; SEQUENCE: 48

Met Lys Thr Tyr Tyr Glu Lys Asp Ala Asn Val Glu Leu Leu Lys Gly  
1 5 10 15

Lys Thr Val Ala Val Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Gln Asn Leu Arg Asp Ser Gly Val Glu Val Val Val Gly Val Arg Pro  
35 40 45

Gly Lys Ser Phe Glu Val Ala Lys Thr Asp Gly Phe Glu Val Met Ser  
50 55 60

Val Ser Glu Ala Val Arg Thr Ala Gln Val Val Gln Met Leu Leu Pro  
65 70 75 80

Asp Glu Gln Gln Ala His Val Tyr Lys Ala Gly Val Glu Glu Asn Leu  
85 90 95

Arg Glu Gly Gln Met Leu Leu Phe Ser His Gly Phe Asn Ile His Phe  
100 105 110

Gly Gln Ile Asn Pro Pro Ser Tyr Val Asp Val Ala Met Val Ala Pro  
115 120 125

Lys Ser Pro Gly His Leu Val Arg Arg Val Phe Gln Glu Gly Asn Gly  
130 135 140

Val Pro Ala Leu Val Ala Val His Gln Asp Ala Thr Gly Thr Ala Leu  
145 150 155 160

His Val Ala Leu Ala Tyr Ala Lys Gly Val Gly Cys Thr Arg Ala Gly  
165 170 175

Val Ile Glu Thr Thr Phe Gln Glu Glu Thr Glu Thr Asp Leu Phe Gly  
180 185 190

Glu Gln Thr Val Leu Cys Gly Gly Val Thr Ala Leu Val Lys Ala Gly  
195 200 205

Phe Glu Thr Leu Thr Glu Gly Gly Tyr Arg Pro Glu Ile Ala Tyr Phe

## US 9,238,801 B2

**177****178**

-continued

210	215	220
Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp	Leu Met Tyr Glu Gly	
225	230	235
Gly Leu Thr Asn Met Arg His Ser Ile Ser Asp	Thr Ala Glu Phe Gly	
245	250	255
Asp Tyr Val Thr Gly Ser Arg Ile Val Thr Asp	Glu Thr Lys Lys Glu	
260	265	270
Met Lys Arg Val Leu Thr Glu Ile Gln Gln Gly	Glu Phe Ala Lys Lys	
275	280	285
Trp Ile Leu Glu Asn Gln Ala Gly Arg Pro	Thr Tyr Asn Ala Met Lys	
290	295	300
Lys Ala Glu Gln Asn His Gln Leu Glu Lys Val	Gly Ala Glu Leu Arg	
305	310	315
Glu Met Met Ser Trp Ile Asp Ala Pro Lys Glu	Leu Val Lys Lys	
325	330	335

```

<210> SEQ ID NO 49
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer pBAD-405
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10)..(11)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 49

```

gctcaagcan nkaacctgaa gg 22

```

<210> SEQ ID NO 50
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer pBAD 427
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(13)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 50

```

ccttcagggtt knntgcttga gc 22

```

<210> SEQ ID NO 51
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer pBAD435
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10)..(11)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 51

```

gtagacgtgn nkgttggcct g 21

```

<210> SEQ ID NO 52
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer pBAD456
<220> FEATURE:

```

-continued

<221> NAME/KEY: misc\_feature  
<222> LOCATION: (11)..(12)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<400> SEQUENCE: 52

caggccaack nnacgtcta c

21

<210> SEQ ID NO 53  
<211> LENGTH: 25  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer pBAD484  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (9)..(10)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (15)..(16)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<400> SEQUENCE: 53

ctgaagccnn kggcnkaaa gtgac

25

<210> SEQ ID NO 54  
<211> LENGTH: 25  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer pBAD509  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (10)..(11)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (16)..(17)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<400> SEQUENCE: 54

gtcactttn ngccknnggc ttca

25

<210> SEQ ID NO 55  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer pBAD519  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (10)..(11)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<400> SEQUENCE: 55

gcagccgttn nkgtgtccga ct

22

<210> SEQ ID NO 56  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer pBAD541  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (12)..(13)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<400> SEQUENCE: 56

agtccggacc knnaacggct gc

22

-continued

<210> SEQ ID NO 57  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer pBAD545  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (11)..(12)  
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 57

catgatcctg nnkccggacg ag

22

<210> SEQ ID NO 58  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer pBAD567  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (11)..(12)  
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 58

ctcggtccggk nnccaggatca tg

22

<210> SEQ ID NO 59  
<211> LENGTH: 23  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer pBAD608  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (11)..(12)  
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 59

caagaagggc nnkactctgg cct

23

<210> SEQ ID NO 60  
<211> LENGTH: 23  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer 60 pBAD631  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (12)..(13)  
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 60

aggccagagt knngcccttc ttg

23

<210> SEQ ID NO 61  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer pBAD663  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (10)..(11)  
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 61

-continued

gttgtgcctn nkgccgacct cg

22

<210> SEQ ID NO 62  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer pBAD685  
<220> FEATURE:  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (12)..(13)  
<223> OTHER INFORMATION: n is a, c, g, or t  
<400> SEQUENCE: 62

cgaggtcggc knnaggcaca ac

22

<210> SEQ ID NO 63  
<211> LENGTH: 491  
<212> TYPE: PRT  
<213> ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 63

Met Ala Asn Tyr Phe Asn Thr Leu Asn Leu Arg Gln Gln Leu Ala Gln  
1 5 10 15

Leu Gly Lys Cys Arg Phe Met Gly Arg Asp Glu Phe Ala Asp Gly Ala  
20 25 30

Ser Tyr Leu Gln Gly Lys Lys Val Val Ile Val Gly Cys Gly Ala Gln  
35 40 45

Gly Leu Asn Gln Gly Leu Asn Met Arg Asp Ser Gly Leu Asp Ile Ser  
50 55 60

Tyr Ala Leu Arg Lys Glu Ala Ile Ala Glu Lys Arg Ala Ser Trp Arg  
65 70 75 80

Lys Ala Thr Glu Asn Gly Phe Lys Val Gly Thr Tyr Glu Glu Leu Ile  
85 90 95

Pro Gln Ala Asp Leu Val Ile Asn Leu Thr Pro Asp Lys Gln His Ser  
100 105 110

Asp Val Val Arg Thr Val Gln Pro Leu Met Lys Asp Gly Ala Ala Leu  
115 120 125

Gly Tyr Ser His Gly Phe Asn Ile Val Glu Val Gly Glu Gln Ile Arg  
130 135 140

Lys Asp Ile Thr Val Val Met Val Ala Pro Lys Cys Pro Gly Thr Glu  
145 150 155 160

Val Arg Glu Glu Tyr Lys Arg Gly Phe Gly Val Pro Thr Leu Ile Ala  
165 170 175

Val His Pro Glu Asn Asp Pro Lys Gly Glu Gly Met Ala Ile Ala Lys  
180 185 190

Ala Trp Ala Ala Ala Thr Gly Gly His Arg Ala Gly Val Leu Glu Ser  
195 200 205

Ser Phe Val Ala Glu Val Lys Ser Asp Leu Met Gly Glu Gln Thr Ile  
210 215 220

Leu Cys Gly Met Leu Gln Ala Gly Ser Leu Leu Cys Phe Asp Lys Leu  
225 230 235 240

Val Glu Glu Gly Thr Asp Pro Ala Tyr Ala Glu Lys Leu Ile Gln Phe  
245 250 255

Gly Trp Glu Thr Ile Thr Glu Ala Leu Lys Gln Gly Gly Ile Thr Leu  
260 265 270

Met Met Asp Arg Leu Ser Asn Pro Ala Lys Leu Arg Ala Tyr Ala Leu  
275 280 285

-continued

Ser Glu Gln Leu Lys Glu Ile Met Ala Pro Leu Phe Gln Lys His Met  
290 295 300

Asp Asp Ile Ile Ser Gly Glu Phe Ser Ser Gly Met Met Ala Asp Trp  
305 310 315 320

Ala Asn Asp Asp Lys Lys Leu Leu Thr Trp Arg Glu Glu Thr Gly Lys  
325 330 335

Thr Ala Phe Glu Thr Ala Pro Gln Tyr Glu Gly Lys Ile Gly Glu Gln  
340 345 350

Glu Tyr Phe Asp Lys Gly Val Leu Met Ile Ala Met Val Lys Ala Gly  
355 360 365

Val Glu Leu Ala Phe Glu Thr Met Val Asp Ser Gly Ile Ile Glu Glu  
370 375 380

Ser Ala Tyr Tyr Glu Ser Leu His Glu Leu Pro Leu Ile Ala Asn Thr  
385 390 395 400

Ile Ala Arg Lys Arg Leu Tyr Glu Met Asn Val Val Ile Ser Asp Thr  
405 410 415

Ala Glu Tyr Gly Asn Tyr Leu Phe Ser Tyr Ala Cys Val Pro Leu Leu  
420 425 430

Lys Pro Phe Met Ala Glu Leu Gln Pro Gly Asp Leu Gly Lys Ala Ile  
435 440 445

Pro Glu Gly Ala Val Asp Asn Gly Gln Leu Arg Asp Val Asn Glu Ala  
450 455 460

Ile Arg Ser His Ala Ile Glu Gln Val Gly Lys Lys Leu Arg Gly Tyr  
465 470 475 480

Met Thr Asp Met Lys Arg Ile Ala Val Ala Gly  
485 490

&lt;210&gt; SEQ ID NO 64

&lt;211&gt; LENGTH: 493

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: gamma proteobacterium N4-7

&lt;400&gt; SEQUENCE: 64

Met Ala Asn Tyr Phe Asn Thr Leu Ser Leu Arg Asp Lys Leu Thr Gln  
1 5 10 15

Leu Gly Lys Cys Arg Phe Met Asp Arg Ser Glu Phe Thr Asp Gly Cys  
20 25 30

Asp Phe Ile Lys Asp Trp Asn Ile Val Ile Ile Gly Cys Gly Ala Gln  
35 40 45

Gly Leu Asn Gln Gly Leu Asn Met Arg Asp Ser Gly Leu Asn Ile Ser  
50 55 60

Tyr Ala Leu Arg Ala Gln Ala Ile Ala Glu Lys Arg Gln Ser Phe Val  
65 70 75 80

Trp Ala Ser Glu Asn Gly Phe Thr Val Gly Thr Ala Glu Glu Leu Val  
85 90 95

Pro Ala Ala Asp Leu Val Leu Asn Leu Thr Pro Asp Lys Gln His Thr  
100 105 110

Ala Ala Val Thr Ala Val Met Pro Leu Met Lys Gln Gly Ala Thr Leu  
115 120 125

Ala Tyr Ser His Gly Phe Asn Ile Val Glu Glu Gly Met Gln Ile Arg  
130 135 140

Pro Asp Leu Thr Val Val Met Val Ala Pro Lys Cys Pro Gly Thr Glu  
145 150 155 160

Val Arg Glu Glu Tyr Lys Arg Gly Phe Gly Val Pro Thr Leu Ile Ala

## US 9,238,801 B2

**187****188**

-continued

165	170	175
Val His Pro Glu Asn Asp Pro Gln Gly Asn Gly His Ala Ile Ala Lys		
180	185	190
Ala Tyr Ala Ser Ala Thr Gly Gly Asp Arg Ala Gly Val Leu Glu Ser		
195	200	205
Ser Phe Ile Ala Glu Val Lys Ser Asp Leu Met Gly Glu Gln Thr Ile		
210	215	220
Leu Cys Gly Met Leu Gln Thr Gly Ala Val Leu Gly His Gln Gln Leu		
225	230	235
Ile Asn Leu Gly Val Asp Ala Ala Tyr Ala Arg Lys Leu Ile Gln Tyr		
245	250	255
Gly Trp Glu Thr Val Thr Glu Gly Leu Lys His Gly Gly Ile Thr Asn		
260	265	270
Met Met Asp Arg Leu Ser Asn Pro Ala Lys Ile Lys Ala Phe Asp Met		
275	280	285
Ser Glu Glu Leu Lys Val Thr Leu Arg Pro Leu Phe Glu Lys His Met		
290	295	300
Asp Asp Ile Ile Glu Gly Glu Phe Ser His Thr Met Met Ile Asp Trp		
305	310	315
Ala Asn Asp Asp Ala Asn Leu Leu Lys Trp Arg Ala Glu Thr Ala Asp		
325	330	335
Ser Ser Phe Glu Gln Ala Ala Asp Cys Asp Ile Glu Ile Thr Glu Gln		
340	345	350
Glu Phe Tyr Asp Lys Gly Ile Tyr Leu Val Ala Met Ile Lys Ala Gly		
355	360	365
Val Glu Leu Ala Phe Glu Thr Met Val Ala Ser Gly Ile Ile Glu Glu		
370	375	380
Ser Ala Tyr Tyr Glu Ser Leu His Glu Thr Pro Leu Ile Ala Asn Cys		
385	390	395
Ile Ala Arg Asn Lys Leu Tyr Glu Met Asn Val Val Ile Ser Asp Thr		
405	410	415
Ala Glu Tyr Asn Tyr Leu Phe Thr His Ala Ala Val Pro Leu Leu		
420	425	430
Gln Ala His Ala Ser Ser Leu Thr Leu Glu Glu Leu Gly Gly Leu		
435	440	445
Ala Asp Ser Ser Asn Ala Val Asp Asn Leu Arg Leu Ile Glu Val Asn		
450	455	460
Asp Ala Ile Arg Asp His Asp Val Glu Ile Ile Gly His Glu Leu Arg		
465	470	475
Gly Tyr Met Thr Asp Met Lys Arg Ile Val Glu Ala Gly		
485	490	

&lt;210&gt; SEQ ID NO 65

&lt;211&gt; LENGTH: 490

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Desulfuromonas acetoxidans

&lt;400&gt; SEQUENCE: 65

Met Gly Gln Asn Tyr Phe Asn Thr Leu Ser Met Arg Glu Lys Leu Asp		
1	5	10
		15
Glu Leu Gly Thr Cys Arg Phe Met Asp Ala Ser Glu Phe Ala Gly Gly		
20	25	30
Cys Glu Tyr Ala Lys Gly Lys Lys Ile Val Ile Val Gly Cys Gly Ala		
35	40	45

-continued

---

Gln Gly Leu Asn Gln Gly Leu Asn Met Arg Asp Ser Gly Leu Asp Val  
50 55 60

Ser Tyr Thr Leu Arg Lys Glu Ala Ile Ala Glu Lys Arg Gln Ser Tyr  
65 70 75 80

Ile Asn Ala Thr Glu Asn Gly Phe Thr Val Gly Ser Tyr Glu Glu Leu  
85 90 95

Leu Pro Thr Ala Asp Ile Val Met Asn Leu Ala Pro Asp Lys Gln His  
100 105 110

Thr Asp Val Val Asn Thr Val Val Pro Leu Met Lys Gln Gly Ala Thr  
115 120 125

Phe Ser Tyr Ala His Gly Phe Asn Ile Val Glu Glu Gly Thr Ile Ile  
130 135 140

Arg Lys Asp Leu Thr Val Ile Met Val Ala Pro Lys Cys Pro Gly Ser  
145 150 155 160

Glu Val Arg Ala Glu Tyr Gln Arg Gly Phe Gly Val Pro Thr Leu Ile  
165 170 175

Ala Val His Lys Glu Asn Asp Pro Asn Gly Asp Gly Leu Glu Leu Ala  
180 185 190

Lys Ala Leu Cys Ser Ala Gln Gly Gly Asp Arg Ala Gly Val Leu Glu  
195 200 205

Ser Ser Phe Val Ala Glu Val Lys Ser Asp Leu Met Gly Glu Gln Thr  
210 215 220

Ile Leu Cys Gly Met Leu Gln Ala Gly Ala Leu Leu Cys Phe Asp Lys  
225 230 235 240

Met Val Glu Asn Gly Ile Glu Ala Pro Tyr Ala Val Lys Leu Ile Gln  
245 250 255

Tyr Gly Trp Glu Thr Ile Thr Glu Ala Leu Lys His Gly Ile Thr  
260 265 270

Asn Met Met Asp Arg Leu Ser Asn Pro Ala Lys Leu Glu Ala Tyr Glu  
275 280 285

Leu Ala Glu Glu Leu Lys Glu Ile Met Arg Pro Leu Phe Arg Lys His  
290 295 300

Met Asp Asp Ile Ile Thr Gly Val Phe Ser Ser Thr Met Met Glu Asp  
305 310 315 320

Trp Ala Asn Asp Asp Ile Asn Leu Leu Thr Trp Arg Glu Gln Thr Gly  
325 330 335

Gln Thr Ala Phe Glu Lys Thr Glu Ala Ala Gly Glu Ile Ser Glu Gln  
340 345 350

Glu Tyr Phe Asp Lys Ala Ile Leu Met Val Ala Met Val Lys Ala Gly  
355 360 365

Val Glu Leu Ala Phe Glu Ser Met Val Glu Val Gly Ile Glu Pro Glu  
370 375 380

Ser Ala Tyr Tyr Glu Ser Leu His Glu Thr Pro Leu Ile Ala Asn Thr  
385 390 395 400

Ile Ala Arg Lys Lys Leu Tyr Glu Met Asn Arg Val Ile Ser Asp Thr  
405 410 415

Ala Glu Tyr Gly Cys Tyr Leu Phe Ala His Ala Cys Val Pro Leu Leu  
420 425 430

Lys Asp Phe Met Ala Ser Val Thr Thr Glu Val Ile Gly Lys Gly Leu  
435 440 445

Asp Asn Val Asp Thr Ser Val Asp Asn Ser Thr Leu Val Arg Val Asn  
450 455 460

Ala Asp Ile Arg Ser His Tyr Ile Glu Glu Ile Gly Glu Glu Leu Arg

-continued

465	470	475	480
-----	-----	-----	-----

Asp Ala Met Gln Gly Met Lys Ala Ile Val  
485 490

&lt;210&gt; SEQ\_ID NO 66

&lt;211&gt; LENGTH: 581

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Pisum sativum

&lt;400&gt; SEQUENCE: 66

Met Ala Ala Val Thr Ser Ser Cys Ser Thr Ala Ile Ser Ala Ser Ser	
1 5	10 15

Lys Thr Leu Ala Lys Pro Val Ala Ala Ser Phe Ala Pro Thr Asn Leu	
20 25	30

Ser Phe Ser Lys Leu Ser Pro Gln Ser Ile Arg Ala Arg Arg Ser Ile	
35 40	45

Thr Val Gly Ser Ala Leu Gly Ala Thr Lys Val Ser Ala Pro Pro Ala	
50 55	60

Thr His Pro Val Ser Leu Asp Phe Glu Thr Ser Val Phe Lys Lys Glu	
65 70	75 80

Arg Val Asn Leu Ala Gly His Glu Glu Tyr Ile Val Arg Gly Gly Arg	
85 90	95

Asp Leu Phe His Leu Leu Pro Asp Ala Phe Lys Gly Ile Lys Gln Ile	
100 105	110

Gly Val Ile Gly Trp Gly Ser Gln Gly Pro Ala Gln Ala Gln Asn Leu	
115 120	125

Arg Asp Ser Leu Val Glu Ala Lys Ser Asp Ile Val Val Lys Val Gly	
130 135	140

Leu Arg Lys Gly Ser Ser Ser Phe Asn Glu Ala Arg Glu Ala Gly Phe	
145 150	155 160

Ser Glu Glu Lys Gly Thr Leu Gly Asp Ile Trp Glu Thr Ile Ser Gly	
165 170	175

Ser Asp Leu Val Leu Leu Ile Ser Asp Ser Ala Gln Ala Asp Asn	
180 185	190

Tyr Glu Lys Ile Phe Ser His Leu Lys Pro Asn Ser Ile Leu Gly Leu	
195 200	205

Ser His Gly Phe Leu Leu Gly His Leu Gln Ser Ile Gly Leu Asp Phe	
210 215	220

Pro Lys Asn Phe Ser Val Ile Ala Val Cys Pro Lys Gly Met Gly Pro	
225 230	235 240

Ser Val Arg Arg Leu Tyr Val Gln Gly Lys Glu Ile Asn Gly Ala Gly	
245 250	255

Ile Asn Ser Ser Phe Gly Val His Gln Asp Val Asp Gly Arg Ala Thr	
260 265	270

Asn Val Ala Leu Gly Trp Ser Val Ala Leu Gly Ser Pro Phe Thr Phe	
275 280	285

Ala Thr Thr Leu Glu Gln Glu Tyr Lys Ser Asp Ile Phe Gly Glu Arg	
290 295	300

Gly Ile Leu Leu Gly Ala Val His Gly Ile Val Glu Ser Leu Phe Arg	
305 310	315 320

Arg Tyr Thr Glu Asn Gly Met Ser Glu Asp Leu Ala Tyr Lys Asn Thr	
325 330	335

Val Glu Ser Ile Thr Gly Val Ile Ser Lys Thr Ile Ser Thr Gln Gly	
340 345	350

-continued

---

Met Leu Ala Val Tyr Asn Ala Leu Ser Glu Asp Gly Lys Lys Glu Phe  
 355 360 365  
 Glu Lys Ala Tyr Ser Ala Ser Phe Tyr Pro Cys Met Glu Ile Leu Tyr  
 370 375 380  
 Glu Cys Tyr Glu Asp Val Ala Ser Gly Ser Glu Ile Arg Ser Val Val  
 385 390 395 400  
 Leu Ala Gly Arg Arg Phe Tyr Glu Lys Glu Gly Leu Pro Ala Phe Pro  
 405 410 415  
 Met Gly Lys Ile Asp Gln Thr Arg Met Trp Lys Val Gly Glu Arg Val  
 420 425 430  
 Arg Ser Thr Arg Pro Ala Gly Asp Leu Gly Pro Leu Tyr Pro Phe Thr  
 435 440 445  
 Ala Gly Val Phe Val Ala Met Met Ala Gln Ile Glu Val Leu Arg  
 450 455 460  
 Lys Lys Gly His Ser Tyr Ser Glu Ile Ile Asn Glu Ser Val Ile Glu  
 465 470 475 480  
 Ser Val Asp Ser Leu Asn Pro Phe Met His Ala Arg Gly Val Ser Phe  
 485 490 495  
 Met Val Asp Asn Cys Ser Thr Thr Ala Arg Leu Gly Ser Arg Lys Trp  
 500 505 510  
 Ala Pro Arg Phe Asp Tyr Ile Leu Thr Gln Gln Ala Leu Val Ala Val  
 515 520 525  
 Asp Ser Gly Ala Pro Ile Asn Gln Asp Leu Ile Ser Asn Phe Val Ser  
 530 535 540  
 Asp Pro Val His Gly Ala Ile Gln Val Cys Ala Glu Leu Arg Pro Thr  
 545 550 555 560  
 Leu Asp Ile Ser Val Pro Ala Ala Ala Asp Phe Val Arg Pro Glu Leu  
 565 570 575  
 Arg Gln Cys Ser Asn  
 580

<210> SEQ ID NO 67  
 <211> LENGTH: 338  
 <212> TYPE: PRT  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: mutant KARI 3361G8  
 <400> SEQUENCE: 67

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1 5 10 15  
 Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
 20 25 30  
 Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys  
 35 40 45  
 Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
 50 55 60  
 Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
 65 70 75 80  
 Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85 90 95  
 Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100 105 110  
 Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115 120 125

-continued

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 68  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: KARI mutant 2H10

&lt;400&gt; SEQUENCE: 68

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys  
35 40 45

Gly Ala Ala Asp Ile Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala

-continued

---

145	150	155	160
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr			
165	170	175	
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe			
180	185	190	
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala			
195	200	205	
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr			
210	215	220	
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu			
225	230	235	240
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr			
245	250	255	
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln			
260	265	270	
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys			
275	280	285	
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys			
290	295	300	
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu			
305	310	315	320
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala			
325	330	335	

Lys Asn

<210> SEQ ID NO 69  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: KARI mutant 1D2

<400> SEQUENCE: 69

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly			
1	5	10	15
Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala			
20	25	30	
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys			
35	40	45	
Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr			
50	55	60	
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile			
65	70	75	80
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn			
85	90	95	
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His			
100	105	110	
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala			
115	120	125	
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly			
130	135	140	
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala			
145	150	155	160
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr			
165	170	175	

## US 9,238,801 B2

**199**

-continued

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325 330 335

Lys Asn

<210> SEQ ID NO 70  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: KARI mutant 3F12  
<400> SEQUENCE: 70

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
 20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys  
 35 40 45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
 50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
 65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
 145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180 185 190

**200**

-continued

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

```
<210> SEQ ID NO 71
<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer pf5-4mtF
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (22)..(23)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (31)..(32)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (37)..(38)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (40)..(41)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 71
gttagacgtga ctgttggcct gnnkaaaggc nnkgctnnkn nkgccaaggc tgaagccac 60
gg 62
```

```
<210> SEQ ID NO 72
<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer pf5-4mtR
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (22)..(23)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (25)..(26)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (31)..(32)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
```

-continued

<221> NAME/KEY: misc\_feature  
 <222> LOCATION: (40)..(41)  
 <223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 72

```
ccgtgggctt cagccttggc knnknnagck nngecttkn ncaggccaac agtcacgtct
ac
```

<210> SEQ ID NO 73  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer pbad-230

<400> SEQUENCE: 73

```
aagatttagcg gatcctact
```

<210> SEQ ID NO 74  
 <211> LENGTH: 24  
 <212> TYPE: DNA  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer pbad-601

<400> SEQUENCE: 74

```
gagtggcgcc cttcttgatg ttcg
```

<210> SEQ ID NO 75  
 <211> LENGTH: 338  
 <212> TYPE: PRT  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: mutant JB1C6

<400> SEQUENCE: 75

Met	Lys	Val	Phe	Tyr	Asp	Lys	Asp	Cys	Asp	Leu	Ser	Ile	Ile	Gln	Gly
1				5				10					15		

Lys	Lys	Val	Ala	Ile	Ile	Gly	Phe	Gly	Ser	Gln	Gly	His	Ala	Gln	Ala
20					25							30			

Leu	Asn	Leu	Lys	Asp	Ser	Gly	Val	Asp	Val	Thr	Val	Gly	Leu	His	Lys
35					40							45			

Gly	Asp	Ala	Tyr	Tyr	Ala	Lys	Ala	Glu	Ala	His	Gly	Phe	Lys	Val	Thr
50					55						60				

Asp	Val	Ala	Ala	Ala	Val	Ala	Gly	Ala	Asp	Leu	Val	Met	Ile	Leu	Ile
65					70				75				80		

Pro	Asp	Glu	Phe	Gln	Ser	Gln	Leu	Tyr	Lys	Asn	Glu	Ile	Glu	Pro	Asn
				85				90				95			

Ile	Lys	Lys	Gly	Ala	Thr	Leu	Ala	Phe	Ser	His	Gly	Phe	Ala	Ile	His
	100					105						110			

Tyr	Asn	Gln	Val	Val	Pro	Arg	Ala	Asp	Leu	Asp	Val	Ile	Met	Ile	Ala
115					120							125			

Pro	Lys	Ala	Pro	Gly	His	Thr	Val	Arg	Ser	Glu	Phe	Val	Lys	Gly	Gly
	130				135							140			

Gly	Ile	Pro	Asp	Leu	Ile	Ala	Ile	Tyr	Gln	Asp	Val	Ser	Gly	Asn	Ala
145					150				155				160		

Lys	Asn	Val	Ala	Leu	Ser	Tyr	Ala	Ala	Gly	Val	Gly	Gly	Arg	Thr	
				165					170				175		

Gly	Ile	Ile	Glu	Thr	Thr	Phe	Lys	Asp	Glu	Thr	Glu	Thr	Asp	Leu	Phe
	180				185							190			

-continued

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 76

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: mutant 16445E4

<400> SEQUENCE: 76

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Pro Lys  
35 40 45

Gly Val Ala Asp Gly Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

-continued

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ\_ID NO 77  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant 16468D7

<400> SEQUENCE: 77

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Thr Lys  
35 40 45

Gly Ile Ala Asp Arg Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu

**209****210**

-continued

225	230	235	240
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr			
245	250	255	
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln			
260	265	270	
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys			
275	280	285	
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys			
290	295	300	
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu			
305	310	315	320
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala			
325	330	335	
Lys Asn			

<210> SEQ\_ID NO 78  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant 16469F3

<400> SEQUENCE: 78

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly			
1	5	10	15
Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala			
20	25	30	
Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Glu Lys			
35	40	45	
Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr			
50	55	60	
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile			
65	70	75	80
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn			
85	90	95	
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His			
100	105	110	
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala			
115	120	125	
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly			
130	135	140	
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala			
145	150	155	160
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr			
165	170	175	
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe			
180	185	190	
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala			
195	200	205	
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr			
210	215	220	
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu			
225	230	235	240
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr			
245	250	255	

-continued

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325 330 335

Lys Asn

<210> SEQ\_ID NO 79

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: mutant JEAI

<400> SEQUENCE: 79

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
 20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Pro Lys  
 35 40 45

Gly Phe Ala Asp Val Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
 50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
 65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
 145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260 265 270

-continued

---

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ\_ID NO 80

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: mutant JEG2

<400> SEQUENCE: 80

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Phe Lys  
35 40 45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys

-continued

290            295            300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305            310            315            320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325            330            335

Lys Asn

<210> SEQ ID NO 81  
 <211> LENGTH: 338  
 <212> TYPE: PRT  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: mutant JEG4

&lt;400&gt; SEQUENCE: 81

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1                5                10                15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
 20                25                30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asn Lys  
 35                40                45

Gly Asn Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
 50                55                60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
 65                70                75                80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85                90                95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100                105                110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115                120                125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130                135                140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
 145                150                155                160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165                170                175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180                185                190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195                200                205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210                215                220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225                230                235                240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245                250                255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260                265                270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275                280                285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290                295                300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305                310                315                320

-continued

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325                   330                   335

Lys Asn

<210> SEQ ID NO: 82  
 <211> LENGTH: 338  
 <212> TYPE: PRT  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: mutant JEA7

<400> SEQUENCE: 82

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1               5               10               15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala  
 20              25              30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Pro Lys  
 35              40              45

Gly Asn Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
 50              55              60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
 65              70              75              80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85              90              95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100             105             110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115             120             125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130             135             140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
 145             150             155             160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165             170             175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180             185             190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195             200             205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210             215             220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225             230             235             240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245             250             255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260             265             270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275             280             285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290             295             300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305             310             315             320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325             330             335

-continued

Lys Asn

<210> SEQ ID NO 83  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant JED1  
<400> SEQUENCE: 83

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1               5                   10                   15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20              25                   30

Leu Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asn Lys  
35              40                   45

Gly Asn Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr  
50              55                   60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Ile  
65              70                   75                   80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85              90                   95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100             105                   110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115             120                   125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130             135                   140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
145             150                   155                   160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165             170                   175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180             185                   190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195             200                   205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210             215                   220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225             230                   235                   240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245             250                   255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260             265                   270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275             280                   285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290             295                   300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305             310                   315                   320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325             330                   335

Lys Asn

&lt;210&gt; SEQ ID NO 84

-continued

```

<211> LENGTH: 338
<212> TYPE: PRT
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: mutant 3361E1

<400> SEQUENCE: 84

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly
1           5          10          15

Lys Lys Val Ala Ile Ile Gly Phe Gly Ser Gln Gly His Ala Gln Ala
20          25          30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Tyr Lys
35          40          45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Phe Lys Val Thr
50          55          60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr
65          70          75          80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn
85          90          95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His
100         105         110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala
115         120         125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly
130         135         140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala
145         150         155         160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr
165         170         175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe
180         185         190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala
195         200         205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr
210         215         220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu
225         230         235         240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr
245         250         255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln
260         265         270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys
275         280         285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys
290         295         300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu
305         310         315         320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala
325         330         335

Lys Asn

```

```

<210> SEQ ID NO 85
<211> LENGTH: 338
<212> TYPE: PRT
<213> ORGANISM: artificial sequence
<220> FEATURE:

```

-continued

&lt;223&gt; OTHER INFORMATION: mutant C2F6

&lt;400&gt; SEQUENCE: 85

Met	Lys	Val	Phe	Tyr	Asp	Lys	Asp	Cys	Asp	Leu	Ser	Ile	Ile	Gln	Gly
1														15	

Lys	Lys	Val	Ala	Ile	Ile	Gly	Tyr	Gly	Ser	Gln	Gly	His	Ala	Gln	Ala
20														30	

Cys	Asn	Leu	Lys	Asp	Ser	Gly	Val	Asp	Val	Thr	Val	Gly	Leu	Pro	Lys
35														45	

Gly	Val	Ala	Asp	Trp	Ala	Lys	Ala	Glu	Ala	His	Gly	Leu	Lys	Val	Thr
50														60	

Asp	Val	Ala	Ala	Ala	Val	Ala	Gly	Ala	Asp	Leu	Val	Met	Ile	Leu	Thr
65														80	

Pro	Asp	Glu	Phe	Gln	Ser	Gln	Leu	Tyr	Lys	Asn	Glu	Ile	Glu	Pro	Asn
85														95	

Ile	Lys	Lys	Gly	Ala	Thr	Leu	Ala	Phe	Ser	His	Gly	Phe	Ala	Ile	His
100														110	

Tyr	Asn	Gln	Val	Val	Pro	Arg	Ala	Asp	Leu	Asp	Val	Ile	Met	Ile	Ala
115														125	

Pro	Lys	Ala	Pro	Gly	His	Thr	Val	Arg	Ser	Glu	Phe	Val	Lys	Gly	Gly
130														140	

Gly	Ile	Pro	Asp	Leu	Ile	Ala	Ile	Tyr	Gln	Asp	Ala	Ser	Gly	Asn	Ala
145														160	

Lys	Asn	Val	Ala	Leu	Ser	Tyr	Ala	Ala	Gly	Val	Gly	Gly	Arg	Thr	
165														175	

Gly	Ile	Ile	Glu	Thr	Thr	Phe	Lys	Asp	Glu	Thr	Glu	Thr	Asp	Leu	Phe
180														190	

Gly	Glu	Gln	Ala	Val	Leu	Cys	Gly	Gly	Thr	Val	Glu	Leu	Val	Lys	Ala
195														205	

Gly	Phe	Glu	Thr	Leu	Val	Glu	Ala	Gly	Tyr	Ala	Pro	Glu	Met	Ala	Tyr
210														220	

Phe	Glu	Cys	Leu	His	Glu	Leu	Lys	Leu	Ile	Val	Asp	Leu	Met	Tyr	Glu
225														240	

Gly	Gly	Ile	Ala	Asn	Met	Asn	Tyr	Ser	Ile	Ser	Asn	Asn	Ala	Glu	Tyr
245														255	

Gly	Glu	Tyr	Val	Thr	Gly	Pro	Glu	Val	Ile	Asn	Ala	Glu	Ser	Arg	Gln
260														270	

Ala	Met	Arg	Asn	Ala	Leu	Lys	Arg	Ile	Gln	Asp	Gly	Glu	Tyr	Ala	Lys
275														285	

Met	Phe	Ile	Ser	Glu	Gly	Ala	Thr	Gly	Tyr	Pro	Ser	Met	Thr	Ala	Lys
290														300	

Arg	Arg	Asn	Asn	Ala	Ala	His	Gly	Ile	Glu	Ile	Ile	Gly	Glu	Gln	Leu
305														320	

Arg	Ser	Met	Met	Pro	Trp	Ile	Gly	Ala	Asn	Lys	Ile	Val	Asp	Lys	Ala
325														335	

Lys Asn

&lt;210&gt; SEQ ID NO 86

&lt;211&gt; LENGTH: 338

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: mutant C3B11

&lt;400&gt; SEQUENCE: 86

-continued

---

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
 20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Phe Lys  
 35 40 45

Gly Ala Ala Asp Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
 50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
 65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
 145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325 330 335

Lys Asn

<210> SEQ\_ID NO 87  
 <211> LENGTH: 338  
 <212> TYPE: PRT  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: mutant C4D12

&lt;400&gt; SEQUENCE: 87

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala

**227**

-continued

20	25	30
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Cys Lys		
35	40	45
Gly Trp Ala Gly Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr		
50	55	60
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr		
65	70	75
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn		
85	90	95
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His		
100	105	110
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala		
115	120	125
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly		
130	135	140
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala		
145	150	155
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr		
165	170	175
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe		
180	185	190
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala		
195	200	205
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr		
210	215	220
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu		
225	230	235
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr		
245	250	255
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln		
260	265	270
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys		
275	280	285
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys		
290	295	300
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu		
305	310	315
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala		
325	330	335
Lys Asn		
<210> SEQ_ID NO 88		
<211> LENGTH: 338		
<212> TYPE: PRT		
<213> ORGANISM: artificial sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: mutant SE		
<400> SEQUENCE: 88		
Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly		
1	5	10
15		
Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala		
20	25	30
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Ala Lys		
35	40	45

**228**

-continued

Gly Trp Ala Gly Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 89

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: mutant SE2

<400> SEQUENCE: 89

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Pro Lys  
35 40 45

Gly Glu Ala Ala Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

-continued

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
 65 70 75 80  
 Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85 90 95  
 Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100 105 110  
 Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115 120 125  
 Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130 135 140  
 Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
 145 150 155 160  
 Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165 170 175  
 Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180 185 190  
 Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195 200 205  
 Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210 215 220  
 Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225 230 235 240  
 Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245 250 255  
 Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260 265 270  
 Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275 280 285  
 Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290 295 300  
 Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305 310 315 320  
 Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325 330 335  
 Lys Asn

<210> SEQ ID NO 90  
 <211> LENGTH: 338  
 <212> TYPE: PRT  
 <213> ORGANISM: artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: mutant SB3  
 <400> SEQUENCE: 90

Met	Lys	Val	Phe	Tyr	Asp	Lys	Asp	Cys	Asp	Leu	Ser	Ile	Ile	Gln	Gly
1			5			10			15						

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
 20 25 30  
 Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Gly Lys  
 35 40 45  
 Gly Trp Ala Gly Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
 50 55 60  
 Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
 65 70 75 80  
 Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn

-continued

---

85	90	95
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His		
100	105	110
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala		
115	120	125
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly		
130	135	140
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala		
145	150	155
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr		
165	170	175
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe		
180	185	190
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala		
195	200	205
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr		
210	215	220
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu		
225	230	235
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr		
245	250	255
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln		
260	265	270
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys		
275	280	285
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys		
290	295	300
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu		
305	310	315
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala		
325	330	335
Lys Asn		

<210> SEQ ID NO 91  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant SD3  
<400> SEQUENCE: 91

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly		
1	5	10
Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala		
20	25	30
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Leu Lys		
35	40	45
Gly Trp Ala Gly Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr		
50	55	60
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr		
65	70	75
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn		
85	90	95
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His		
100	105	110

-continued

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 92  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant 9650E5

<400> SEQUENCE: 92

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asn Lys  
35 40 45

Gly Trp Ala Gly His Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

-continued

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 93  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant 9667A11

&lt;400&gt; SEQUENCE: 93

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asn Lys  
35 40 45

Gly Asn Ala Gly His Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala

## US 9,238,801 B2

**239****240**

-continued

145	150	155	160
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr			
165	170	175	
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe			
180	185	190	
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala			
195	200	205	
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr			
210	215	220	
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu			
225	230	235	240
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr			
245	250	255	
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln			
260	265	270	
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys			
275	280	285	
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys			
290	295	300	
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu			
305	310	315	320
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala			
325	330	335	

Lys Asn

<210> SEQ ID NO 94  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant 9862B9

<400> SEQUENCE: 94

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly			
1	5	10	15
Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala			
20	25	30	
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asp Lys			
35	40	45	
Gly Trp Ala Gly Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr			
50	55	60	
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr			
65	70	75	80
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn			
85	90	95	
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His			
100	105	110	
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala			
115	120	125	
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly			
130	135	140	
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala			
145	150	155	160
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr			
165	170	175	

-continued

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 95  
<211> LENGTH: 338  
<212> TYPE: PRT  
<213> ORGANISM: artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: mutant 9875B9

<400> SEQUENCE: 95

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asn Lys  
35 40 45

Gly Asn Ala Asp Trp Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

-continued

---

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
210 215 220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
225 230 235 240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
245 250 255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

<210> SEQ ID NO 96

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: mutant 11461D8

<400> SEQUENCE: 96

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
1 5 10 15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
20 25 30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Phe Lys  
35 40 45

Gly Ala Ala Asp Ala Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
50 55 60

Asp Val Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
65 70 75 80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
85 90 95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
100 105 110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
115 120 125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
130 135 140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala  
145 150 155 160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
165 170 175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
180 185 190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
195 200 205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr

## US 9,238,801 B2

**245**

-continued

---

210	215	220
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu		
225	230	235
Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr		
245	250	255
Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln		
260	265	270
Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys		
275	280	285
Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys		
290	295	300
Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu		
305	310	315
Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala		
325	330	335
Lys Asn		
<210> SEQ ID NO 97		
<211> LENGTH: 338		
<212> TYPE: PRT		
<213> ORGANISM: artificial sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: mutant 11463		
<400> SEQUENCE: 97		
Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly		
1	5	10
Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala		
20	25	30
Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Pro Lys		
35	40	45
Gly Phe Ala Asp Val Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr		
50	55	60
Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr		
65	70	75
Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn		
85	90	95
Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His		
100	105	110
Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala		
115	120	125
Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly		
130	135	140
Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Ala Ser Gly Asn Ala		
145	150	155
Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr		
165	170	175
Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe		
180	185	190
Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala		
195	200	205
Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr		
210	215	220
Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu		
225	230	235
240		

---

-continued

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245                    250                    255

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
 260                    265                    270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
 275                    280                    285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
 290                    295                    300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
 305                    310                    315                    320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
 325                    330                    335

Lys Asn

<210> SEQ ID NO 98

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: mutant 1151B4

<400> SEQUENCE: 98

Met Lys Val Phe Tyr Asp Lys Asp Cys Asp Leu Ser Ile Ile Gln Gly  
 1                    5                    10                    15

Lys Lys Val Ala Ile Ile Gly Tyr Gly Ser Gln Gly His Ala Gln Ala  
 20                    25                    30

Cys Asn Leu Lys Asp Ser Gly Val Asp Val Thr Val Gly Leu Asn Lys  
 35                    40                    45

Gly Asn Ala Asp Ala Ala Lys Ala Glu Ala His Gly Leu Lys Val Thr  
 50                    55                    60

Asp Val Ala Ala Ala Val Ala Gly Ala Asp Leu Val Met Ile Leu Thr  
 65                    70                    75                    80

Pro Asp Glu Phe Gln Ser Gln Leu Tyr Lys Asn Glu Ile Glu Pro Asn  
 85                    90                    95

Ile Lys Lys Gly Ala Thr Leu Ala Phe Ser His Gly Phe Ala Ile His  
 100                    105                    110

Tyr Asn Gln Val Val Pro Arg Ala Asp Leu Asp Val Ile Met Ile Ala  
 115                    120                    125

Pro Lys Ala Pro Gly His Thr Val Arg Ser Glu Phe Val Lys Gly Gly  
 130                    135                    140

Gly Ile Pro Asp Leu Ile Ala Ile Tyr Gln Asp Val Ser Gly Asn Ala  
 145                    150                    155                    160

Lys Asn Val Ala Leu Ser Tyr Ala Ala Gly Val Gly Gly Arg Thr  
 165                    170                    175

Gly Ile Ile Glu Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe  
 180                    185                    190

Gly Glu Gln Ala Val Leu Cys Gly Gly Thr Val Glu Leu Val Lys Ala  
 195                    200                    205

Gly Phe Glu Thr Leu Val Glu Ala Gly Tyr Ala Pro Glu Met Ala Tyr  
 210                    215                    220

Phe Glu Cys Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu  
 225                    230                    235                    240

Gly Gly Ile Ala Asn Met Asn Tyr Ser Ile Ser Asn Asn Ala Glu Tyr  
 245                    250                    255

-continued

---

Gly Glu Tyr Val Thr Gly Pro Glu Val Ile Asn Ala Glu Ser Arg Gln  
260 265 270

Ala Met Arg Asn Ala Leu Lys Arg Ile Gln Asp Gly Glu Tyr Ala Lys  
275 280 285

Met Phe Ile Ser Glu Gly Ala Thr Gly Tyr Pro Ser Met Thr Ala Lys  
290 295 300

Arg Arg Asn Asn Ala Ala His Gly Ile Glu Ile Ile Gly Glu Gln Leu  
305 310 315 320

Arg Ser Met Met Pro Trp Ile Gly Ala Asn Lys Ile Val Asp Lys Ala  
325 330 335

Lys Asn

---

What is claimed is:

1. A recombinant mutant ketol-acid reductoisomerase enzyme having the amino acid sequence of SEQ ID NO: 29. 20
2. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 24 wherein the substitution is an amino acid substitution of phenylalanine.
3. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 50 wherein the substitution is an amino acid substitution of alanine. 25
4. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 52 wherein the substitution is an amino acid substitution of aspartic acid.
5. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 53 wherein the substitution is an amino acid substitution of alanine. 30
6. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 61 wherein the substitution is an amino acid substitution of phenylalanine.
7. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme further comprises a substitution at position 115 wherein the substitution is an amino acid substitution of leucine.
8. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme further comprises a substitution at position 165 wherein the substitution is an amino acid substitution of methionine.
9. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 33 wherein the substitution is an amino acid substitution of leucine.
10. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 80 wherein the substitution is an amino acid substitution of isoleucine.
11. The recombinant mutant ketol-acid reductoisomerase enzyme of claim 1, wherein the enzyme comprises a substitution at position 156 wherein the substitution is an amino acid substitution of valine.

\* \* \* \* \*